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Abstract
Multiple-frequency bioimpedance devices for fluid
management in people with chronic kidney disease
receiving dialysis: a systematic review and economic
evaluation
Graham Scotland,1 Moira Cruickshank,2 Elisabet Jacobsen,1
David Cooper,2 Cynthia Fraser,2 Michal Shimonovich,2
Angharad Marks3 and Miriam Brazzelli2*
1Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
2Health Services Research Unit, University of Aberdeen, Aberdeen, UK
3NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK
*Corresponding author m.brazzelli@abdn.ac.uk
Background: Chronic kidney disease (CKD) is a long-term condition requiring treatment such as conservative
management, kidney transplantation or dialysis. To optimise the volume of fluid removed during dialysis
(to avoid underhydration or overhydration), people are assigned a ‘target weight’, which is commonly
assessed using clinical methods, such as weight gain between dialysis sessions, pre- and post-dialysis blood
pressure and patient-reported symptoms. However, these methods are not precise, and measurement devices
based on bioimpedance technology are increasingly used in dialysis centres. Current evidence on the role of
bioimpedance devices for fluid management in people with CKD receiving dialysis is limited.
Objectives: To evaluate the clinical effectiveness and cost-effectiveness of multiple-frequency
bioimpedance devices versus standard clinical assessment for fluid management in people with CKD
receiving dialysis.
Data sources: We searched major electronic databases [e.g. MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations, EMBASE, Science Citation Index and Cochrane Central Register of Controlled Trials
(CENTRAL)] conference abstracts and ongoing studies. There were no date restrictions. Searches were
undertaken between June and October 2016.
Review methods: Evidence was considered from randomised controlled trials (RCTs) comparing fluid
management by multiple-frequency bioimpedance devices and standard clinical assessment in people receiving
dialysis, and non-randomised studies evaluating the use of the devices for fluid management in people
receiving dialysis. One reviewer extracted data and assessed the risk of bias of included studies. A second
reviewer cross-checked the extracted data. Standard meta-analyses techniques were used to combine results
from included studies. A Markov model was developed to assess the cost-effectiveness of the interventions.
Results: Five RCTs (with 904 adult participants) and eight non-randomised studies (with 4915 adult
participants) assessing the use of the Body Composition Monitor [(BCM) Fresenius Medical Care, Bad
Homburg vor der Höhe, Germany] were included. Both absolute overhydration and relative overhydration
were significantly lower in patients evaluated using BCM measurements than for those evaluated using
standard clinical methods [weighted mean difference –0.44, 95% confidence interval (CI) –0.72 to –0.15,
p = 0.003, I2 = 49%; and weighted mean difference –1.84, 95% CI –3.65 to –0.03; p = 0.05, I2 = 52%,
respectively]. Pooled effects of bioimpedance monitoring on systolic blood pressure (SBP) (mean difference
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–2.46 mmHg, 95% CI –5.07 to 0.15 mmHg; p = 0.06, I2 = 0%), arterial stiffness (mean difference –1.18,
95% CI –3.14 to 0.78; p = 0.24, I2 = 92%) and mortality (hazard ratio = 0.689, 95% CI 0.23 to 2.08;
p = 0.51) were not statistically significant. The economic evaluation showed that, when dialysis costs were
included in the model, the probability of bioimpedance monitoring being cost-effective ranged from 13%
to 26% at a willingness-to-pay threshold of £20,000 per quality-adjusted life-year gained. With dialysis
costs excluded, the corresponding probabilities of cost-effectiveness ranged from 61% to 67%.
Limitations: Lack of evidence on clinically relevant outcomes, children receiving dialysis, and any
multifrequency bioimpedance devices, other than the BCM.
Conclusions: BCM used in addition to clinical assessment may lower overhydration and potentially
improve intermediate outcomes, such as SBP, but effects on mortality have not been demonstrated. If
dialysis costs are not considered, the incremental cost-effectiveness ratio falls below £20,000, with modest
effects on mortality and/or hospitalisation rates. The current findings are not generalisable to paediatric
populations nor across other multifrequency bioimpedance devices.
Future work: Services that routinely use the BCM should report clinically relevant intermediate and
long-term outcomes before and after introduction of the device to extend the current evidence base.
Study registration: This study is registered as PROSPERO CRD42016041785.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
People undergo dialysis because of kidney problems. During dialysis, it is important to check the volumeof fluid being removed, as removing too much or not enough fluid can cause serious health problems.
Assessment of fluid levels in people receiving dialysis has traditionally been done by doctors and medical
staff using their expertise and judgement, but this can be inaccurate. Recently, a type of technical device
(called a multifrequency bioimpedance device) has been introduced to estimate a person’s fluid level by
sending painless electrical currents through the body by way of pads, which are placed on certain parts of
the body (e.g. the hand and foot). This assessment looked at all clinical studies comparing the use of such
devices with doctors’ judgement in assessing the fluid levels of people receiving dialysis. Results from 13
clinical studies assessing 5819 adults showed that the use of these bioimpedance devices reduced
overhydration levels, but blood pressure, arterial stiffness (the heart has to work harder to pump blood
through stiffer arteries and stiffness can mean an increased risk of negative events such as heart attacks)
and the number of deaths were similar regardless of the method of fluid assessment. The cost of using
these devices was too high for the NHS budget when the actual costs of dialysis were included in the
economic evaluation, but was acceptable when dialysis costs were not taken into account. The quality of
the studies was generally poor and only one device was used by all the studies. In addition, the long-term
effects of using these devices have yet to be established. It would be useful if dialysis centres, which have
introduced the use of these devices in their routine practice, could provide further information on the
effects of bioimpedance devices on people receiving dialysis over an extended period of time.
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Scientific summary
Background
Chronic kidney disease (CKD) is a long-term condition in which the kidneys do not function effectively.
In the most severe stage of CKD, the kidneys operate at ≤ 15% of their normal function, and treatment in
the form of conservative management, kidney transplantation or dialysis will be required. Dialysis involves
removing waste products and excess fluid from the bloodstream, and there are two main types:
1. Haemodialysis (HD), in which the person is connected to a dialysis machine that uses a semipermeable
membrane to filter out excess salts and water in the blood; HD is commonly prescribed for 4 hours,
three times per week, administered either in hospital, in a satellite unit or at home.
2. Peritoneal dialysis (PD), in which dialysis fluid is passed into the peritoneal cavity through a permanent
catheter and waste products and excess fluid are drawn from the blood into the dialysis fluid by the
blood vessels lining the cavity. The process of fluid exchange can either be carried out overnight by a
machine (automated PD) or conducted manually, four times daily, taking 30–40 minutes for each fluid
exchange (continuous ambulatory PD).
To optimise the volume of fluid to be removed during dialysis (to avoid underhydration or overhydration,
both of which are associated with potentially serious complications), people are assigned a ‘target weight’,
which is commonly assessed using clinical methods, such as weight gain between dialysis sessions, pre-
and post-dialysis blood pressure and patient-reported symptoms. However, these methods are not precise,
and measurement devices based on bioimpedance technology, which are non-invasive, simple and
inexpensive, are increasingly used in dialysis centres. There is currently limited evidence on the clinical
effectiveness and cost-effectiveness of bioimpedance devices compared with standard clinical assessment
for fluid management in people with CKD receiving dialysis.
Objectives
The specific objectives of this assessment were to:
l systematically review the evidence on the clinical effectiveness of multiple-frequency bioimpedance
devices [i.e. Body Composition Monitor (BCM; Fresenius Medical Care, Bad Homburg vor der Höhe,
Germany), MultiScan 5000 (Bodystat, Douglas, Isle of Man), BioScan 920-II (Maltron International,
Essex, UK), BioScan touch i8 (Maltron International, Essex, UK) and InBody S10 (InBody, Seoul, South
Korea)] compared with that of standard clinical assessment for fluid management in people with CKD
receiving dialysis treatment
l systematically review existing economic evaluations on multiple-frequency bioimpedance devices for
people with CKD receiving dialysis treatment
l develop a de novo economic model to assess the cost-effectiveness of multiple-frequency
bioimpedance technologies (using BCM, MultiScan 5000, BioScan 920-II, BioScan touch i8 or InBody
S10) for fluid management in people with CKD receiving dialysis treatment versus standard clinical
assessment.
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Methods
Clinical effectiveness
Comprehensive electronic searches were undertaken between June and October 2016 to identify relevant
reports of published studies. There were no date restrictions. Databases searched included MEDLINE,
MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Science Citation Index and Cochrane
Central Register of Controlled Trials (CENTRAL). Evidence was considered from randomised controlled
trials (RCTs) assessing multiple-frequency bioimpedance devices versus standard clinical assessment, and
non-randomised cohort studies. The population was people with CKD being treated with HD or PD. The
comparator was standard clinical assessment, consisting of blood pressure, presence of oedema, changes
in weight, residual renal function, pre-existing cardiovascular (CV) conditions and/or patient-reported
symptoms of overhydration or underhydration.
Data on clinical outcomes, intermediate outcomes and patient-reported outcomes were extracted from the
included studies. Binary and continuous data were meta-analysed (when appropriate) as pooled summary
effect sizes using standard inverse variance methods.
Cost-effectiveness
A Markov model was developed to simulate the progression of the prevalent dialysis cohort through a set
of mutually exclusive health states capturing mortality, CV events and other causes of hospitalisation,
transplantation (for those listed) and graft failure post transplant. The model included costs to the health
service of providing dialysis treatment, costs of inpatient hospitalisation, costs of outpatient attendance,
costs of kidney transplantation, post-transplant follow-up and immunosuppressant costs and costs of
dialysis following transplant graft failure. Health state utility multipliers were identified and incorporated for
the dialysis and post-transplant states in the model, allowing cumulative quality-adjusted life-years (QALYs)
to be estimated. Further proportional reductions in health state utility were modelled in the short term for
all hospitalisation events and in the long term following incident CV hospitalisation events.
The added costs and plausible effects of bioimpedance-guided fluid management (based on four tests per
year) were added to the baseline model, and the cumulative costs and QALYs were simulated over the
lifetime of the cohort in the alternative arms of the model. In the base-case clinical effectiveness scenarios,
proportional reductions in all-cause mortality and CV event-related or all-cause hospitalisation were applied in
the bioimpedance-guided arm of the model. Given the limited direct evidence from the clinical effectiveness
review, these effects [incorporated as hazard ratios (HRs)] were primarily estimated by linking effects on
surrogate end points [arterial stiffness (pulse wave velocity; PWV) and hydration status] to possible effects on
the final outcomes using secondary published sources.
Results
Clinical effectiveness
A total of five RCTs (published in six papers) analysing a total of 904 participants, and eight non-randomised
studies (published in nine papers) analysing a total of 4915 participants were included in the review of
clinical effectiveness. All included studies investigated the use of the BCM in the relevant population, all of
which were adults. Of the RCTs, one trial was rated as having a high risk of bias, and four trials did not
provide sufficient information to make a robust judgement. We further identified four ongoing trials.
The results of the meta-analyses conducted for this assessment showed that both absolute overhydration
and relative overhydration were significantly lower in the BCM group than in the standard clinical assessment
group [weighted mean difference –0.44, 95% confidence interval (CI) –0.72 to –0.15, p = 0.003, I2 = 49%;
and weighted mean difference –1.84, 95% CI –3.65 to –0.03, p = 0.05, I2 = 52%, respectively]. The pooled
effects of bioimpedance monitoring on blood pressure (mean difference –2.46, 95% CI –5.07 to 0.15;
p = 0.06, I2 = 0%), arterial stiffness (mean difference –1.18, 95% CI –3.14 to 0.78; p = 0.24, I2 = 92%) and
mortality (HR 0.689, 95% CI 0.23 to 2.08; p = 0.51, I2 = 54%) were not statistically significant.
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Evidence from non-randomised studies suggested that there were no statistically significant differences in
blood pressure between the following subgroups: patients in whom overhydration was reduced within
6 months compared with those whose overhydration was not reduced within 6 months, patients receiving
short-term versus long-term dialysis and patients who were normohydrated compared with those who
were overhydrated.
Cost-effectiveness
Six main clinical effectiveness scenarios were explored in the cost-effectiveness modelling, with HRs of
varying magnitude applied to all-cause mortality and CV event-related or all-cause hospitalisation rates.
One of the scenarios also explored the impact of modelling a reduction in the use (cost) of blood pressure
medication with bioimpedance-guided fluid management. There was insufficient evidence to justify the
inclusion of effects on dialysis requirements (number and duration of sessions), residual renal function and
the health-related quality of life of patients receiving dialysis (independent of effects on hospitalisation).
When dialysis costs were included in the model, the incremental cost-effectiveness ratios (ICERs) for
bioimpedance-guided fluid management ranged from £58,723 to £66,007 per QALY gained. These ICERs
related to mean incremental costs that varied between £4518 and £35,676, and corresponding lifetime
incremental QALY gains that varied from 0.07 to 0.58. The costs of dialysis in added years made up the
vast majority of the incremental costs. When dialysis costs were excluded from the model, the base-case
ICERs ranged from £15,215 to £21,201.
Sensitivity analyses
Beyond the inclusion/exclusion of dialysis costs, the cost-effectiveness results were found to be most
sensitive to the effect of bioimpedance-guided fluid management on all-cause mortality. When dialysis
costs were included in the model, the ICER was most favourable (≈ £40,300) when the HR for all-cause
mortality was set equal to one, that is, no reduction in mortality leading to no extra dialysis costs, but
retained benefits on non-fatal hospitalisation events. With dialysis costs and an effect on mortality included
in the model, there would need to be an accompanying effect of bioimpedance monitoring on the cost of
dialysis and/or health state utility over the lifetime of patients receiving dialysis. There is currently limited
available evidence to justify such scenarios.
When dialysis costs were excluded from the model, the ICER for bioimpedance-guided fluid management
remained below £20,000 in most scenarios assessed. Given the relatively low cost of adding bioimpedance
testing four times a year, the ICERs remained favourable with modest effects on mortality and hospitalisation
rates. With dialysis costs excluded, probabilities of cost-effectiveness ranged from 61% to 67% at a
willingness-to-pay threshold of £20,000 per QALY gained.
Discussion
Strengths, limitations of the analyses and uncertainties
The methods used to conduct this assessment were detailed and thorough. The main limitation was the
lack of evidence on any of the specified devices, with the exception of the BCM, and on children receiving
dialysis.
In light of the limited available clinical effectiveness evidence, the economic modelling relied on estimated
effects on surrogate end points (hydration status, arterial stiffness and blood pressure) to model plausible
reductions in all-cause mortality and CV event-related/all-cause hospitalisation. Critically, there were no ideal
sources of evidence to link intervention-induced changes in the relevant surrogates to effects on mortality
and hospitalisation rates. Therefore, the possible effects were informed by reference to cross-sectional
prognostic studies, leading to great uncertainty in the robustness of the cost-effectiveness findings.
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Generalisability of the findings
The included trials involved only the BCM, and it is not known if the effects of this device generalise across
the other multiple-frequency bioimpedance devices specified for this appraisal. None of the included studies
was conducted in the UK or involved paediatric populations, so the applicability of our findings in those
contexts is unclear. The generalisability of the modelled cost-effectiveness scenarios is also dependent on the
generalisability of the estimated pooled effects of bioimpedance-guided management on arterial stiffness
(PWV) or inferred effects on hydration status. As all the included RCTs were conducted outside the UK, this
remains uncertain.
Conclusions
Our findings indicate that both absolute overhydration and relative overhydration are significantly lower
among people with CKD receiving dialysis who are managed using the BCM instead of standard clinical
methods. The use of bioimpedance monitoring may reduce systolic blood pressure (SBP), although the
pooled estimates of effects show a certain degree of heterogeneity and a non-significant effect. The current
evidence does not demonstrate a significant effect on arterial stiffness and on mortality. There is currently
no evidence to indicate that these findings are generalisable to paediatric populations or across other
multifrequency bioimpedance devices. With possible effects on mortality and hospitalisation rates modelled
indirectly through estimated pooled reductions in surrogate end points (PWV or overhydration), it appears
unlikely that the ICER for bioimpedance-guided fluid management will fall below standard thresholds for
cost-effectiveness with dialysis costs included. If dialysis costs are excluded from the model, the ICER may
feasibly fall below £20,000, with modest effects on mortality and/or hospitalisation rates. The economic
modelling is subject to substantial uncertainty, given the limitations in the clinical evidence base.
Implications for service provision
The current evidence suggests that BCM use, in addition to routine clinical assessment, may reduce
overhydration and potentially improve intermediate outcomes such as SBP, but significant effects on
mortality have not been demonstrated.
It would be useful if services that are currently, or subsequently, routinely using the BCM to augment
routine clinical assessment could provide information on long-term outcomes before and after introduction
of the bioimpedance device to extend the current evidence base.
Services that plan to introduce the routine use of the BCM to augment routine clinical assessment may
consider adopting a protocol that is transparent and reproducible.
Suggested research priorities
The ultimate aim of introducing multiple-frequency bioimpedance device measurement in addition to
standard clinical assessment into clinical practice is to reduce clinically important events such as mortality,
CV events and hospital admissions, whether this is through a reduction in overhydration- or underhydration-
related events. However, clinical effectiveness has not been demonstrated yet for these important health
outcomes. The effects of introducing multiple-frequency bioimpedance device measurement on intermediate
outcomes, such as SBP control and hydration status, have been documented. The timeline from these
intermediate end points to those end points that are clinically relevant, however, may not be captured within
the identified clinical trials. The studies were generally short-lived and the sustainability of introducing a
change in routine practice has yet to be established.
Those centres that have introduced routine multiple-frequency bioimpedance device measurement to
augment clinical assessment of dialysis patients may consider conducting adjusted retrospective analyses to
estimate effects on clinically relevant and intermediate outcomes both before and after the introduction of
the device. It would also be useful to obtain further information on the sustainability of the measurement
and its use in clinical practice over a sustained period.
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It is important that currently ongoing and future clinical trials are adequately powered to identify any
clinical benefit (not just intermediate benefits) and the likely timeline of how any benefit (e.g. through
better blood pressure control) is factored in to allow such studies to truly demonstrate whether or not an
important clinical effect exists.
Future trials should adopt protocols that are likely to be clinically applicable in multiple areas (e.g. 3-monthly
testing to allow use at routine review appointments).
Future trials should also carefully match their included population to the outcomes of interest. For
example, if the primary outcome is a reduction in blood pressure, an appropriate clinical population would
be patients who had high blood pressure and were fluid overloaded post HD, as they would be likely to
have overhydration-related hypertension. Removing fluid from patients with hypertension who are not
overhydrated may result in harm to some participants.
Related to further key uncertainties identified in the economic modelling, we recommend that future
studies:
l assess the impact of hydration status and bioimpedance-guided fluid management on health-related
quality of life, preferably using a generic preference-based instrument suitable for the estimation
of QALYs
l assess the impact of bioimpedance testing on the frequency and duration of dialysis, and
associated costs
l further develop and strengthen the evidence base for linking changes in surrogate end points (e.g. fluid
management-induced changes in blood pressure and PWV) to changes in health outcomes (mortality, CV
events, hospitalisation rates). Ideally, data from relevant randomised studies should be used to quantify
relationships between intervention-induced changes in the surrogate end points and longer-term
changes in health outcomes
l quantify the risks and cost burdens of different types of hospitalisation event in people receiving
dialysis, and better characterise the impact of hydration status on these risks.
Study registration
This study is registered as PROSPERO CRD42016041785.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and definition of the
decision problem(s)
Condition(s) and aetiology(ies)
Brief statement describing the health problem
Chronic kidney disease (CKD) is a long-term condition in which the kidneys do not function effectively.
There are many causes of CKD, including hereditary disease and autoimmune disorders, but the most
common causes are high blood pressure or diabetes mellitus.1 The progression of CKD can be measured
according to five stages of severity. In the most severe stage of the disease, stage 5, the kidneys will be
working at ≤ 15% of their normal function. At this point, the patient will need to start treatment in the
form of conservative management, dialysis or kidney transplantation.2
Collectively, these treatments are referred to as renal replacement therapy (RRT). Dialysis involves removing
waste products and excess fluid from the bloodstream.3 There are two types of dialysis treatment:
haemodialysis (HD) and peritoneal dialysis (PD). To calculate the volume of fluid to be removed during
dialysis, a person will be assigned a target weight, which is what they should weigh in the morning if they
receive PD, or at the end of a HD session. Maintaining the correct volume of fluid in the body is essential
for people receiving dialysis.4 Multiple-frequency bioimpedance devices, which measure the fluid status of
people receiving dialysis for CKD, have been proposed for the monitoring of fluid status and for assisting
the decision about the optimum target weight for people receiving dialysis.
Aetiology, pathology and prognosis
The primary function of the kidneys is to remove waste products from the blood and expel them into the
urine. The kidneys are also involved in maintaining blood pressure, regulating the levels of chemicals in
the body, and producing vitamin D and erythropoietin. CKD is a long-term condition in which the ability of
the kidney(s) to function is reduced,3,4 and is defined as either kidney damage (i.e. abnormalities of kidney
function or structure; albuminuria) or glomerular filtration rate (GFR) of < 60 ml/minute/1.73 m2 for at least
3 months.5–9 In healthy people, the level of GFR varies according to age, sex and body size. Normal GFR in
young adults is approximately 120–130 ml/minute/1.73 m2 and declines with age.6,10 Therefore, a GFR of
< 60 ml/minute/1.73 m2 represents a loss of at least half of the normal adult kidney function and, below
this level, the prevalence of CKD complications increases.6 GFR is the ‘gold standard’ for assessment of
kidney function, but its measurement is awkward and calculated creatinine clearance is often used as a
proxy measure of GFR for practical purposes.11
Risk factors for CKD lie within the following categories: (1) factors that increase the risk of kidney damage,
for example age, diabetes mellitus, hypertension, family history; (2) factors that initiate kidney damage, for
example diabetes mellitus, hypertension, autoimmune diseases, primary glomerulopathies; or (3) factors
that cause progressive decline in renal function after onset of kidney disease, for example persistent activity
of underlying disease, elevated blood pressure or blood glucose, diet including a high level of protein/
phosphates, hyperlipidaemia, anaemia, cardiovascular (CV) disease, smoking.6,11
Chronic kidney disease is classified into a continuum of five stages, based on renal function:5,6,11
1. normal or increased GFR
2. early renal insufficiency
3. moderate renal failure
4. severe renal failure
5. kidney failure.
DOI: 10.3310/hta22010 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Scotland et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
In the early stages, kidney disease is often asymptomatic and can be reversible. Most diseases evolve slowly
over time, but rapidly progressive diseases can result in kidney failure within months.12 Kidney failure is
considered to be the most serious outcome of CKD, with symptoms generally caused by reduced kidney
function. Kidney failure is defined as GFR of < 15 ml/minute/1.73 m2, which is accompanied, in most
cases, by signs and symptoms of uraemia, or the need to start kidney replacement therapy (dialysis or
transplantation).6,13–16
The two main types of dialysis that are available are (1) HD and (2) PD. The key factors in determining what
type of dialysis people receive are patients’ preference, availability of options and clinical contraindications.17
In HD, the patient is connected to a dialysis machine containing a semipermeable membrane and dialysis
fluid. The patient’s blood is passed into the machine, in which electrolytes, water and metabolic waste
products in the blood pass across the semipermeable membrane and the waste products are retained in
the dialysis fluid. The most common HD prescription is for 4 hours, three times per week. HD can be given
in hospital, in a satellite unit or at home.18
Peritoneal dialysis involves dialysis fluid (usually containing glucose) being passed into the peritoneal cavity
(via a permanent catheter), where blood vessels lining the cavity draw waste products and excess fluid
from the blood into the dialysis fluid, which is then drained from the cavity. Changing the fluid takes
around 30–40 minutes and is repeated four times daily (continuous ambulatory PD). Alternatively, the
process of fluid exchange can be carried out by a machine overnight (automated PD).3,4,19 It is also possible
to have a combination of manual and automatic exchanges.
Incidence and/or prevalence
The UK Renal Registry 18th Annual Report indicates that the prevalence of patients receiving RRT in 2014
was 913 per million population.20 Prevalence rates were observed to increase across the whole of the UK in
2014. The median age of prevalent patients was 59 years (HD, 67 years; PD, 64 years; and transplant,
53 years). It is worth noting that while half of all patients receiving RRT continued to be aged 40–69 years,
the prevalent population is becoming more elderly, with 16% of patients aged > 75 years. For all ages, the
prevalence rate in men exceeded that in women. The proportion of patients treated with PD, which has been
falling since the early 1990s, was reported to be just 6% in 2014. In general, large variations in prevalence
were observed between centres across the UK. This variation is likely to be explained by the proportion of
patients requiring RRT, but also by the type and quality of clinical care delivered by renal centres.20 In 2014,
21.5% of the prevalent UK population receiving RRT were from minority ethnic groups (23.7% in England).
This figure represented an increase from 14.9% in 2007.21 Ethnic origin has been shown to be associated
with CV events and death in people with end-stage renal disease (ESRD) receiving dialysis.22 In 2014,
917 children with established renal failure were receiving treatment, with 11.2% receiving HD and 9.5%
receiving PD. Of these, 72 children were aged < 4 years. The body composition of children is different from
that of adults23 and requires more frequent monitoring because of their rapid growth.24
Impact of health problem: significance for patients in terms of ill health (burden of
disease) and significance for the NHS
In replacing normal renal function, dialysis needs to remove any excess fluid. When HD is used, this is fluid
that has accumulated in the body since the last dialysis session. In people receiving dialysis, it is vital to
balance fluid status, as both overhydration (also referred to as hypervolaemia or fluid overload) and
underhydration (also referred to as hypovolaemia) are associated with negative outcomes, such as
mortality, intradialytic morbidity and long-term CV complications.19,25–30 Removal of an appropriate volume
of fluid is required to minimise complications caused by being either ‘overhydrated’ or ‘underhydrated’.
Determining when a person is ‘overhydrated’ or ‘underhydrated’ varies depending on the parameter
being used to determine fluid status, and also the cut-off points used to designate overhydration or
underhydration, which differ between studies. When clinical assessment is used, fluid status is classified
qualitatively. Individuals are classified as overhydrated or underhydrated if any corresponding symptoms are
present, and normohydrated (or ‘euvolaemic’) when they are absent.
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Overhydration resulting from removal of too little fluid during dialysis contributes to hypertension, CV
complications, mortality, oedema and left-ventricular hypertrophy.25,26,30–36 A negative association between
higher diastolic blood pressure and residual renal function has also been reported.37
Complications associated with overhydration can be asymptomatic. Oedema, for example, may not be
detectable until interstitial fluid volumes rise to approximately 30% above normal.32 The use of blood
pressure as a surrogate measure for fluid status is not entirely reliable, as factors, such as age and
comorbidities, may cause volume-independent hypertension.
Underhydration, which is caused by excessive volumes of fluid being removed during dialysis, can result in
cramps, intradialytic hypotension and increased recovery time following dialysis.38–41 In addition, there is an
association between reduction of fluid volume in people commencing HD and loss of residual kidney
function, along with a related increase in the risk of morbidity and mortality.42,43
In the UK, on 31 December 2014, there were 58,968 adults receiving RRT (49,842 in England and 2842 in
Wales). Of these, 27,804 patients were receiving dialysis (23,734 in England and 1308 in Wales). In
particular, 86.9% received HD (38.6% in hospital, 44% in satellite units and 4.3% at home), 5.8%
received continuous ambulatory PD and 7% received automated PD.20,44 In addition, 190 children and
young people aged < 18 years were receiving dialysis (103 receiving HD and 87 receiving PD).20,44
The Hospital Episode Statistics for England for the 2014–15 period45 reported 40 finished consultant
episodes and six outpatient attendances for renal dialysis (code X40.1), 2265 finished consultant episodes
and 931 outpatient attendances for PD (code X40.2), 44,457 finished consultant episodes and 16,941
outpatient attendances for HD (code X40.3) and 570 finished consultant episodes and one outpatient
attendance for automated PD (code X40.5). However, there is a possibility that the outpatient data are not
complete, as procedure/intervention is not a mandated field in the outpatients’ data set and coverage
within this field is poor.
Measurement of disease
To enable an assessment of the volume of fluid to be removed during dialysis (known as the ‘ultrafiltration
volume’19), people are assigned a ‘dry weight’ or ‘target weight’ (i.e. euvolaemic), which is commonly
defined as the lowest tolerated post-dialysis weight at which there are minimal signs or symptoms of
underhydration or overhydration. This is achieved via gradual change in post-dialysis weight.25,28,46,47 It can
also be defined as how much a person should weigh in the morning, if receiving PD, or at the end of a HD
session.4 Although the terms ‘dry weight’ and ‘target weight’ are often used interchangeably in clinical
practice and in the published literature, hereafter the term ‘target weight’ will be used in this report.
Target weight is commonly estimated using methods, such as weight gain between dialysis sessions,
pre-dialysis and post-dialysis blood pressure, and subjective symptoms.38 However, methods for assessing
target weight are not precise and it has been reported that approximately half of people who achieve their
‘ideal target weight’ are actually overhydrated.48 Dialysis centres are now increasingly using measurement
devices based on bioimpedance technology, as they are non-invasive, simple and inexpensive.27,49,50
Description of technology(ies) under assessment
Summary of the multiple-frequency bioimpedance devices under assessment
Bioimpedance technology involves assessment of fat-free mass and total body water in people without
significant fluid and electrolyte abnormalities.51 Extracellular water (ECW) and intracellular water (ICW)
contains ions and, therefore, conducts, so its volume measurement is based on its resistance, or
impedance, as cell membranes may act as capacitors at low or intermediate frequencies. There are various
bioimpedance methods, depending on the frequency of current involved and body site of measurement.
Single-frequency bioimpedance analysis uses only one single current (e.g. 50 kHz), multiple-frequency
bioimpedance analysis uses currents of multiple frequencies (e.g. 5, 50 and 100 kHz) and bioimpedance
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spectroscopy uses a range of frequencies (5–1000 kHz).33,52 In particular, bioimpedance spectroscopy uses
an electrical circuit of tissues with parallel resistances and a conductivity theory to take account of
non-conducting elements to measure ECW and ICW volumes.49 In a simple direct current electrical circuit,
resistance is the determining factor of flow at a given voltage. However, when an alternating current is
applied, there is a second factor causing resistance (or ‘reactance’) to flow and it is this factor that provides
the additional metric to enable fluid compartments to be characterised. When an alternating current is
applied to tissue, the resistance measurement is inversely proportional to the total content (ICW and ECW)
between two electrodes on the skin; the reactance, a measure of electrical capacitance, is proportional to
the cell mass in this tissue volume. The various methods of capturing and interpreting this information all
obtain indirect measures of tissue water content and the proportion contained in the intracellular and
extracellular spaces.27,53 The limbs provide a disproportionate amount of information (> 80%), as compared
with the trunk, by way of bioimpedance analysis, as a result of the neurovascular bundles and high muscle
content in proportion to their cross-sectional area. As a result, measuring segments of the body, such as
the lower leg54 or chest wall,55 is sometimes preferred.27
The technologies relevant to this assessment are the Body Composition Monitor [(BCM) Fresenius Medical
Care, Bad Homburg, Germany]; the MultiScan 5000 (Bodystat, Douglas, Isle of Man), the BioScan 920-II
(Maltron International, Essex, UK), the BioScan touch i8 (Maltron International, Essex, UK), and the InBody
S10 (InBody, Seoul, South Korea). Characteristics of these devices are reported below.
Body Composition Monitor
The BCM is a portable, stand-alone device, which uses bioimpedance spectroscopy to estimate a person’s
fluid and nutritional status. The person is placed in a supine position and four electrodes are attached: two
to the back of one hand and two to the foot on the same side of the body. The electrodes are connected
to the BCM device via a cable. The device passes a painless alternating current at 50 different frequencies
(5–1000 kHz) through the body and measures the impedance between the hand and foot, giving relative
impedance values for each frequency. This range of measurements determines the electrical resistances of
the total body water and ECW and allows distinction of ECW and ICW.27,56 The software also calculates
fluid overload using two physiological models. The volume of ECW that should be present based on the
identified amounts of lean and adipose tissue is calculated and compared with the measured volume of
extracellular fluid.57,58 The resulting volume difference between predicted and actual extracellular fluid is
used as a measure of a person’s overhydration volume and is reported by the device in litres.
The BCM is intended to be used as an objective measure of fluid imbalance, to complement clinical
judgement. The associated software uses two validated physiological models to obtain the clinically
relevant parameters: overhydration, lean tissue mass and adipose tissue mass.4,56 There are no restrictions
on the age of the person that this device can be used on. Results from the BCM are available within
2 minutes and are stored on a ‘PatientCard’ automatically, from which it can be loaded onto a database.
Cards are reusable and can be reprogrammed for a new patient, or can have a patient’s data deleted if
they become full, and remain programmed for that patient.
Good agreement has been shown between BCM assessment and current standard methods for measuring
ECW and total body volumes, ICW volume, total fat, fat-free mass and fluid overload in adults and urea
distribution volume in children.24,59 The evidence of association between BCM assessment and improved
patient outcomes is mixed. The Canadian Agency for Drugs and Technologies in Health (CADTH)’s
rapid-response report, published in 2015,53 identified two randomised controlled trials (RCTs) of 131 and
189 participants, respectively60,61 and one observational study of 110 participants, which assessed the use
of the BCM in people receiving HD.62 The report concluded that there was improvement in some patient
outcomes, such as decreased blood pressure and reduced fluid overload, with patient management guided
by BCM assessments, but that the evidence base was limited. A study of people receiving PD compared
assessment of overhydration status using the BCM with assessment using a standard protocol. Results
showed that ECW volume and ECW-to-ICW volume ratio decreased steadily over the 3-month follow-up
period in the group assessed using the BCM, but increased in the group assessed using standard methods.
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In addition, systolic blood pressure (SBP) decreased significantly in the group assessed using the BCM, but
increased significantly in the group assessed using standard methods.63
Further information on the BCM is available from the manufacturer’s website.56
MultiScan 5000
The MultiScan5000 is a portable device that uses bioimpedance spectroscopy to measure at 50 frequencies
(ranging from 5 kHz to 1000 kHz), which are used to calculate body composition and hydration by a
mathematical model called Cole–Cole analysis (also used in the BCM models). Values for ECW, ICW, total
body water, and volume of over/underhydration are obtained from similar physiological models as used in
the BCM.57,58
The volume of overhydration output is recommended for the assessment of hydration status in people
aged 18–70 years. Outside this age range, this output can be used to track relative changes over time.
In addition, the ratio of total body water to ECW volume calculated by the device (called the ‘prediction
marker’) can be used as an additional marker to track hydration status over time in all age groups. The
device can measure body segments, depending on the placement of the electrodes,64 and provides a
bioelectrical impedance vector analysis. Additional parameters related to body composition, such as fat
weight, lean weight, skeletal muscle mass and body cell mass, can also be estimated. These parameters
can be used to estimate nutritional status and, therefore, help to identify malnutrition status in people with
CKD who are treated with dialysis. Further information on the MultiScan 5000 device can be found on the
product webpage.64
BioScan 920-II
The BioScan 920-II is a portable multiple-frequency bioimpedance analysis device, which measures at 5,
50, 100 and 200 kHz. The eight electrodes allow monitoring of fluid changes in the whole body, thorax,
trunk, legs or arms. All data are recorded and displayed immediately for analysis by the system. Alongside
the standard output parameters related to hydration status [target water (minimum/maximum), target
weight, target weight (minimum/maximum), extracellular fluid, ECW volume, ICW volume, total body
water, ECW (%), ICW (%), total body water (%), ECW-to-ICW volume ratio, plasma fluid (intravascular),
fat-free mass hydration], the device estimates additional parameters related to body composition
[comprising body mass index (BMI), body density, body cell mass, protein mass, fat mass, fat-free mass
and glycogen mass] and mineral content.
These parameters can be used to evaluate nutritional status and help to identify malnutrition in people
with CKD receiving dialysis. Further information can be found on the product webpage.65 The use of the
BioScan 920-II is recommended for people aged 5–99 years. A version of the BioScan 920-II device
(the BioScan 920-II-P) is also available for monitoring hydration status in preterm, neonatal and paediatric
patients (for use from 23 weeks’ gestational age up to 18 years).
BioScan touch i8
According to the manufacturer, an updated version of the BioScan 920-II device, the BioScan touch i8 with
an updated user interface, is due to be released during the course of this assessment. As with the BioScan
920-II, it is anticipated that there will be two versions: one suitable for people aged 0–18 years and one
suitable for people aged 5–99 years.
InBody S10
The InBody S10 is a portable device that uses a direct multiple-frequency bioimpedance analysis method to
provide measurements across six different frequencies (1, 5, 50, 250, 500 and 1000 kHz). Measurements of
five segments of the body are available: right arm, left arm, trunk, right leg and left leg. Hydration-related
outputs include water volumes (ECW, ICW), ratio of extracellular to total body water and history of body
water condition.
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These parameters are estimated along with a suggested standard range of values to facilitate identification
of overhydrated or underhydrated individuals. In addition, the InBody S10 provides estimates related to
body composition such as body cell mass, basal metabolic rate, bone mineral content, skeletal muscle
mass, fat-free mass, and BMI. These parameters can be used to evaluate nutritional status and help to
identify malnutrition in people with CKD who are on dialysis. A full list of outputs can be found on the
product webpage.66 The use of the InBody S10 device is recommended for people aged 3–99 years.
Identification of important subgroups
This assessment focuses on people with CKD who are treated with HD or PD.
Relevant patient subgroups may include:
l people who are treated with HD
l people who are treated with PD
l people of different ethnic origins
l people for whom recommended configurations of electrodes cannot be used or who cannot assume
the required positions for measurements to be made
l people at extremes of body composition measurements
l children aged < 5 years who may require more frequent monitoring.
Current usage in the NHS
In the UK, multiple-frequency bioimpedance devices are used in some renal centres alongside clinical
judgement to estimate fluid levels in patients receiving HD or PD. The Leeds Teaching Hospitals NHS Trust,
for example, has prepared a standard operating procedure document for using the BCM in UK clinical
practice.4,67 However, there is currently no national guidance in England and Wales on the role and
adoption of these devices in clinical practice.
Comparators
In UK clinical practice, standard clinical assessment (without the use of bioimpedance devices) is used to
determine fluid status and set, or adjust, target weights for people with CKD who are treated with dialysis.
This may include the consideration of clinical parameters such as blood pressure measurements, changes in
weight, the presence of oedema, assessment of residual renal function, any pre-existing CV conditions, and
any patient-reported symptoms, intradialytic or interdialytic, of overhydration or underhydration (e.g. cramps,
fatigue, diarrhoea, nausea, dizziness, fainting, breathlessness, decreased appetite or visual disturbances).
It is worth pointing out that clinical assessment does not directly measure fluid levels in the body to
identify if a person is over- or underhydrated, but rather relies on the presence of symptoms and signs of
overhydration and underhydration. This approach could, therefore, miss individuals who are asymptomatic
despite having an excess or deficit of body water. For example, symptoms such as oedema may not appear
until individuals are substantially overhydrated and people with fluid overload do not always exhibit high
blood pressure.
Additionally, some clinical features are only surrogate markers for fluid overload and can, therefore, be the
result of other unrelated causes. This could lead to fluid levels being inappropriately adjusted. For example,
a response to high blood pressure assumed to be caused by fluid overload (but actually caused by other
factors) may involve the removal of increasing volumes of fluid during dialysis, which, in turn, may lead to
underhydration with potential loss of residual renal function.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM(S)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Care pathways
Figure 1 illustrates the management of stage 5 CKD currently recommended by the National Institute for
Health and Care Excellence (NICE).68
FIGURE 1 Management of stage 5 CKD. Reproduced with permission from NICE. Management of Stage 5 Chronic
Kidney Disease: NICE Pathway. London: NICE; 2017.68
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Chapter 2 Assessment of clinical effectiveness
Methods for systematic review of effectiveness
An objective synthesis of the evidence of the clinical effectiveness of multiple-frequency bioimpedance devices
in comparison with standard clinical assessment for fluid management in people with CKD having dialysis was
conducted. The evidence synthesis was conducted in accordance with the general principles of the Centre for
Reviews and Dissemination guidance for conducting reviews in health care,69 the recommendations of the
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.070 and the NICE Diagnostics
Assessment Programme Manual.71 The methods for this assessment were prespecified in a research protocol
(www.crd.york.ac.uk/prospero/display_record.php?RecordID=41785; last accessed 12 December 2017).
Identification of studies
Comprehensive electronic searches were conducted to identify relevant reports of published studies. Highly
sensitive search strategies were designed, including appropriate subject headings and text-word terms, to
retrieve studies that assessed the selected bioimpedance devices for CKD patients receiving dialysis. Three
facets were combined using the Boolean operator AND: CKD, RRT and devices. There were no date or
language restrictions. MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Science
Citation Index and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for primary
studies, while the Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of
Effects (DARE) and the Health Technology Assessment database were searched for reports of evidence
syntheses. The searches were undertaken during the period of 27 June to 4 July 2016. The MEDLINE and
EMBASE searches were rerun on 10 October 2016 to identify any recent reports. An additional search in
MEDLINE and EMBASE was undertaken on 27 September 2016 to identify any published reports on
validation of the devices that had not been identified by the main clinical effectiveness searches.
Reference lists of all included studies were perused in order to identify additional potentially relevant
reports. The expert panel provided details of any additional potentially relevant citations.
Searches for recent conference abstracts (2014–16) were also undertaken and included the following annual
conferences: European Renal Association – European Dialysis and Transplant Association (ERA-EDTA),
Kidney Week (American Society of Nephrology) and the Annual Dialysis Conference.
Ongoing studies were identified through searching ClinicalTrials.gov, the European Union Clinical Trials
Register and the World Health Organization’s International Clinical Trials Registry. Websites of professional
organisations and health technology agencies were checked to identify additional reports. Full details of
the search strategies used are presented in Appendix 1.
Inclusion and exclusion criteria
Studies fulfilling the following criteria were eligible for inclusion in this assessment.
Population
People with CKD treated with HD or PD.
Interventions
The multiple-frequency bioimpedance devices considered in this assessment were:
l BCM
l MultiScan 5000
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l BioScan 920-II and BioScan touch i8
l InBody S10.
Comparator
The comparator considered in this assessment was standard clinical assessment, which takes account of
the following parameters:
l blood pressure
l presence of oedema
l changes in weight
l residual renal function
l pre-existing CV conditions
l any patient-reported symptoms of overhydration or underhydration, for example cramps, fatigue,
nausea, dizziness, breathlessness, decreased appetite or visual disturbances.
Outcomes
The following outcome measures were considered:
l intermediate measures, including –
¢ number and length of HD sessions
¢ number of unplanned hospital visits/admissions as a result of fluid overload or dehydration
¢ use of antihypertensive medication
¢ incidence of anaemia
¢ blood pressure
¢ left ventricular hypertrophy
¢ left ventricular mass index (LVMI)
¢ arterial stiffness
¢ incidence of overhydration or underhydration
¢ changes of dialysis modality (from PD to HD) because of fluid overload
¢ adherence with recommended fluid intake.
l clinical outcomes, including –
¢ incidence of CV events (including stroke and heart attack)
¢ mortality
¢ residual renal function
¢ incidence of oedema
¢ incidence of peritonitis
¢ adverse effects associated with hypotensive episodes (including cramps, fatigue, diarrhoea, nausea,
dizziness and fainting).
l patient-reported outcomes, including –
¢ post-dialysis recovery time and fatigue
¢ health-related quality of life.
One further relevant outcome not specified in the scope or protocol was also considered because of its
clinical importance: achievement of target weight.
Study design
Priority was given to RCTs assessing multiple-frequency bioimpedance devices versus standard clinical
assessment and RCTs comparing the effectiveness of one device with that of another. To supplement the
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evidence provided by RCTs, we also included non-randomised evidence, solely consisting of observational/
cohort studies. As there was a large body of non-randomised evidence, which was not manageable in the
time frame of this assessment, we decided to focus exclusively on non-randomised studies with a sample
size of at least 100 participants, which assessed the hydration status of people with CKD receiving dialysis.
Of the non-randomised studies, which were excluded based on these last criteria, three studies (published
in four papers) with < 100 participants focused on paediatric populations.24,72–74 Appendix 2 presents the
characteristics of these studies. In the list of non-randomised studies that were not deemed suitable for
inclusion based on the above criteria, no UK-based studies, studies that included any of the specified
devices (other than the BCM) or studies reporting relevant outcomes not otherwise described in the report
were identified.
The following types of studies were also excluded from this assessment:
l narrative reviews, editorials and opinions
l case reports
l conference abstracts for which a full publication or further methodological information could not
be found
l non-English-language reports for which a translation could not be organised
l studies reporting cross-sectional data only.
Data extraction strategy
One reviewer (MC) screened the titles and abstracts identified by the search strategies. A second reviewer
(MB) independently screened a random sample of 10% of the titles and abstracts. Owing to time
constraints, this strategy differed from that detailed in the protocol, which stated that two reviewers would
independently screen all titles and abstracts.
A data extraction form was designed and piloted specifically for this assessment (see Appendix 3).
One reviewer (MC or MS) extracted information on characteristics of studies and participants, details of
interventions and comparators (when applicable) and relevant outcome measures. All extracted data were
cross-checked by a second reviewer (DC, MC, MB or MS). Any disagreements were resolved by discussion
between reviewers.
Assessment of risk of bias in included studies
The standard Cochrane risk-of-bias tool was used to assess the risk of bias in randomised trials (see
Appendix 4).70 One reviewer (MC) rated the risk of bias in each included RCT and the results of these
assessments were cross-checked by a second reviewer (DC or MS). There were no disagreements between
reviewers. Studies were not included or excluded based on the risk of bias rating. The Cochrane risk-of-bias
tool incorporates the following domains: sequence generation, allocation concealment, blinding, incomplete
outcome data and selective outcome reporting. Assessment of other sources of bias was based mainly upon
the source of funding for the conduct of the study and potential links with the manufacturers of the devices
under investigation. Individual risk-of-bias domains were rated as being at a high, low or unclear risk of bias.
Overall classification of studies was based on the assessment of three key domains: sequence generation,
allocation concealment and blinding of outcome assessor. Studies were rated as being at a high risk of
bias if one or more key domains were rated as being at a high risk of bias; an unclear risk of bias if one or
more key domains were rated as being at an unclear risk of bias; or a low risk of bias if all key domains
were rated as being at a low risk of bias.
Risk of bias of cohort studies was assessed using a modified version of a 17-item checklist previously
developed by our research team (see Appendix 5). The checklist was originally adapted from several
sources and developed through a partnership with the Review Body for Interventional Procedures (ReBIP)
for NICE. The case series tool assessed the following domains: bias and generalisability, sample definition
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and selection, description of the intervention, outcome assessment, adequacy of follow-up and performance
of statistical analyses. Individual items were rated as ‘yes’, ‘no’ or ‘unclear’. A rating of ‘yes’ indicated the
study as being at a low risk of bias. When available, NCT records (published on clinicaltrials.gov) were checked
for stated outcomes. We had originally intended to use the ROBINS-I (Risk Of Bias in Non-randomised studies
of Interventions) tool75 to assess the risk of bias in the included non-randomised studies. However, as a
result of time constraints, and the fact that many studies were non-comparative cohort studies, we opted for
the use of the ReBIP tool.
Data analysis
The general approach recommended by the Cochrane Collaboration was used for data analysis and
synthesis.70 When possible, for binary outcomes, the DerSimonian and Laird method was used to pool
hazard ratios (HRs) derived from each study, with the estimate of heterogeneity taken from the
Mantel–Haenszel model. A random-effects model was used to calculate the pooled estimates of effect.
For continuous outcomes, mean differences between groups were pooled.
The statistical analyses focused on the five separate outcome measures for which consistent data were
reported by at least two studies and were suitable for combining across studies: mortality, SBP, arterial
stiffness, absolute overhydration and relative overhydration (ROH). Other relevant outcomes that were
reported, but not meta-analysed because they were inconsistently reported across studies, were achievement
of target (dry) weight (reported as proportion of patients within 1.1 kg of bioimpedance-recommended dry
weight, dry weight according to the BCM and proportion of patients reaching between 1 litre above and
2 litres below post-dialysis fluid overload specified by the BCM, respectively),60,61,76 hospitalisation (number of
patients hospitalised at least once, all-cause hospitalisation events or hospitalisation events caused by new
CV events, respectively),61,76,77 left ventricular hypertrophy,77 LVMI,77 incidence of CV events,76 adverse effects
associated with hypotensive episodes (reported as hypotension/cramp events/patient/year, frequency of
hypotensive events, hypotension as an intradialysis complication or frequency of intradialytic hypotensive
events/1000 dialysis sessions, respectively)60,61,76,77 and fatigue.76
Of the five outcome measures that were meta-analysed, mortality was reported in three trials.60,61,76 Two
trials60,76 reported the HR at 12 months and, for the trial by Ponce et al.,61 this was computed by obtaining
the probability of death in both the treatment group and the control group, and using the formula r = –ln
(1 – p) to estimate the hazard rate in the two groups. The HR was then calculated from the estimated
hazard rates. The standard error (SE) was estimated using the method described by Parmar et al.78
The remaining four outcomes were all continuous measures, so mean differences between the treatment
and control groups were pooled from the included trials and a 95% confidence interval (CI) was calculated
to test whether or not the pooled summary effect showed a significant difference between treatment and
control.
Heterogeneity across trials was explored by visual inspection of forest plots and assessed by means of the
chi-squared test and I2-statistic.
There are five trials60,61,63,76,77 in the meta-analyses. Four of these trials60,63,76,77 randomised at the individual
level, while Ponce et al.61 randomised centres rather than individual patients. In order to include the trial by
Ponce et al.61 in our meta-analyses, the method described by Fawzi et al.79 was used to inflate the SE.
In order to include a cluster randomised trial in a meta-analysis it is necessary to allow for the correlation of
participants within clusters. This would be done by inflating the variance of the cluster randomised trial by
the ‘design factor’. The design factor is 1 + (m – 1)ρ, in which m is the number of clusters and ρ is the
intracluster correlation coefficient.
Many trials fail to report estimates of the design effect and, therefore, different strategies are used to
obtain this required information.
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The meta-analysis by Fawzi et al.79 examined the relationship of vitamin A supplementation and child
mortality. In Fawzi et al.,79 there were four cluster randomised trials that did not adjust for clustering.
The authors decided to increase the variance of the unadjusted trials by 30%. The Fawzi et al.79 adjustment
referred to in this report is therefore to increase the variances of the estimated intervention effects by an
arbitrary amount of 30% as previously used.
A subgroup analysis was performed according to the type of dialysis: HD versus PD. Only the Luo et al.
trial63 assessed PD, whereas the remaining four trials assessed HD. We were able to conduct subgroup
analyses only for the following outcome measures: SBP and absolute hydration.
Results
Performance of multiple-frequency bioimpedance devices
A formal evaluation of the accuracy and validation of the multiple-frequency bioimpedance devices under
assessment was beyond the scope of this assessment. However, information on the validation and
accuracy of the specified devices was gathered from the available literature. Only information on the
validation of the BCM was found in the current literature.
Wabel et al.59 reviewed a number of studies on HD patients comparing the BCM against standard clinical
methods for measuring extracellular and total body water, as well as ICW volume. The authors concluded
that there was good agreement between the BCM and the standard clinical measurements of fluid overload.
Chen et al.80 assessed the relationship between the dry weight determined by clinical evaluation and the
‘normally hydrated’ weight estimated by the BCM from serial follow-up data. The authors used serial
measurements of six fluid parameters in the same HD patients to demonstrate that intraperson precision of
the device was at an acceptable level of reliability for clinical use.
No studies have validated the BCM in people receiving PD. The BCM manufacturer maintains that the
method used is valid across both forms of dialysis.4
Quantity of evidence available
Records retrieved by the database searches totalled 4106. In addition, 18 conference abstracts were
obtained by searching the selected recent conference abstracts, giving a total of 4124 records. After
de-duplication, 2592 abstracts were screened for relevance. Of these, 129 were selected for full-text
assessment, from which 15 met our inclusion criteria (Figure 2). All 15 studies involved use of the BCM
and none enrolled paediatric populations. A list of all excluded studies is presented in Appendix 6 together
with the main reasons for exclusion.
Characteristics of the included studies
A total of five RCTs (published in six papers60,61,63,76,77,81) and eight non-randomised studies (published in
nine papers30,50,82–88) were included in the review of clinical effectiveness. There was some question over
whether or not the RCTs by Onofriescu et al.81 and Onofriescu et al.60 may be reporting the same trial or
outcomes from an overlapping patient population. The principal investigators of each trial were contacted,
but no replies were forthcoming. The decision was taken to include Onofriescu et al.60 as the primary study
and Onofriescu et al.81 as a secondary publication. The Onofriescu et al.60 study reports more relevant
outcomes and is more recent. Similarly, there is a possibility that the non-randomised studies by O’Lone
et al.82 and Oei et al.83 may involve an overlapping patient population, as both studies recruited at the
same centre in the same time period. The corresponding authors of both studies were contacted for
further clarification, but no replies were received. It is therefore unclear whether or not the studies are
completely separate. Both studies have been included in the review, but only the results of the O’Lone
et al.82 study have been used for our cost-effectiveness analyses. Characteristics of the included studies are
detailed in Appendix 7.
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Randomised controlled trials
All five included RCTs were available in full-text format.60,61,63,76,77 The BCM was the multiple-frequency
device used in all five trials. One trial was conducted in Romania,60 one trial in Taiwan,76 one in Turkey77
and one in Portugal,61 and the remaining trial did not provide this information.63 One trial recruited
patients from 23 dialysis centres,61 one trial recruited from two dialysis centres,77 another trial from six
dialysis centres76 and one trial recruited from a single dialysis centre.60 In the remaining trial, it was unclear
whether patients were recruited from a single dialysis centre or from multiple dialysis centres.63 Four trials
enrolled solely patients who were treated with HD,60,61,76,77 and one trial enrolled continuous ambulatory
PD patients.63 All five trials involved dialysis in a hospital setting. The multiple-frequency bioimpedance
device used for assessment of fluid status by all five trials was the BCM. All five trials included only adults
aged ≥ 18 years.60,61,63,76,77 The main exclusion criteria reported in the trials, which assessed patients
receiving HD, were coronary stents or pacemakers;76,77 metallic devices in the body, such as joint
prostheses;60,61,76,77 limb amputations;60,76,77 and pregnancy.60,61 One trial, which assessed PD patients,63
excluded those who had been on one or two exchanges per day because of economic limitation and
those patients with acute infection and CV events in the month prior to enrolment.
The length of follow-up of the included trials ranged from 3 months61 to 2.5 years,60 with two trials
reporting a follow-up period of 12 months.61,77 In the case of the trial by Luo et al.,63 the authors decided
to terminate follow-up at 3 months rather than at 6 months, as originally planned, as the emerging
differences between the groups and the adverse effect of fluid overload led the decision to extend the
follow-up period to be considered unethical.
Three of the five trials had links to Fresenius Medical Care, the company that manufactures the BCM,60,61,77
albeit two of these trials reported that Fresenius had no involvement in the design or conduct of the
trial.60,77 Two trials were supported by grants from independent sources.63,76
Database searches
MEDLINE/EMBASE, n = 3187
Science Citation Index, n = 870
CENTRAL, n = 46
CDSR, n = 2
DARE, n = 1
Conference abstracts, n = 18
Total, n = 4124
After de-duplication, n = 2592
Excluded at screening
(n = 2463)
Selected for full-text screening
Full-text papers
(n = 129)
Included at full-text assessment
(n = 15)
Excluded at full-text assessment
(n = 114)
• Ineligible study design, n = 34
• Ineligible device, n = 67
• Ineligible participants, n = 3
• Ineligible outcomes, n = 8
• Non-English language and unable
   to obtain translation, n = 2
• RCTs, n = 6
• Non-RCTs, n = 9
FIGURE 2 Flow diagram outlining the study selection process.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Non-randomised studies
The eight non-randomised studies were reported in nine full-text papers,30,50,82–88 with the study by O’Lone
et al.82 also reported in a secondary study with an additional 51 participants and a 21-month longer
follow-up period.84 The BCM was the multiple-frequency device used in all eight studies. None of these
studies enrolled paediatric populations. Two studies were conducted in the UK,82,83 two in Seoul, South
Korea,50,85 and one each in Spain,86 Poland,87 Romania88 and Europe.30 Three studies were multicentred30,85,86
and the remaining five studies were conducted in single dialysis centres.50,82,83,87,88 Six studies involved
patients receiving HD30,50,85–88 and the remaining two studies involved solely patients treated with PD.82,83
The length of follow-up in the eight non-randomised studies ranged from 16 weeks85 to 3.5 years.30 Four
studies reported median follow-up periods of 24 months,50 23.9 months,83 27 months82 and 66.2 months.88
O’Lone et al.82 further specified that patients were enrolled between January 2008 and March 2012 and
followed up until September 2012, with follow-up continuing until June 2014. Three studies had no
apparent links with Fresenius Medical Care50,83,87 and the other five studies reported either funding from
Fresenius Medical Care85 or some form of connection with the company.30,82,86,88
Two studies involved blood pressure being taken after 10 minutes’ rest or recumbence60,76 and one study
after 5 minutes’ rest.63 The study by Hur et al.77 involved hourly ambulatory blood pressure measurement
over a 48-hour period from the start of one dialysis session until the following session. The technique used
to measure blood pressure in the remaining study is unclear.61
Characteristics of participants
Table 1 summarises the baseline characteristics of the randomised and non-randomised studies included in
this assessment.
TABLE 1 Summary of baseline characteristics of included studies
Characteristic
Included studies (N= 13)
RCTs (N= 5) NRS (N= 8)
Enrolled 1032 (n = 5) 993 (n = 3)
Randomised 939 (n= 5) N/A
Analysed 904 (n= 5) 4915 (n = 8)a
Age (years): median (range) of means 60 (51.7–66.3) (n= 5) 61.9 (53.8–68.2) (n= 7)
Sex (male): median (range) % 52.7 (46.3–76.2) (n = 5) 62 (52.5–64.7) (n= 7)
Diabetes mellitus: median (range) % of participants 27.5 (9.5–39.2) (n = 5) 29.9 (10.4–37) (n= 6)
Dialysis vintage (months): median (range) of means 61.9 (34.2–105.5) (n= 3) 44.7 (10.7–66)b (n= 4)
Dialysis modality
HD 867 (n= 4) 4050 (n = 6)
Of which was haemodiafiltration 218 (n= 1) 1305 (n = 1)
PD 165 (n= 1) 865 (n = 2)
N/A, not applicable; NRS, non-randomised study.
a Not including the 51 patients reported by Santhakumaran et al.,84 who were additional to the original O’Lone et al.82 study.
b Hoppe et al.87 converted from 42.8 weeks to 10.7 months (42.8/4); and Kim et al.85 converted from 5.5 years to
66 months (5.5 × 12).
Note
Dialysis vintage refers to the length of time on dialysis. n refers to the number of studies reporting the pertinent data; not
all studies reported all data.
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Randomised controlled trials
The five RCTs60,61,63,76,77 randomised a total of 939 participants: 469 to bioimpedance measurements and
470 to standard clinical assessment.
The mean age for each intervention group was reported in all five RCTs60,61,63,76,77 and ranged from
50.9 years77 to 65.8 years61 in the bioimpedance intervention group and from 52.5 years77 to 66.7 years61
in the standard clinical assessment group.
The five RCTs each reported the proportion of males and females for each intervention group.60,61,63,76,77
Study populations tended to involve approximately equal proportions of men and women, with the
exception of the studies by Hur et al.77 (69% men) and Ponce et al.61 (76.2% men). The proportion of men
ranged from 43.6%63 to 71.3%61 in the bioimpedance intervention group, and from 48.8%63 to 81.8%61
in the standard clinical assessment group. The prevalence of diabetes mellitus among participants varied
across trials. The proportion of participants with diabetes mellitus was reported by all five trials60,61,63,76,77
and ranged from 10%60 to 39.8%61 in the bioimpedance intervention group, and from 9%60 to 38.6%61
in the standard clinical assessment group. The mean dialysis vintage was reported in three RCTs60,63,77
and ranged from 35.2 months63 to 107 months57 in the bioimpedance assessment group, and from
33.2 months to 104 months60 in the control group.
Non-randomised studies
The eight included non-randomised cohort studies assessed a total of 4915 participants.30,50,82,83,85–88
The studies were of two main types: in some studies, the BCM was used to classify patients into groups
(e.g. overhydrated/non-overhydrated) and then outcomes were compared across the groups;30,88 and in
other studies, the BCM was used as a basis for adjustment of dry weight50,82,85,86 or to obtain hydration
parameters.83,87 Six cohort studies reported the mean age of participants, which ranged from 53.8 to
68.2 years.30,50,85–88 The two remaining cohort studies reported the median ages of participants of 57.9 years83
and 57 years.82 Three studies reported the mean age for normohydrated and overhydrated groups.30,50,85
The age range was 55.9 years85 to 66 years30 for the normohydrated groups and 58.4 years85 to 65.6 years50
for the overhydrated groups, respectively. The proportion of men in the seven studies reporting this
information50,82,83,85–88 ranged from 52.5%88 to 64.7%87 and was, in general, higher than reported in the
included RCTs. The proportion of participants with diabetes mellitus was reported by six of the observational
studies30,82,83,86–88 and ranged from 10.4%88 to 37%.83 The mean dialysis vintage was reported by half of the
studies and ranged from 10.7 months87 to 66 months.85 In the study by Hoppe et al.,87 participants were split
into those with a short-dialysis vintage (≤ 24 months) or a long-dialysis vintage (> 24 months), with mean
dialysis vintage being 9.3 weeks and 76.2 weeks, respectively. The trial by Kim et al.85 reported mean dialysis
vintage separately for dehydrated, normohydrated and hyperhydrated participants, which was 6.0, 4.1 and
5.7 years, respectively.
Frequency of Body Composition Monitor measurements
Randomised controlled trials
The frequency of measurements using the BCM in the RCTs was at least every 3 months. The most
frequent use of the device was twice monthly in the bioimpedance intervention group (and every
3 months in the control group).77 Three-month assessments were reported by Onofriescu et al.;60
monthly assessments by Huan-Sheng et al.76 and Ponce et al.61 and 6-week assessments by Luo et al.63
Non-randomised studies
The frequency of BCM assessments in the non-randomised studies varied across studies: one study
involved only one assessment within the first week of dialysis;50 two studies involved three assessments
per week;30,88 another study involved weekly assessments;87 two other studies involved monthly
assessments;85,86 one study involved quarterly assessments;82 and the remaining study did not report the
frequency of the BCM use.83
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Standard clinical assessment: randomised controlled trials
In general, the type of standard clinical assessment in the included RCTs was not consistently reported
across the included trials. Only one trial provided details of its control intervention; Onofriescu et al.60
reported that:
The target dry weight was set according to clinical criteria by the attending physicians from the dialysis
unit; i.e. target BP [blood pressure] equal to or less than 140/90 mm Hg, absence of oedema, and
absence of intra-dialytic or inter-dialytic hypotension or other symptoms.
Onofriescu et al.60
In the other four trials,61,63,76,77 details of the assessment in the control group were not reported. Bioimpedance
analysis was carried out on both intervention and control groups of all studies at the frequencies reported in
Frequency of Body Composition Monitor measurements (with the difference between the groups being that
treated physicians in the control groups were blinded to the results). It was not explicitly stated by any of the
studies whether or not standard clinical assessment was also carried out at these visits, and no further
information on the frequency of standard clinical assessments was reported.
Risk of bias
Randomised controlled trials
Figure 3 presents the summary of risk-of-bias assessments for all included trials. Risk-of-bias assessments of
individual studies are presented in Figure 4.
According to the prespecified criteria for the assessment of the overall risk of bias, one of the five RCTs
was rated as being at a high risk of bias,63 and the remaining four trials did not provide sufficient
information on which to make a robust judgement.60,61,76,77
Selection bias
Two trials reported sufficient information on which to make a full assessment of selection bias. Full details
of allocation concealment were not reported, but the method of generation of sequence (i.e. random
generation by computer) implies that the study personnel would be unable to predict the allocation, thus
fulfilling the criterion of low risk. The trial by Ponce et al.61 involved randomisation of centres, as opposed
to randomisation of individuals within centres. No details of the randomisation process were reported.
The remaining two trials merely stated that they were randomised trials, but provided no details of how
randomisation was achieved.60,63,77
Performance and detection bias
Only one trial reported that participants were blinded.60 One trial reported that participants were not
blinded.63 In the remaining three trials, both the intervention group and the control group received BCM
assessments but the measurements were used to assess the intervention group only.61,76,77
0% 25% 50% 75% 100%
Other bias
Selective reporting (reporting bias)
Incomplete outcome data (attrition bias)
Blinding of outcome assessment (detection bias)
Blinding of participants and personnel (performance bias)
Allocation concealment (selection bias)
Random sequence generation (selection bias)
Low
Unclear
High
Risk of bias
FIGURE 3 Summary of risk-of-bias assessments for all included trials.
DOI: 10.3310/hta22010 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Scotland et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Two trials reported that outcome assessors were blinded.61,77 Luo et al.63 reported that patients, investigators
and dialysis staff were not blinded to treatment assignment; the trial was, therefore, rated as being at a high
risk of bias for the blinding of outcome assessors domain and for overall risk. In the trials by Huan-Sheng
et al.76 and Onofriescu et al.,60 it was unclear whether or not outcome assessors had been blinded.
Attrition bias
One trial reported a low number of dropouts63 and was, therefore, rated as being at a low risk of attrition
bias. The remaining four studies were rated as being at a high risk of bias because of the high number of
participants who dropped out.60,61,76,77 It is worth noting that, in the Ponce et al.61 trial, 29 out of 101
(28.7%) and 42 out of 88 (47.7%) discontinuations were observed in the intervention and control groups,
respectively. The reasons given for terminating the trial prematurely were as follows: ‘no valid data available
within the time frame, death, transplant or transfer to another clinic’. The proportion of participants within
each of these categories and distribution of dropouts across centres were, however, not given.
Reporting bias
In four of the five included trials, the outcomes reported were in accordance with those specified in the
respective methods section.60,61,63,76 The trial by Hur et al.77 was rated as being at a high risk of reporting
bias, as some outcome measures that had not been previously specified were reported, such as iron dose,
right ventricle end-diastolic diameter, urine output, triglyceride levels and cholesterol.
Other bias
Three RCTs reported links with Fresenius Medical Care (either in the form of funding, as an honorary
speaker or through employment) and were rated as being at a high risk of ‘other bias’.60,61,77 Two trials
were supported by grants from independent sources.63,76 No other sources of bias were apparent in the
included trials.
? ? ? + – + –
+ + + ? – – –
? ? – – + + +
? ? ? + – – –
+ + ? ? – + +
Ponce et al., 201461
Onofriescu et al., 201460
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FIGURE 4 Risk-of-bias assessments of individual studies.
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Non-randomised studies
Figure 5 presents a summary of the risk-of-bias assessments for the included non-randomised cohort
studies. The results of individual study-level assessments are presented in Appendix 8.
The majority of studies identified important prognostic factors, provided information on non-respondents/
dropouts, included a sufficient length of follow-up, used objective outcome measures, considered
important outcomes, delivered the intervention in an appropriate setting and by an experienced person,
clearly defined the intervention, collected data prospectively, clearly defined the inclusion/exclusion criteria
and involved a representative sample. None of the studies involved blinding of participants or study
personnel. Two studies enrolled participants who entered the study at varying points in their disease
progression. The study by Hoppe et al.87 compared short- versus long-dialysis vintage and the study by
O’Lone et al.82 compared incident and prevalent patients. The majority of studies failed to provide
information on the characteristics of participants who withdrew or did not complete follow-up.30,50,82,83,85,88
Clinical effectiveness results
Data on the following relevant outcomes were not reported by any of the included studies: number and
length of HD sessions, number of unplanned hospital visits/admissions as a result of fluid overload or
dehydration, incidence of anaemia, incidence of overhydration or underhydration (although absolute
overhydration and ROH were reported), changes of dialysis modality as a result of fluid overload,
adherence with recommended fluid intake, incidence of oedema, incidence of peritonitis and health-
related quality of life.
Evidence from randomised controlled trials: meta-analyses results
Meta-analyses of relevant clinical outcomes were performed, when appropriate, using random-effects
models. As the trial by Ponce et al.61 is a cluster randomised trial, the variance was inflated by the method
used in Fawzi et al.79 to allow it be included in the meta-analysis. The uninflated summary data for the
Ponce et al.61 trial are presented in Table 2.
0 10 20 30 40 50 60 70 80 90 100
Representative sample
Inclusion/exclusion criteria clearly defined
Participants in similar point in disease progression
Selection of patients consecutive
Data collection undertaken prospectively
Intervention clearly defined
Intervention delivered by an experienced person
Intervention delivered in an appropriate setting
Important outcomes considered
Objective outcome measures used
Blind assessment of main outcome
Follow-up long enough
Information on non-respondents, dropouts
Withdrawals likely to introduce bias
Similar length of follow-up between groups
Important prognostic factors identified
Analysis adjusted for confounding factors
Yes
No
Unclear
FIGURE 5 Summary risk of bias for non-randomised cohort studies.
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Full details of the relevant outcome measures extracted from the included RCTs are presented in Appendix 9.
Blood pressure
Five trials (one rated as being at a high risk of bias and four as being at an unclear risk of bias) reported SBP
measurements, which were included in a meta-analysis.60,61,63,76,77 Figure 6 shows that SBP was lower in
participants who underwent bioimpedance measurements using the BCM device than in those assessed by
standard clinical assessment, but the difference was not statistically significant (mean difference –2.46 mmHg,
95% CI –5.07 to 0.15 mmHg; p = 0.06, I2 = 0%).
Arterial stiffness
Two trials (both rated as being at an unclear risk of bias) reported arterial stiffness results, which were
included in a meta-analysis.60,77 The measurement of pulse wave velocity (PWV) is generally accepted
as the most simple, non-invasive, robust and reproducible method of determining arterial stiffness, with
carotid–femoral PWV regarded as the gold standard. The PWV increases from 4–5 m/second in the
ascending aorta to 5–6 m/s in the abdominal aorta and 8–9 m/s in the iliac and femoral arteries.89 Normal
values, using standardised calculation of PWV, are a mean of 7.2 m/s in people aged 40–49 years and
8.3 m/s in people aged 50–59 years.90 Figure 7 shows that arterial stiffness (as assessed by carotid–femoral
PWV) was lower, but not statistically significantly lower, in the bioimpedance assessment group than that
in the standard clinical assessment group (mean difference –1.18 m/s, 95% CI –3.14 to 0.78 m/s; p = 0.24,
I2 = 92%). Substantial statistical heterogeneity between trials was observed.
Mortality
Three of the included trials (all rated as being at an unclear risk of bias) reported mortality data.60,61,76 As
mortality was reported with a HR, the log-HR and log-SE for the three trials were input manually (Table 3).
A total of 19 out of 311 (6.1%) participants in the bioimpedance assessment group and 23 out of 307
(7.5%) participants in the standard clinical assessment group died. Figure 8 shows that, compared with
standard clinical assessment, the use of the BCM had no significant effects on mortality (HR 0.69, 95% CI
0.23 to 2.08; p = 0.51, I2 = 54%). Moderate statistical heterogeneity was evident among trials.
Absolute overhydration
Four trials (one rated as being at a high risk of bias and three rated as being at an unclear risk of bias)
assessed absolute overhydration,61,63,76,77 which was defined as the difference between expected ECW
and actual ECW. No data on underhydration were available. Figure 9 shows that absolute overhydration
was significantly lower in the BCM assessment group than in the standard clinical assessment group
[weighted mean difference (WMD) –0.44, 95% CI –0.72 to –0.15; p = 0.003, I2 = 49%]. Moderate
statistical heterogeneity between trials was apparent.
TABLE 2 Uninflated summary data for the Ponce et al.61 trial
Outcome
Trial arm
Treatment Control
Mean (SD) n Mean (SD) n
SBP (mmHg) 134.6 (27.3) 101 136.5 (24.7) 88
Absolute hydration (L) 2.92 (1.47) 101 3.36 (1.75) 88
Relative hydration (%) 15.4 (6.36) 101 16.26 (8.48) 88
SD, standard deviation.
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FIGURE 6 Meta-analysis for SBP. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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FIGURE 7 Meta-analysis for arterial stiffness. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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Relative overhydration
Three trials (all rated as being at an unclear risk of bias) reported data on ROH,60,61,76 which was defined as
the ratio of absolute fluid overload to ECW volume. Figure 10 shows that ROH was significantly lower in
the BCM assessment group than in the standard clinical assessment group (WMD –1.84, 95% CI –3.65 to
–0.03; p = 0.05, I2 = 52%). ROH was assessed by the BCM in both groups, therefore these results should
be interpreted with caution.
Randomised controlled trial evidence: subgroup and sensitivity analyses
We had initially planned to perform subgroup analyses according to the type of dialysis (HD or PD), the type
of population (children aged < 5 years) and ethnicity group, and according to certain characteristics of the
patient population, that is, people for whom recommended configurations of electrodes could not be used,
people who could not assume the required positions for measurements to be made or people at extremes
of body composition measurements. However, because of a lack of available data, we were able to perform
only subgroup analyses of SBP and absolute overhydration according to the type of dialysis utilised.
Figure 11 presents the forest plot of the subgroup analysis of SBP according to the type of dialysis. As
there was only one trial in the PD group, we considered that testing for subgroup effects would have been
statistically unsound. We considered that the comparison of the overall effect with the HD group effect
(similar to a sensitivity analysis) was a better, more reliable approach. In this case, the effect on blood
pressure was still not significant (WMD –1.76, 95% CI –4.61 to 1.08; z = 1.21, p = 0.22).
Figure 12 presents the subgroup analysis for absolute hydration according to the type of dialysis. As
described above, we did not perform a test of subgroup effects. In the case of absolute overhydration,
there is a difference between the overall effect compared with the HD subgroup effect (WMD –0.33,
95% CI –0.60 to –0.07; z = 2.50, p = 0.01), but this is not large enough to suggest a significant dialysis effect.
We were unable to perform the planned sensitivity analyses (i.e. based on studies rated as being at a low
risk of bias only or according to the type of multiple-frequency bioimpedance device), as only one trial was
rated as being at a low risk of bias and only one device (the BCM) was used in all included trials.
Randomised controlled trial evidence: other outcomes
Intermediate reported outcomes
Hospitalisation
Three trials reported data on hospitalisation.61,76,77 Huan-Sheng et al.76 (at unclear risk of bias) reported
71 events of all-cause hospitalisation, with an incidence of 0.52 (95% CI 0.44 to 0.61) per patient-year,
in the bioimpedance assessment group. In the standard clinical assessment group, there were 73 all-cause
hospitalisation events, with an incidence of 0.54 (95% CI 0.46 to 0.63). The HR was 1.19 (95% CI 0.79
TABLE 3 Log-HR and log-SE for the three trials60,61,76 included in the meta-analysis of mortality
First author of study and
year of publication
Trial arm
Weight
(%) HR (95% CI)
Treatment Control
Number of
events
Total number
of events
Number of
events
Total number
of events
Huan-Sheng et al., 201676 6 148 7 150 39.4 0.850 (0.288 to 2.511)
Onofriescu et al., 201460 1 62 8 69 19.4 0.112 (0.014 to 0.907)
Ponce et al., 201461 12 101 8 88 41.2 1.327 (0.479 to 3.680)
Overall 19 311 23 307 100.0 0.689 (0.228 to 2.084)
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FIGURE 9 Meta-analysis for absolute overhydration. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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FIGURE 10 Meta-analysis of ROH. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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FIGURE 11 Subgroup analysis for SBP according to the type of dialysis. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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FIGURE 12 Subgroup analysis for absolute overhydration according to the type of dialysis. df, degrees of freedom; IV, inverse variance; SD, standard deviation.
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to 1.80). Hur et al.77 (at unclear risk of bias) reported six participants in the bioimpedance assessment group
hospitalised because of new CV events during the study period, with a hospitalisation rate/100 patient-years
of 12.5. Four participants were hospitalised in the standard clinical assessment group, with a hospitalisation
rate/100 patient-years of 30.9. The difference between the groups was not statistically significant. Ponce
et al.61 (at unclear risk of bias) reported that 39.6% of the bioimpedance assessment group and 31.8% of
the standard clinical assessment group were hospitalised at least once.
Left ventricular hypertrophy
Hur et al.77 (rated as being at an unclear risk of bias) reported presence of left ventricular hypertrophy at
12 months in 44% of the bioimpedance assessment group and 50% of the standard clinical assessment
group. The difference from baseline, although not statistically significant, decreased in both groups (from
67% and 53%, respectively).
Left ventricular mass index
Hur et al.77 2013 (rated as being at an unclear risk of bias) reported a significant reduction in LVMI in the
bioimpedance assessment group from 131 [standard deviation (SD) 36] at baseline to 116 (SD 29) at
12 months (p < 0.001). In contrast, there was no change in LVMI in the standard clinical assessment group
[from 121 (SD 35) at baseline to 120 (SD 30) at 12 months; p = 0.9].
Clinical outcomes
Incidence of cardiovascular events
One study reported a combination of acute fluid overload or CV-related events, which included hospitalisation
related to CV or cerebrovascular events and episodes of acute fluid overload. Huan-Sheng et al.76 (rated as
being at an unclear risk of bias) reported 14 events in the bioimpedance assessment group, with an incidence
rate of 0.10 (95% CI 0.06 to 0.17) per patient-year, and 28 events in the control group, with an incidence rate
of 0.21 (95% CI 0.15 to 0.29) per patient-year. The overall incidence ratio was 0.50 (95% CI 0.26 to 0.94)
per patient-year (p = 0.03).
Residual renal function
No trials reported residual renal function, but two studies reported urinary volume, which could be considered
a surrogate measure thereof. Hur et al.77 (rated as being at an unclear risk of bias) reported a significant
increase in the proportion of anuric patients and a significant decrease in urine output in non-anuric patients
at 12 months in the bioimpedance assessment group. By contrast, there was no change in the proportion
of anuric patients in the control group and the decrease in urine output in non-anuric patients was not
significant at follow-up. Luo et al.63 (rated as being at a high risk of bias) reported non-significant decreases in
urine volume in both the BCM group and the standard clinical assessment group at 12 weeks, although the
bioimpedance assessment group showed a numerically larger decrease.
Adverse effects associated with hypotensive episodes
The top five intradialytic complications reported by Huan-Sheng et al.76 (rated as being at an unclear risk of bias)
were hypotension, cramping, skin itching, chest tightness and headache. There were significant differences
between the bioimpedance assessment group and the standard clinical assessment group for all of these
complications, but not in the same direction. In the bioimpedance assessment group, there was significantly
more cramping, chest tightness and headaches, but significantly less hypotension and skin itching.
Frequency of intradialytic hypotensive events was reported by Hur et al.77 (rated as being at an unclear risk
of bias); there was no difference between groups at baseline (63.2 events/1000 dialysis sessions in the
bioimpedance assessment group and 63.8 events/1000 dialysis sessions in the standard clinical assessment
group; p = 0.9) or at 12 months (66.6 and 63.9 events/1000 dialysis sessions, respectively; p = 0.4). Similarly,
Onofriescu et al.60 (rated as being at an unclear risk of bias) reported no difference between groups in
hypotension, cramps or patient-year (p = 0.6). Ponce et al.61 (rated as being at an unclear risk of bias)
defined hypotensive events as SBP reduced by at least 30 mmHg during dialysis or intradialytically below
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90 mmHg, and reported no significant difference between groups at baseline (39 events in 17 patients in
the bioimpedance assessment group, and 38 events in 12 patients in the standard clinical assessment group)
or 12 months (48 events in 20 patients and 41 events in 15 patients, respectively).
No data were available on incidence of oedema or incidence of peritonitis.
Patient-reported outcomes
Fatigue
Only one trial reported details of any specified patient-reported outcomes. Huan-Sheng et al.76 (rated as
being at an unclear risk of bias) reported four events of intradialytic fatigue in the bioimpedance
assessment group and five events in the standard clinical assessment group. The difference between
groups was not statistically significant (p = 0.7).
Other relevant outcomes
Achievement of target weight
Three trials reported achievement of target weight. Huan-Sheng et al.76 (rated as being at an unclear risk of
bias) reported that post-dialysis target weight (PDTW) adjustment was performed in 816 months (out of a
total of 1658 monthly assessments across the 148 participants in the intervention group over the 12-month
follow-up period). PDTW was achieved in 650 of these months (80%). Of the 816 months, clinical signs and
symptoms were comparable with the BCM results in 482 months (59%), of which PDTW was reached in
426 months (88%). The authors further reported that PDTW adjustments based on BCM results were not
supported by firm and clear clinical evidence in up to 41% of occasions. Onofriescu et al.60 (rated as being
at an unclear risk of bias) stated that a significantly higher proportion of participants in the bioimpedance
assessment group than in the control group maintained dry weight within 1.1 kg of the bioimpedance-
recommended level. However, there is some uncertainty around the number of participants at each time
point, and replicating the analysis was not possible. Ponce et al.61 (rated as being at an unclear risk of bias)
reported that, at 12 months, target weight was generally less overestimated in the BCM assessment group
than in the standard clinical assessment group (0.67 vs. 1.00 kg).
Non-randomised evidence
Table 4 presents the relevant results reported by the eight included non-randomised cohort studies.
Use of antihypertensive medication
Two studies reported the use of antihypertensive medication in specified patient subgroups.85,86 Castellano
et al.86 reported significantly higher consumption of antihypertensive medications per month in the group
with average ROH not reduced within 6 months than in those for whom average ROH was reduced within
6 months.86 Kim et al.85 reported no significant difference in the consumption of antihypertensive drugs
between dehydrated and hyperhydrated patients, although the number of drugs used at week 16 was
significantly lower than that at baseline or week 8 in the hyperhydrated group.
Blood pressure
Four studies reported blood pressure among specified subgroups.85–88 There were no statistically significant
differences between groups in which average overhydration within 6 months was reduced versus not
reduced,86 short- versus long-dialysis groups87 or groups in which relative fluid overload was < 17.4%
versus > 17.4%.88 Kim et al.85 compared the blood pressure of dehydrated and hyperhydrated patients,
and found that SBP was higher in the hyperhydrated group, although the statistical significance of the
comparison was not reported.
Left ventricular hypertrophy
One study assessed left ventricular hypertrophy87 and showed that the thickness of the left ventricle wall
(in mm) was not significantly different for short- versus long-dialysis vintage subgroups.
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TABLE 4 Summary of included non-randomised study outcomes
Study outcomes relevant to this review Study authors’ conclusions
Castellano et al., 201486 (Spain, cohort study, 6-month follow-up)
Average ROH reduced within 6 months (n = 325) vs. average ROH not
reduced within 6 months
Reduction in hyperhydration status related to
better control of blood pressure and anaemia
with fewer AHT drugs and ESAs
Intermediate outcomes (n = 494), mean:
l Time undergoing HD (months): 52.56 (SD 43.69) vs. 59.88
(SD 50.51); p = 0.028
l Use of AHT medication (use/month): 37.97 (SD 47.99) vs. 50.0
(SD 58.12); p = 0.001
l SBP (mmHg): 136.31 (SD 20.44) vs. 137.74 (SD 22.93), p= NS
l Diastolic blood pressure (mmHg): 65.78 (SD 11.71) vs. 67.25
(SD 13.35); p = NS
l Average ROH (%): 18.52 vs. 21.59; p= 0.000
Clinical outcomes, mean:
l Age-adjusted Charlson Comorbidity Index: 5.82 (SD 1.81) vs. 5.55
(SD 1.90); p= 0.050
Maintained hyperhydrated patients, patients
with diabetes mellitus with many comorbidities
and young males with longer time on HD and
non-adherence treatment may benefit from
close monitoring of hydration state and
individualised dialysis and drug treatments
Hoppe et al., 201587 (Poland, cohort study, 30-month follow-up)
Short (n= 119) vs. long (n= 122) dialysis vintage subgroups Longer dialysis vintage associated with CV
dysfunction, overhydration and increased
mortality, which may be predicted with
overhydration percentage and cardiac troponin T
Intermediate outcomes:
l SBP (mmHg): 137.0 (SD 17.1) vs. 138 (SD 17.4); p= NS
l Diastolic blood pressure (mmHg): 82.8 (SD 9.6) vs. 83.7 (SD 10.4);
p= NS
l Left ventricular hypertrophy: 13.3 (SD 1.6) vs. 13.8 (SD 2.0); p= 0.61
l Overhydration (%): 2.8 (SD 2.1) vs. 3.5 (SD 2.4); p= 0.013
Clinical measures:
l Incidence of CV events (n): AMI, 7 vs. 11; p= NS; stroke,
3 vs. 3; p= NS
l Mortality (n): 15 vs. 27, p= 0.045
Kim et al., 201285 (South Korea, interventional cohort study, 16-week follow-up)
Dehydration (n= 18) vs. hyperhydration (n = 44) subgroups BCM-guided optimisation of body fluid status
may lead to improvement of inflammatory
markers and anti-atherogenic adipokines as
well as haemodynamic parameters in people
receiving HD
Intermediate outcomes:
l Number of AHT drugs, mean: 1.33 (SD 1.5) vs. 4.05 (SD 2.53);
p= NR
l SBP (mmHg): 130 (SD 22.3) vs. 143 (SD 21.9); p= NR
l Diastolic blood pressure (mmHg): 70.7 (SD 14.9) vs. 70.7 (SD 11.2);
p= NR
Kim et al., 201550 (South Korea, cohort study, median 24-month follow-up)
Overhydrated group (n= 160) vs. non-overhydrated group (n= 80) The ratio of overhydration to ECW volume
measured with the BCM is related to the
overall survival of ESRD patients who have
started MHD
Intermediate outcomes:
l Hospital days: mean days/event: 8.0 (SD 19.4) vs. 6.3 (SD 14.7);
p= 0.438
l Presence of overhydration as a risk factor of death during entire
follow-up: OR 2.569 (95% CI 1.077 to 6.126); p = 0.033
Clinical outcomes:
l CV disorder (events/year): 0.3 (SD 0.9) vs. 0.2 (SD 0.5); p = 0.126
continued
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TABLE 4 Summary of included non-randomised study outcomes (continued )
Study outcomes relevant to this review Study authors’ conclusions
Oei et al., 201683 (UK, cohort study, median 23.9-month follow-up)
Death from cardiac vs. non-cardiac causes Patients who were overhydrated had higher
cTnT, and their deaths were more likely to be
cardiac related. Reduction in overhydration
correlated with lowering of cardiac troponin T
Clinical outcomes:
l Overhydration level in people who died (litres): 2.95 vs. 1.35;
p< 0.05
O’Lone et al., 201482 (UK, cohort study, median 27-month follow-up)
Intermediate outcomes:
l Effect of overhydration (per litre) on mortality (all participants): HR
1.10 (95% CI 1.01 to 1.20); p= 0.025
l Effect of overhydration (per litre) on mortality (severely overhydrated
participants): HR 1.83 (95% CI 1.19 to 2.82); p = 0.01
l Overhydration/ECW: HR 2.09 (95% CI 1.36 to 3.20); p = 0.00
Clinical outcomes:
l Peritonitis (n= 580; mean 17.1-month follow-up): 289 new episodes
(rate of 1 episode in 34.3 patient-months)
BMI did not influence the hydration parameter
of overhydration/ECW, which remained an
independent predictor of mortality when BMI
and lean tissue index were included in a
multivariate model. However, it remains to be
determined if correcting the overhydration
status of a patient will lead to improvement in
mortality
Onofriescu et al., 201588 (Romania, cohort study, median 66.2-month follow-up)
RFO< 17.4% (n= 135) vs. RFO > 17.4% (n= 22) Hydration status is associated with the
mortality risk in a HD population,
independently of cardiac morphology and
function
Intermediate outcomes:
l All-cause hospitalisations (n= 181 vs. n = 40, events/100
patient-years): 60.4 vs. 77.8, RR: 0.78 (95% CI 0.64 to 0.95)
l SBP (mmHg): 142.9 (SD 15.6) vs. 143.6 (SD 14.2); p= 0.89
l Diastolic blood pressure (mmHg): 81.4 (SD 9.9) vs. 81.1
(SD 9.3); p= 0.76
l LVMI (g/m2): 147.1 (IQR 120.9–178.1) vs. 151.8 (IQR 119.7–184.2);
p= 0.79
l Absolute fluid overload (litres): 1.3 (SD 1.1) vs. 3.6 (SD 0.8); p< 0.001
l Relative fluid overload (litres): 7.7 (SD 6.4) vs. 20.1 (SD 3.1); p< 0.001
Clinical outcomes:
l CV comorbidities, n (%): CAD, 34 (25.2) vs. 3 (13.6); p = 0.24; PVD,
17 (12.6) vs. 2 (9.1); p = 0.64; heart failure, 50 (37.0) vs. 8 (36.4);
p= 0.95; stroke, 6 (4.4) vs. 1 (4.5); p= 0.98
Wizemann et al., 200930 (Europe, cohort study, 3.5-year follow-up)
Clinical outcomes:
l Mortality risk, Cox-adjusted HRs:
¢ Age, HR 1.05, 1/year (90% CI 1.029 to 1.066); p< 0.001
¢ SBP, HR 0.986 1/mmHg (90% CI 0.979 to 0.995); p= 0.014
¢ Diabetes mellitus, HR 2.766 (90% CI 1.879 to 4.073); p < 0.001
¢ Peripheral vascular disease, HR 1.683 (90% CI 1.097 to 2.583);
p= 0.045
¢ Relative hydration status, HR 2.102 (90% CI 1.389 to 3.179);
p= 0.003
Hydration state is an important and
independent predictor of mortality in chronic
HD patients secondary only to the presence of
diabetes mellitus. It is essential to measure
hydration status objectively and quantitatively
to obtain a more clearly defined assessment of
HD patients’ prognosis
AHT, antihypertensive; AMI, acute myocardial infarction; CAD, coronary artery disease; cTnT, cardiac-specific troponin;
ESA, erythropoiesis-stimulating agent; IQR, interquartile range; MHD, maintenance HD; NR, not reported; NS, not
significant; OR, odds ratio; PVDD, peripheral vascular disease; RFO, relative fluid overload; RR, risk ratio.
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Hospitalisation
Two studies reported data on hospitalisation.50,88 Kim et al.50 reported a non-significant difference between
overhydrated and non-overhydrated patients in the number of hospital-days per event. Onofriescu et al.88
reported a significantly higher all-cause hospitalisation rate for patients classified as overhydrated according
to a 17.4% cut-off point than for those classified as being not overhydrated. The value of 17.4% was
proposed by the authors as a threshold for classifying a patient as overhydrated (i.e. relative fluid overload
of at least 17.4%), as opposed to the value widely accepted in the literature of 15%. In contrast, there
was no significant difference between all-cause hospitalisation rates for patients classified as overhydrated
according to the traditional 15% threshold and those patients classified as being not overhydrated.
Hydration status
The majority of studies reported hydration status at follow-up, although not in a consistent way.
Subgroups in which higher levels of overhydration at follow-up were reported were the subgroup whose
average ROH was not reduced to < 15% in 6 months, as compared with the subgroup whose values were
reduced to the desired level;86 the long versus short-dialysis vintage subgroup;87 patients with a cardiac
cause of death, as opposed to those with a non-cardiac cause of death;83 and both absolute fluid overload
and relative fluid overload in subgroups with a relative fluid overload of > 17.4%, as compared with
subgroups with a relative fluid overload of < 17.4%.88
Some studies reported the effects of hydration status on mortality. Kim et al.50 reported a significant
effect of overhydration as a risk factor for death; O’Lone et al.82 reported a significant effect of absolute
overhydration on mortality; Onofriescu et al.88 reported that patients assessed as being overhydrated were
at significantly increased risk for all-cause mortality; and Wizemann et al.30 reported a significant risk of
relative hydration status on mortality.
Cardiovascular events
Three studies reported data on CV events.50,87,88 A non-significant difference in the incidence of acute
myocardial infarction and stroke was observed between short- and long-dialysis vintage subgroups;87 no
differences were found in the number of CV events per year between overhydrated and non-overhydrated
subgroups;50 and no significant differences in the incidence of coronary heart disease, peripheral vascular
disease, heart failure or stroke were detected between the subgroup with a relative fluid overload of
< 17.4% and that with a relative fluid overload of > 17.4%.88
Mortality
One study reported a significantly higher number of deaths in the long versus short-dialysis vintage
subgroup.87
Ongoing trials
Four relevant ongoing trials were identified. Table 5 summarises the main characteristics of the ongoing
trials. More detailed study characteristics are presented in Appendix 10.
Summary of clinical effectiveness section
A total of five RCTs and eight non-randomised studies investigating the use of the BCM in adult populations
were included in the review of clinical effectiveness. Taken together, evidence from randomised and
non-randomised studies showed that using the BCM reduced SBP more than standard clinical practice, but
not to the level of statistical significance. However, where the BCM was used, there was no difference in
blood pressure between subgroups, such as long versus short vintage or normo- versus overhydrated. As
compared with standard clinical practice, use of the BCM had no effect on mortality; however, the use of
the BCM had a significant effect on mortality in long versus short-dialysis vintage subgroups. There was a
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non-significant effect on arterial stiffness of using the BCM versus standard clinical practice. A significant
difference in the incidence of CV events was noted between the BCM assessment group and the standard
clinical practice group, although there were no differences between subgroups using the BCM, such as long
versus short-dialysis vintage and overhydrated versus non-overhydrated groups. Both absolute and ROH
were significantly lower in the bioimpedance assessment group and subgroups, such as long versus short-
dialysis vintage, and patients in whom ROH was not reduced to < 15% versus those whose overhydration
was reduced to the desired level had higher levels of overhydration.
Overhydration was identified as a risk factor for mortality. Left ventricular hypertrophy was reported to
decrease in both bioimpedance and standard clinical assessment groups, although not to the level of
statistical significance; there was no difference in left ventricular hypertrophy between long and short-
dialysis vintage subgroups. Findings regarding hospitalisation of the bioimpedance versus standard clinical
assessment groups and overhydrated versus non-overhydrated subgroups were variable and inconclusive.
TABLE 5 Main characteristics of relevant ongoing trials
Study name (trial acronym),
ClinicalTrials.gov identifier or
ISRCTN and country of study Study aim Primary outcome(s)
Probing the Dry Weight (DW) by
Bioimpedance (BIA): Which is the Gold
Standard Between Clinical DW and BIA
DW?
NCT0244653591
Italy
To verify if BIA-based DW control is truly
superior to current volume management
in HD patients
The definition for each patient of
the gold standard DW when
comparing the clinical and the
BIA-guided DW
Fluid Management Guided by
Bioimpedance Analysis in Peritoneal
Dialysis (PD) Patients
NCT0200012892
China
To investigate the effect of bioimpedance
analysis-guided fluid management vs.
experiential way on clinical outcomes in
PD patients
All-cause mortality; CV-related
mortality
Control Of fluid balance guided by
body composition Monitoring in
Patients on PeritoneAl dialySiS
(COMPASS)
NCT0188726293
South Korea
Bioimpedance-guided fluid management
in PD patients may provide better
protection of RRF over a 1-year period,
compared with management guided by
clinical information alone
Change of GFR from baseline to
the twelfth month
Bio-Impedance Spectroscopy To
maintain Renal Output (BISTRO)
ISRCTN1134200794
UK
NIHR-funded open-label multicentre RCT
to test whether or not taking regular
measurements with a bioimpedance device
improves outcomes for people aged
> 18 years who have recently started HD
treatment for kidney failure CKD stage 5.
The target sample size is 516 patients from
30 UK dialysis units. The trial opened for
recruitment 6 April 2017
Time to anuria (loss of urine
output), < 100ml/day or 200 ml
in the short interdialytic period
confirmed by a further collection
after 2 weeks to exclude
temporary illness
BIA, bioimpedance analysis; DW, dry weight; ISRCTN, International Standard Randomised Controlled Trial Number;
NIHR, National Institute for Health Research; RRF, residual renal function.
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Chapter 3 Assessment of cost-effectiveness
The aim of the economic evaluation for this assessment was to assess the cost-effectiveness of usingmultiple-frequency bioimpedance technologies versus standard clinical assessment for fluid
management in people with CKD receiving dialysis. The bioimpedance technologies considered were the
BCM, MultiScan 5000, BioScan 920-II, BioScan touch i8 and the InBody S10.
The specific objectives were to:
l review existing economic evaluations of multiple-frequency bioimpedance devices for fluid
management in people with CKD receiving dialysis
l develop a de novo economic model to assess the cost-effectiveness of using the identified
multiple-frequency bioimpedance devices compared with standard clinical assessment alone to guide
fluid management in people with CKD receiving dialysis, from a UK NHS and personal social services
perspective.
Systematic review of existing cost-effectiveness evidence
Electronic searches were undertaken to identify reports of economic evaluations. The following
bibliographic databases were included: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations,
EMBASE, National Institute for Health Research Economic Evaluations Database (NEED), the Health
Technology Assessment database and the Research Papers in Economics (RePEC) database. No date or
language restrictions were imposed, and searches were undertaken on 5 July 2016. Details of the search
strategies are reproduced in Appendix 1. In addition, recent conference proceedings (over the period of
2014–16), including those of the European Renal Association, American Society of Nephrology, the Annual
Dialysis Conferences and the International Society for Pharmacoeconomics and Outcomes Research, were
also screened. Relevant websites of key professional organisations, registries and device manufacturers
were checked for additional data and information. The searches identified no full economic evaluations of
relevance to the scope of this assessment.
To help inform the design of the de novo economic model, broader searches were carried out to identify
existing economic models in the area of CKD/ESRD, and NHS cost data applicable to relevant patient
populations and health states were included in the model. A separate search was also developed for
health state utility data relevant to the health states included in the economic model. Databases searched
included MEDLINE, EMBASE, the Cost-effectiveness Analysis (CEA) Registry and ScHarrHUD (School of
Health and Related Research Health Utilities Database). The searches were undertaken on 8 July 2016 and
no date or language restrictions were imposed. The search strategies are reproduced in Appendix 1.
Discussion of the potential data sources identified by these broader searches are provided under the
relevant subheadings below.
Independent economic assessment
A de novo economic model was developed in TreeAge Pro (TreeAge Software, Williamstown, MA, USA).
The model was designed to assess the cost-effectiveness using multiple-frequency bioimpedance testing to
help guide fluid management decisions in people with CKD receiving dialysis.
The model structure was informed by the hypothesised benefits of bioimpedance testing and review of
published models in the area of ESRD, with particular emphasis on models previously used to inform NHS
policy surrounding the provision of dialysis.17,95–98
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The model was populated using data derived from focused reviews of the literature (to inform baseline
mortality and hospitalisation risks in patients with ESRD), the systematic review of clinical effectiveness
(to inform relative treatment effects) and other focused reviews to inform sources of cost and utility data.
The model was built and analysed in accordance with the NICE reference case for the evaluation of
diagnostic tests and devices.17,98 It compares cumulative costs to the health service and quality-adjusted
life-years (QALYs) gained for the alternative monitoring strategies.
Methods
Relevant patient population(s)
The model compared the alternative fluid management strategies for a prevalent cohort of people with
ESRD receiving either HD or PD. The base-case analysis was conducted using the weighted average of the
median age and sex distribution for the respective prevalent dialysis cohorts, as reported in the UK Renal
Registry report:99 aged 67.2 years, 61% male for those receiving HD, and aged 64.2 years, 61% male for
those receiving PD. Thus, the base-case analysis was run for a mixed cohort at the average age of 66 years,
61% male, with 87% receiving HD and 13% receiving PD. Separate subgroup analyses were also conducted
for the PD and HD cohorts, applying the median ages for the respective subgroups. In addition, comorbidity
burden is also used in the model in the estimation of baseline hospitalisation risks, and this was estimated
from UK registry data.99,100 Based on these sources, 63% of patients aged ≥ 65 years and 36% of patients
aged < 65 years are modelled to have at least one comorbidity at baseline. The estimated mean number of
comorbidities in those with any comorbidity is 1.6 and 2.0 for the PD and HD cohorts, respectively.
Monitoring strategies evaluated
Bioimpedance monitoring strategies, to help adjust target weight and guide fluid management, were
compared with standard clinical assessment, in which target weight is set based on clinical signs and
symptoms, including blood pressure, presence of oedema, changes in weight, residual renal function,
pre-existing CV conditions and patient-reported symptoms of overhydration or underhydration. For the
bioimpedance strategies, it was assumed that all patients would have their hydration status assessed every
3 months (four times per year), and have their target weight modified in line with the results if necessary.
The above monitoring strategy is in line with clinical opinion regarding the necessary frequency of
bioimpedance testing in an adult dialysis population, and is also consistent with the approach used in two
of the trials included in the systematic review of clinical effectiveness.60,81 It is less intensive than the testing
strategies applied in the other RCTs included in the clinical effectiveness review, which varied from once
per week101 to once every 6 weeks.63 It is assumed in the base-case cost-effectiveness scenarios that
quarterly testing can deliver effects in keeping with those observed across all the included randomised
trials. The impact of increased testing frequency is addressed in sensitivity analysis.
The bioimpedance technologies included in the scope for this assessment were the BCM, MultiScan 5000,
BioScan 920-II, BioScan touch i8 and the InBody S10. However, the review of existing literature only
uncovered clinical effectiveness evidence relating to the BCM. Therefore, the economic modelling focused
on assessing the cost-effectives of bioimpedance testing using the BCM device. For comparison, we include
cost-per-test estimates using each of the other competitor devices, and assess the impact of applying these
costs in a sensitivity analysis (assuming equivalent effects).
Framework (method of synthesis)
A discrete-time Markov cohort model was developed to assess the clinical effectiveness and cost-effectiveness
of using multiple-frequency bioimpedance testing compared with standard clinical practice for guiding fluid
management decisions in the dialysis cohort. This state-transition framework was chosen for its ability to
capture the evolving disease process and recurrent event risks over time, while being relatively parsimonious
in terms of data and computational requirements. Key states included in the model are ‘stable on HD’,
‘stable on PD’, ‘post-incident CV event – haemodialysis’, ‘post-incident CV event – peritoneal dialysis’, ‘post
transplant’ ‘post transplant, post CV event’, ‘dialysis post transplant’, ‘dialysis post transplant, post CV event’
and ‘death’. The model also includes an option to dichotomise the ‘stable’ and ‘post CV event’ dialysis states
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by baseline ROH status into either severely overhydrated (> 15% ROH) or normohydrated (≤ 15% ROH),
as measured by the BCM. This is to allow mortality and hospitalisation rates for the severely overhydrated
portion of the prevalent cohort to be factored upwards, reflecting the observed adjusted association between
hydration status and these outcomes.26,30,60,82
Modelled transitions between the relative hydration states were then used to drive effects in an alternative
scenario analysis (see Further adjustments to baseline risks for further details). States representing
underhydration were not included in this alternative model structure because of a dearth of evidence on
(1) the prevalence of underhydration, as measured by the BCM, in UK dialysis cohorts; (2) the impact of
underhydration, as measured by the BCM, on the risk of adverse events and/or quality of life; and (3) the
effectiveness of bioimpedance-guided fluid management on reducing the prevalence of underhydration.
If underhydration (as measured by bioimpedance spectroscopy) is associated with adverse outcomes and
quality of life, and bioimpedance-guided fluid management can reduce the prevalence of this, then this
secondary model may fail to capture the associated benefits.
The model simulates mortality, hospitalisation events and transition to transplant over the lifetime of the
modelled cohorts on a constant 3-monthly cycle (in keeping with the BCM testing cycle). All-cause
hospitalisation events are disaggregated across CV events and other causes. It is assumed in the model
that hospitalisation for incident CV events results in an increased comorbidity burden, which increases the
risk of subsequent hospitalisations.
Costs of dialysis (by modality), background medication [blood pressure, erythropoiesis-stimulating agents
(ESAs)], transplant, all-cause hospitalisation and outpatient attendances are included in the baseline model.
Health state utility multipliers are applied to the dialysis states, and utility decrements are also incorporated
for hospitalisations. These decrements are applied for an acute period for all hospitalisations. For
hospitalisations caused by CV events, a long-term utility multiplier is also applied. This reflects the lasting
impact that these events can have on health-related quality of life. A schematic of the model structure is
provided in Figure 13. A simplifying assumption of the model precludes switching between dialysis modes.
This is unlikely to have a significant impact on results since an equal baseline mortality rate is applied for
patients on dialysis irrespective of modality, and the estimated costs of PD and HD were also found
to be similar based on current reference costs (see Costs of renal replacement therapy). Furthermore,
the clinical effectiveness evidence was insufficient to estimate bioimpedance effects by dialysis modality.
The baseline model is replicated for the strategy of bioimpedance-guided fluid management, and
correspondingly incorporates the additional cost of quarterly testing on top of standard practice. The
bioimpedance model also allows for the incorporation of effects of bioimpedance monitoring on mortality,
hospitalisation rates, background management costs (e.g. blood pressure medications) and within-state
health state utility. The incorporation of these hypothesised benefits, in light of the available supporting
evidence, is discussed in detail under the relevant headings below. The model can also capture
downstream cost-savings and quality-of-life benefits associated with reduced hospitalisation rates and
prolonged survival.
Modelled baseline risks
The baseline risks of mortality were derived from a number of sources. The UK Renal Registry report44
was first consulted as a source of population-based data. However, this report provides detailed data on
survival only (by age) for the incident RRT cohort as a whole, without censoring for transplantation.
This is not suited to the decision model structure (see Figure 13), in which mortality rates dependent on
continuing to receive dialysis and on transitioning to transplant are required. Therefore, the ERA-EDTA annual
report was consulted.102 This report includes adjusted 5-year survival curves with censoring for transplantation
in the dialysis survival estimates. The data are reported from day 91, with adjustment based on Cox regression
for age, gender and primary diagnosis. The survival estimates on different modalities are expressed for a cohort
of people aged 60 years and 60%male, with the following distribution for cause of renal disease: diabetes
mellitus (20%), hypertension (17%), glomerulonephritis (15%) and other causes (48%). This distribution of
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characteristics is reasonably similar to that of the UK dialysis population, although age is slightly higher in
the incident UK cohort at 63 years, and diabetes mellitus and hypertension are reported as the primary
renal diagnosis in 26% and 6.5% of incident patients, respectively.99 Although is preferable to reconstruct
patient-level data from published Kaplan–Meier curves for the purpose of extrapolating survival in decision
models,103 the adjusted nature of the reported data precluded estimation of numbers of events and censoring
events. Therefore, a simple regression-based method was used to fit a Weibull distribution to the summary
survival curve data.104 Given limitations in the evidence base to support differences in survival by mode of
dialysis, we based extrapolation on the survival curve for all dialysis modalities combined. The scale and shape
parameters from the derived Weibull curves (Table 6) were incorporated in the model and used to extrapolate
mortality risks out to 10 years. The scale parameter (λ) was further adjusted to reflect the starting age of the
modelled cohort (67 years), using a published HR for mortality (beyond 91 days) associated with a 10-year
increase in age:99
λadjusted = λ × HR
ACM(start age−60)
, (1)
in which HRACM is the HR for all-cause mortality associated with a 10-year increase in age, and ‘start_age’
is the starting age of the modelled dialysis cohort.
For those transitioning to renal transplant, survival data were derived from a combination of sources
(see Table 6). In the first year following transplant, survival probabilities by age groups were taken from
the ERA-EDTA Registry annual report.102 The reported 1-year survival probabilities differ by donor type
(deceased/living), and were weighted accordingly. Beyond 1 year, we used published 10-year Kaplan–Meier
survival data from a UK population-based study of transplant recipients.105 The individual patient data
were reconstructed for 2887 subjects aged 60–69 years following the approach described by Hoyle et al.,103
Death
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FIGURE 13 Schematic of the baseline model structure.
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TABLE 6 Clinical parameters used to model mortality, renal transplant and graft failure
Clinical parameter Value (95% CI)
Parameter
distribution Source
Mortality on dialysis (to 10 years)
Weibull scale parameter (cohort of
people aged 60 years)
0.114 – ERA-EDTA Registry annual
report (2013)102
Weibull shape parameter 1.035 – ERA-EDTA Registry annual
report (2013)102
HR (10-year age increase on RRT) 1.65 (1.56 to 1.75) Log-normal UK Renal Registry Report
(2015)99
Mortality year 1 post transplant (deceased donor)
Rate per patient-year (0–19) 0.018 (0.006 to 0.029) Log-normal ERA-EDTA Registry annual
report (2013)102
Rate per patient-year (20–44) 0.019 (0.016 to 0.022) Log-normal
Rate per patient-year (45–64) 0.044 (0.040 to 0.048) Log-normal
Rate per patient-year (65–74) 0.104 (0.090 to 0.120) Log-normal
Mortality year 1 post transplant (living donor)
Rate per patient-year (0–19) 0.007 (0.004 to 0.010) Log-normal ERA-EDTA Registry annual
report (2013)102
Rate per patient-year (20–44) 0.007 (0.004 to 0.010) Log-normal
Rate per patient-year (45–64) 0.02 (0.014 to 0.026) Log-normal
Rate per patient-year (65–74) 0.053 (0.028 to 0.079) Log-normal
Mortality 1–10 years post transplant
Weibull scale parameter (cohort of
people aged 65 years)
0.05 Multivariate normal Karim et al., 2014105
Weibull shape parameter 1.027 Multivariate normal
HR (10-year increase in transplant
recipient age)
1.766 (1.540 to 2.028) Log-normal Karim et al., 2014105
HR for all-cause mortality with
transplant vs. dialysis (applied beyond
10 years post transplant)
0.42 (0.16 to 0.76) Log-normal Tonelli et al., 2011106
Proportion of prevalent dialysis population on waiting list for transplant
Aged < 65 years 0.346 (0.338 to 0.354) Beta Annual Report on Kidney
Transplantation (2014);107
UK Renal Registry Report
(2015)99
Aged 65–75 years 0.135 (0.128 to 0.142) Beta
Aged > 75 years 0 –
Probability of transplant (3-monthly)
among those on waiting list
0.057 (0.055 to 0.058) Beta Annual Report on Kidney
Transplantation (2014)107
Probability of graft failure (3-monthly)
Deceased donors 0.0075 (0.007 to 0.0081) Beta Annual Report on Kidney
Transplantation (2014)107
Living donors 0.0047 (0.004 to 0.005) Beta
Proportion of transplants from
deceased donors (aged 60–70 years)
0.723 (0.706 to 0.40) Beta Karim et al., 2014;105
varies by age of recipient
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using reported numbers at risk and steps in the published Kaplan–Meier curve. Parametric survival models
were then fitted using R statistical software, version 3.1 (The R Foundation, Vienna, Austria), and the
best-fitting model selected based on the Bayesian information criterion. This was a Weibull model. The scale
parameter of the derived Weibull curve is adjusted in the model for the recipient’s age at time of transplant
using the HRs for age reported by Karim et al.105 All of the parameters used to model survival are presented
in Table 6.
To minimise uncertainty associated with the use of parametric curves to extrapolate survival beyond
10 years, we applied an alternative approach to model mortality in the longer term. Mortality rates on RRT
were estimated by applying reported relative risks of mortality in the RRT population compared with the
UK general population99 to general population mortality rates adjusted for age/sex from UK life tables. For
those remaining in a post-transplant state beyond 10 years following transplant, an adjusted relative risk106
was applied to the modelled annual mortality rate of age-matched patients on dialysis. Tonelli et al.106
conducted a systematic review of observational studies reporting an adjusted HR for all-cause mortality
with renal transplant versus dialysis.106 Although a formal meta-analysis of these data was not conducted
because of diversity across the included observational studies, the central estimate (0.42) of the reported
range (0.16–0.76) across 23 included studies was applied in the base-case model. The reported range was
treated as a CI for the purposes of assigning a log-normal distribution to this parameter.
Three-monthly probabilities of renal transplantation for those on dialysis were derived from the percentage
of dialysis patients on a waiting list for a transplant (aged < 65 and ≥ 65 years),99 combined with the
median duration of time to transplant (1082 days).107 The graft failure rate for those receiving a transplant
was derived from the 5-year graft survival rates reported for grafts from living and deceased donors.107
All-cause inpatient hospitalisation was modelled using the first part of a published two-part cost model
developed by Li et al.100 Li et al.100 used a data set for a cohort of patients on the UK Renal Registry who
started receiving dialysis or received a kidney transplant in England between 1 April 2003 and 31 December
2006. The data on these patients were linked to Health Episode Statistics (HES) data for inpatient hospital
activity (excluding activity for maintenance dialysis or transplant surgery) up to 6 years following initiation of
dialysis or transplant. Each hospital event was costed using the appropriate Healthcare Resource Group
(HRG) Payment by Results tariff for the admission. The data were then analysed using a two-part model:
logistic regression was used to predict the probability of a patient incurring any inpatient hospital costs in a
given year on RRT (up to year 6), and a general linear model was used to predict total inpatient costs in
those who had at least one hospital episode in a given year. The models were adjusted for age, gender,
years receiving dialysis, mode of dialysis, comorbidities, transplant and year of death (to account for
increased hospital resource use in the year of death and year preceding death). The published two-part
models for dialysis and transplant patients are replicated in Tables 7 and 8.
These models were incorporated in our decision model to predict the annual probability of hospitalisation
each year based on the characteristics of the modelled cohort, and then to apply the associated inpatient
hospitalisation costs. To keep the approach manageable in the context of a Markov cohort model, the
odds ratios and cost coefficients associated with comorbidities were collapsed into a single weighted
average for any one comorbidity, based on the reported frequency of each individual comorbidity. We
then estimated the risk of hospitalisation at the cohort level by computing the weighted average of the risk
for males and females, with and without comorbidities. The expected number of comorbidities among
those in the cohort with any comorbidity was derived from the UK Renal Registry report,99 and the
weighted average odds of hospitalisation associated with any one comorbidity was raised to this power in
the calculation of hospitalisation risk in this segment of the cohort.
To fit the 3-month Markov cycle, the annual probabilities of hospital admission were converted to
3-monthly probabilities, assuming a constant inpatient hospitalisation rate over the year. Furthermore, the
underlying rate was disaggregated into CV event- and other cause-related hospitalisation rates. To inform
this process, we conducted a focused search of the literature for data on cause of hospitalisation in
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TABLE 7 Odds of annual inpatient hospitalisation and associated costs for dialysis patients
Term
Dialysis inpatient,
OR (95% CI)
Mean annual cost (£) for dialysis
patients (GLM), coefficient (95% CI)
Constant 2.34 (2.18 to 2.51) 7782 (7423 to 8140)
Age group (years)
< 50 Reference Reference
50–64 0.98 (0.91 to 1.05) –170 (–489 to 149)
65–75 0.91 (0.85 to 0.97) –181 (–513 to 151)
> 75 0.87 (0.81 to 0.94) –444 (–806 to –83)
Sex
Male Reference Reference
Female 1.1 (1.05 to 1.16) 208 (–23 to 439)
Years on dialysis
1 Reference Reference
2 0.59 (0.56 to 0.62) –1189 (–1487 to –891)
3 0.5 (0.47 to 0.52) –1434 (–1729 to –1140)
4 0.58 (0.54 to 0.62) –1848 (–2166 to –1530)
5 0.61 (0.56 to 0.67) –1709 (–2099 to –1319)
6 0.65 (0.57 to 0.74) –2270 (–2774 to –1767)
Dialysis modality
HD Reference Reference
PD 0.83 (0.79 to 0.88) –612 (–838 to –385)
Comorbidities
Myocardial infarction (17%) 1.22 (1.14 to 1.31) 390 (96 to 683)
Congestive heart failure (17%) 1.11 (1.04 to 1.19) 321 (58 to 584)
Peripheral vascular disease (16%) 1.33 (1.24 to 1.42) 721 (423 to 1019)
Cerebrovascular disease (11%) 1.15 (1.07 to 1.24) 506 (174 to 383)
Pulmonary (15%) 1.26 (1.17 to 1.35) 412 (128 to 696)
Liver (1%) – 1682 (–161 to 3524)
Diabetes mellitus (34%) 1.27 (1.21 to 1.34) 1191 (929 to 1453)
Cancer (8%) 1.22 (1.11 to 1.33) –
Hypertension (62%) 1.09 (1.04 to 1.14) –
Transplant 1.11 (1.02 to 1.21) –1863 (–1863 to –1585)
Recovered renal function 0.82 (0.69 to 0.96) 1293 (513 to 2073)
Death 1.94 (1.81 to 2.07) 2403 (2152 to 2654)
Death in the first half of the following year 2.61 (2.34 to 2.92) 4415 (3926 to 4904)
GLM, generalised linear model; OR, odds ratio.
Reproduced from Springer European Journal of Health Economics, Predicting hospital costs for patients receiving renal
replacement therapy to inform an economic evaluation, vol. 17, 2016, pp. 663–5, Li B et al.100 (© Springer-Verlag Berlin
Heidelberg 2015). With permission of Springer.
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TABLE 8 Odds of annual inpatient hospitalisation and associated costs following renal transplant
Term
Transplant inpatient,
OR (95% CI)
Mean annual costs (£) for transplant
patients (GLM), coefficient (95% CI)
Constant 1.89 (1.65 to 2.16) 4735 (4331 to 5138)
Age group (years)
< 35 Reference Reference
36–45 0.81 (0.72 to 0.92) –318 (–664 to 29)
46–55 0.73 (0.64 to 0.82) –310 (–676 to 56)
> 55 0.76 (0.67 to 0.87) –91 (–487 to 306)
Sex
Male Reference Reference
Female 1.35 (1.22 to 1.49) 190 (–76 to 455)
Years following transplant
1 Reference Reference
2 0.21 (0.19 to 0.23) –1576 (–1881 to –1271)
3 0.18 (0.16 to 0.2) –1919 (–2228 to –1611)
4 0.19 (0.17 to 0.22) –2138 (–2485 to –1790)
5 0.19 (0.16 to 0.23) –2061 (–2502 to –1620)
6 0.18 (0.14 to 0.22) –2654 (–3212 to –2096)
Transplant type
Deceased donor Reference Reference
Living donor 0.82 (0.75 to 0.9) –223 (–486 to 39)
Comorbidities
Myocardial infarction (8%) 1.47 (1.24 to 1.73) 641 (145 to 1138)
Congestive heart failure (6%) 1.48 (1.22 to 1.73) 1248 (646 to 1851)
Peripheral vascular disease (11%) 1.87 (1.62 to 2.16) 1222 (729 to 1715)
Cerebrovascular disease (6%) 1.38 (1.16 to 1.65) 898 (271 to 1524)
Pulmonary (13%) 1.24 (1.09 to 1.4) 264 (–87 to 616)
Liver (1%) 2.18 (1.37 to 3.47) 2093 (30 to 4155)
Diabetes mellitus (26%) 1.62 (1.46 to 1.8) 1046 (734 to 1395)
Cancer (4%) 1.62 (1.31 to 2.01) 485 (2 to 969)
Hypertension (74%) 1.33 (1.21 to 1.46) 324 (56 to 592)
Graft failure – 2438 (1723 to 3152)
Death 1.62 (1.14 to 2.31) 4924 (3726 to 6123)
Death in the first half of the following year 4.55 (2.47 to 8.39) 5725 (3350 to 8100)
GLM, generalised linear model; OR, odds ratio.
Reproduced from Springer European Journal of Health Economics, Predicting hospital costs for patients receiving renal
replacement therapy to inform an economic evaluation, vol. 17, 2016, pp. 663–5, Li B et al.100 (© Springer-Verlag Berlin
Heidelberg 2015). With permission of Springer.
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ESRD patients receiving dialysis. A number of studies were identified, suggesting that CV event-related
hospitalisation rates account for ≈ 20% of all hospitalisations in dialysis cohorts.108–110 The most relevant
source of evidence to the UK RRT population reported that CV events made up 17.6% of the annual
inpatient event rate in a cohort of 1226 UK HD patients.110 This value was applied in the base case. We then
further disaggregated expected CV hospitalisation events across types of CV events, in line with the reported
relative frequency of CV event histories in the dialysis population (see Table 7). Although this is an uncertain
assumption, we could not identify any better UK population-based data by which to model the relative
frequency of different types of CV event in the dialysis population. A further limitation of the models used to
predict annual hospitalisation risk, is the fact that these require extrapolation beyond the period of follow-up
in the data sets used to develop them (i.e. beyond 6 years). We therefore had to assume that estimated
probabilities of hospitalisation at 6 years on dialysis are generalisable across future years on dialysis.
Further adjustments to baseline risks
To allow for modelled scenarios in which effects are mediated through associations between hydration
status and outcomes, the model was structured to enable mortality and hospitalisation rates to be adjusted
upwards for proportions of the dialysis cohorts estimated to be severely overhydrated (ROH of > 15%).
Modelled reductions in severe overhydration were then used to drive effects in scenarios using this version
of the model.
The expected prevalence of severe overhydration (ROH of > 15%) was based on studies taking BCM
measures at clinic visits (not necessarily first thing in the morning) for the PD cohort, and pre dialysis for
the HD cohort. The threshold of ROH of > 15% was selected because, as noted in Non-randomised
evidence, it has been associated with increased rates of mortality and hospitalisation in observational
studies.30,50,82,88 Time-averaged volume overload may give a more accurate estimate of the average
exposure to fluid overload, but this measure has not been linked with mortality in observational studies.
Limited data were identified regarding the prevalence of ROH of > 15% in UK dialysis cohorts. One
observational study of 529 PD patients from a single UK centre82 reported that ≈ 31% of patients had
ROH of > 10%. A multicentre European study, which included 734 patients from centres in Belgium,
France, Romania, the UK (167 patients from two centres) and Switzerland, reported that 25.2% of the
cohort were severely overhydrated (ROH of > 15%).111 There were fewer published data available on the
prevalence of severe overhydration in the UK HD population. However, a further multicentre European
study matched PD patients from France, Romania and the UK with HD patients from the corresponding
countries.112 This study showed that pre-dialysis ROH in HD patients was similar to ROH in PD patients –
although the time-averaged volume overload in HD patients was lower than the ROH value of PD patients.
Based on these available data, the baseline prevalence of ROH of > 15% was set at 25% for both the HD
and the PD cohorts.
The mortality rate for the severely overhydrated proportion of the HD cohort was increased using an adjusted
HR of 1.87 (95% CI 1.12 to 3.13), as reported by Onofriescu et al.88 The all-cause hospitalisation rate was
also inflated upwards using an adjusted HR of 1.19 (95% CI 0.99 to 1.41), as reported by Onofriescu et al.88
For the corresponding segment of the PD cohort, all-cause mortality was adjusted upwards using the HR of
1.83 (95% CI 1.19 to 2.82) reported by O’Lone et al.82 No data were identified reporting the increased risk
of all-cause hospitalisation in severely overhydrated PD patients, and so the same value as that used for HD
patients was applied. It is plausible that any mortality/morbidity benefits associated with bioimpedance
testing are also partly attributable to the avoidance of underhydration. However, no studies were identified
linking underhydration, as measured using bioimpedance spectroscopy, to mortality and adverse events.
Therefore, an underhydration state was not included in the model. As mentioned in Framework (method of
synthesis), this could potentially underestimate the benefits if bioimpedance-guided fluid management can
simultaneously reduce the proportion of patients that are seriously over- and underhydrated. Conversely,
if the use of bioimpedance testing to guide fluid management decreases the proportion of patients who
are overhydrated at the expense of increasing the proportion who are underhydrated, this model could
potentially overestimate the benefits.
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Incorporation of relative treatment effects
Alternative approaches to modelling effects of bioimpedance-guided fluid management on the
baseline event rates were considered. Given the limitations in the existing evidence base for the clinical
effectiveness of bioimpedance testing, combined with further limitations in the evidence base to inform
certain baseline events, the modelled cost-effectiveness scenarios are subject to a significant degree of
uncertainty.
With the availability of some trial evidence for the technology, the application of direct evidence for effects
on final health outcomes was considered the preferred approach for modelling benefits. However, given
the limitations in the trial evidence base, this was only possible for all-cause mortality. Of the three available
BCM trials that included all-cause hospitalisation rates,61,76,77 these showed inconsistent and insignificant
effects on this outcome. Therefore, we did not incorporate an effect on the overall hospitalisation rate in
scenarios applying direct estimates of effects. Alternative approaches were explored in further scenario
analyses to model plausible effects on CV event-related and non-CV event-related hospitalisation rates.
As a number of the trials reported effects on surrogate end points, including LVMI and PWV, we conducted
a focused literature search to identify appropriate published sources of evidence to link changes in these
surrogates to final health outcomes in the relevant patient population. A hierarchical approach was adopted
to identify suitable sources of evidence, with priority given in descending order to the following types of
evidence:
1. evidence linking intervention-induced changes in available surrogate outcomes to changes in the risk of
final health outcomes
2. evidence linking non-intervention-induced longitudinal changes in surrogate outcomes to changes in
the risk of final health outcomes
3. evidence from large UK or European cohort studies assessing the prognostic value of baseline measures
of the surrogate measures for final health outcomes.
One systematic review, conducted in 2016, considered the value of LVMI as a treatment target in the area
of ESRD, and concluded that there was no clear and consistent association between intervention-induced
LVM change and all-cause or CV event-related mortality.113 Furthermore, as only one of the BCM trials
included this as an outcome, LVMI was considered no further. The search of available evidence did not
identify any existing data showing a clear link between intervention-induced changes in PWV and final
health outcomes in ESRD, but a large European observational study was identified.114 This study assessed
the prognostic value of baseline PWV on all-cause mortality and non-fatal CV events in a cohort of 1084
patients recruited from 47 European dialysis centres over a period of 2 years. It highlighted the importance
of simultaneously considering abdominal aortic calcification (AAC) when assessing the prognostic value of
PWV. Based on a multivariate Cox regression, both variables were found to be significant predictors of
mortality and non-fatal CV events, but the effect of PWV was ameliorated at higher levels of aortic
calcification (incorporated as tertiles), as a result of a significant negative interaction. The relevant HRs from
the published Cox regression are provided in Table 9. Based on these estimates, and assuming that the UK
dialysis cohort is similarly distributed across aortic calcification tertiles, we estimated an average effect on
all-cause mortality and non-fatal CV events of a unit change in PWV, accounting for the interaction.
This yielded a HR of 0.942 (95% CI 0.879 to 1.009) per unit reduction in PWV. We then explored the
impact of scaling this effect to the magnitude of the pooled mean reduction in PWV (1.18 m/s) across the
included BCM trials (see Figure 7), and applying it to the modelled proportion of all-cause hospitalisation
events estimated to be attributable to CV events (assumes that a 1.18 m/s reduction in PWV is
generalisable to the UK dialysis cohort). We also explored the impact of applying it to the all-cause
mortality rate in the model. These analyses should be treated with caution, as they rely on cross-sectional
associative evidence from an observational study to inform possible effects of bioimpedance monitoring.
It should be further noted that the pooled estimate for the effect of bioimpedance monitoring on PWV is
non-significant and based on results from only two trials, showing inconsistent results (see Figure 7).
However, the point estimate is applied in the base-case model and the uncertainty surrounding it is
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propagated through the probabilistic analysis. Furthermore, the negative interaction between increasing AAC
tertiles and the effect of baseline PWV on mortality and CV event-related hospitalisation, suggests that the
relative effect of reductions in PWV may be greater in lower-risk groups (with lower AAC scores). On the
other hand, evidence for an interaction in the prognostic value of baseline measures of these two variables
does not necessarily mean that the AAC score would modify the effect of an intervention-induced reduction
in PWV. Therefore, this model could potentially over- or underestimate the likely effects of the estimated
reduction in PWV on final health outcomes. Better evidence on the effects of intervention-induced reductions
in PWV are required to inform this issue.
As an alternative approach to indirectly estimate possible effects of bioimpedance-guided fluid management
on mortality and CV event-related hospitalisation, we considered linking the estimated pooled reduction in
SBP (2.46 mmHg; see Figure 11) to effects on CV events and mortality using a meta-analysis on the effects of
blood pressure-lowering medications in dialysis patients. Heerspink et al.115 estimated pooled relative risks
of 0.71 (0.55 to 0.92) for CV events and 0.8 (0.66 to 0.96) for all all-cause mortality across eight trials;
corresponding to a mean reduction in SBP of 4.5 mmHg. Assuming a log-linear relationship between SBP
reduction and the relative risk of events, these effects can be rescaled to the mean reduction in SBP across
included BCM trials (2.46 mmHg):
Relative risk for CV events for a 2.46-mmHg reduction in SBP:
= exp½ln(0:71) × (2:46 / 4:5)
=0:829:
(2)
Relative risk for all-cause mortality for a 3.44-mmHg reduction in SBP:
= exp½ln(0:80) × (3:44 / 4:5)
=0:885.
(3)
These effects are substantially larger than the estimated effects using PWV above, and suggest a potentially
larger effect on CV events than on all-cause mortality. However, it is uncertain if effects on SBP induced by
blood pressure medication can be generalised to potential reductions in SBP induced by the management of
fluid status, that is, some blood pressure medications are thought to have effects on CV events that are
independent of their blood pressure-lowering effects.116 Furthermore, there is a complex relationship
between fluid management and blood pressure,117 which makes it difficult to generalise. Nevertheless, the
effect of bioimpedance-guided fluid management on SBP (bordering on significance), suggests a possible
beneficial effect on both CV events and mortality. Therefore, we explored the impact of applying larger and
differential relative effects on these outcomes in further scenario analyses.
TABLE 9 Effect of a unit change in PWV on mortality and non-fatal CV events adapted from Verbeke et al.114
Variable HR (95% CI) Distribution Source
PWV (m/s) 1.154 (1.085 to 1.228) – Verbeke et al., 2011114
PWV × lower AAC 1 – –
PWV ×middle AAC 0.895 (0.828 to 0.968) – Verbeke et al., 2011114
PWV × upper AAC 0.865 (0.808 to 0.925) – Verbeke et al., 2011114
Average effect per unit change in PWV
across AAC tertiles = 1/{[(1.154 × 1) +
(1.154 × 0.895) + (1.154 × 0.865)]/3}
0.942 (0.879 to 1.009) Log-normal Assessment Group calculation
Inferred average effect for a 1.18 m/s
reduction in PWV of 0.942^1.18
0.9318 (0.829 to 1.048) Log-normal Assessment Group calculation
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Finally, we also explored the impact of using associations between overhydration and all-cause mortality
and hospitalisation rates to drive effects in the model. For this analysis, we used data from Chen et al.,80 to
estimate the proportion of patients who could be shifted from the overhydrated to the normally hydrated
states in the bioimpedance assessment and standard care arms of the model. This analysis assumed that
for everyone who is moved from the overhydrated (relative fluid overload > 15%) to the normally hydrated
state, the increased risks associated with overhydration are completely reversed. This was an optimistic
assumption, as, again, cross-sectional associations between baseline measures and final outcomes were
used to drive the effects of bioimpedance-guided fluid management in the model. The increased risk
associated with baseline overhydration may not be fully reversible for those that can be returned to normal
hydration status (≤ 15%).
A further problem with this approach is the lack of reporting in the RCTs on the effect of bioimpedance-
guided fluid management on the proportion of patients with pre-dialysis ROH of > 15% at baseline and
follow-up. Onofriescu et al.88 did report proportions of patients within, and > 1.1 kg above and below, the
BCM-guided target weight, and this study suggested no real change in the average percentage of patients
who were > 1.1 kg above target weight throughout the follow-up period. Yet, the study did demonstrate
a significant effect on PWV and mortality, leading the authors to speculate that the mechanism for effect
may be as much a result of the avoidance of chronic underhydration as overhydration. Huan-Sheng et al.76
reported a significantly larger reduction in mean overhydration (per litre) in patients with ROH of > 15%
at baseline. We used these data to approximate percentage reductions in ROH of > 15% (absolute
overhydration of > 2.5 litres) over the follow-up period by (1) assuming normal distributions for absolute
overhydration at follow-up up and (2) subtracting mean reported reductions in overhydration (per litre)
from simulated gamma distributions of baseline overhydration of > 2.5 litres. This yielded plausible
percentage reductions in ROH of > 15% from 28% to 38% with bioimpedance-guided management
relative to control. These were applied in model scenarios utilising the change in ROH status to drive
effects on all-cause mortality and all-cause hospitalisation.
Further hypothesised benefits of bioimpedance-guided fluid management that were not incorporated in
the main analyses included changes in quality of life (independent of effects on hospitalisation and CV
events), maintenance of residual renal function and effects on dialysis requirements (number and duration
of sessions).
None of the identified BCM trials reported on health-related quality of life, and only one included any
patient-reported outcomes.80 One observational study was identified that reported an association between
hydration status and quality of life in Korean PD patients, as measured by the Kidney Disease Quality of
Life-Short Form (KDQOL-SF) questionnaire. This showed that reductions in absolute overhydration (per litre)
between baseline and 12 months were associated with improvements in the physical component score
(1.81 points, 95% CI 0.78 to 2.84 points), mental component score (0.92 points, 95% CI 0.2 to 1.65
points) and the kidney disease component score (0.9 points, 95% CI 0.36 to 144 points), as measured by
the KDQOL-SF questionnaire. These analyses were adjusted for various potential confounders, including
age, sex, dialysis vintage, haemoglobin level, baseline overhydration status and comorbidities (as measured
by the Charlson Comorbidity Index). Although this study suggests that use of the BCM could lead to
improvements in heath-related quality of life (independent of effects on adverse events), it is not clear how
generalisable the reported changes are to the UK population. In addition, it is not possible to map from
changes in the reported aggregate component scores of the KDQOL-SF questionnaire to changes in health
state utility values. Furthermore, our model already captures QALY gains associated with prevention of
hospitalisation events and increasing comorbidity, and, therefore, including a constant utility increment
associated with the use of bioimpedance testing could lead to double-counting of QALY gains.
Nevertheless, the impact of including a 2% and 5% improvement in health state utility as a result of
improved interdialytic symptoms was assessed in a further scenario analysis.
The omission of residual renal function as an explicitly modelled state, and its knock-on effects on dialysis
requirements and outcomes as potential benefits, is justified by a current lack of supporting evidence.
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The only BCM trial that assessed proxies for residual renal function in HD patients reported a significant
increase in the proportion of anuric patients and a significant decrease in urine output in non-anuric
patients at 12 months in the bioimpedance assessment group.77 In the only other bioimpedance trial to
report renal output, PD patients randomised to bioimpedance-guided fluid management showed a slightly
larger reduction in mean urine volume at 12 weeks, although this was not statistically significant.88
There is a recognised risk that aggressively pursuing lower target weights using a high ultrafiltration rate
may in fact lead to increased morbidity/mortality as a result of hypoperfusion-induced ischaemic injury
and accelerated loss of residual renal function.118,119 Conversely, identifying patients that are severely
underhydrated and adjusting their target weight upwards may help to preserve residual renal function.
This question is currently being evaluated in two ongoing RCTs, one in PD patients120 and one in HD patients
based in the UK (see Table 5).94 If bioimpedance testing can preserve residual renal function in non-anuric
patients, then our model may underestimate the average benefits in the population as a whole. Conversely,
if the use of bioimpedance testing leads to decisions that accelerate the loss of residual renal function, this is
a disbenefit that could have knock-on effects on dialysis costs and adverse outcomes.
Related to the above issue, there is also a lack of evidence on the effects of bioimpedance monitoring on
the number, and the duration, of dialysis sessions required to achieve the prescribed target weight. A
potential cost-saving could be achieved through a requirement for fewer dialysis sessions in some incident
patients, if it is found to be effective in preserving residual renal function. As discussed above, this question
remains currently unanswered. Conversely, the use on bioimpedance spectroscopy could result indirectly in
increased dialysis costs through identification of patients that are severely overhydrated and require longer
or additional dialysis sessions to achieve their new target weight without exceeding safe ultrafiltration rates
and volumes.118 Our cost-effectiveness model assumes that any effects of bioimpedance-guided fluid
management on dialysis requirements are cost neutral.
Resource use estimation
The base-case cost-effectiveness model incorporates health service costs associated with maintenance
dialysis, blood pressure medication and ESAs (on dialysis), all-cause inpatient hospitalisation, renal
transplantation (including work-up, surgery and follow-up), post-transplantation immunosuppression and
outpatient visits (all expressed in 2014–15 pounds sterling).
Costs of renal replacement therapy
It has previously been noted that dialysis treatment for CKD results in high costs to the health service, and
that this can undermine the cost-effectiveness of technologies that prolong survival on dialysis. In some
circumstances, a technology that prolongs survival for patients receiving dialysis may not be cost-effective
at a price of zero. This has led to inconsistency across economic evaluations in the area of ESRD with
respect to whether or not dialysis costs are included. Some have argued that they should not be included
for interventions that aim to extend survival without impacting the need for dialysis.121 A further argument
for their exclusion is that a decision has already been made to fund dialysis on broader ethics/equity
considerations that are not reflected in the cost-effectiveness of dialysis itself. It may then seem unfair to
include dialysis costs when they act as an insurmountable barrier to demonstrating the cost-effectiveness
of other technologies that prolong survival on dialysis. The alternative argument is that dialysis costs do
represent a real opportunity cost associated with ongoing treatment for ESRD, and thus should be
included in the analysis. The NICE Decision Support Unit has produced a report on assessing technologies
that are not cost-effective at a price of zero, and this suggests that all NHS and Personal Social Services
costs that differ between the technology being appraised and the comparator technologies should be
included within the incremental cost-effectiveness ratio (ICER), as this provides the ICER that reflects the
real opportunity cost of recommending the technology being appraised.122 However, the report does also
note that a case could have been made in a previous technology appraisal of cinacalcet123 for treating
secondary hyperparathyroidism in ESRD, to exclude dialysis costs on the grounds that they are unrelated to
the treatment of secondary hyperparathyroidism (the condition of interest in the appraisal). A similar
argument was adopted in the modelling assessing the cost-effectiveness of alternative phosphate binders
for people with stages 4 and 5 CKD with hyperphosphataemia.98 In this example, the costs associated with
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dialysis were argued to be unaffected and unrelated to the choice of phosphate binder, with the target
condition being hyperphosphataemia.
Considering the above, it is difficult to argue that dialysis costs are unrelated to a technology being used
to guide fluid management decisions in patients receiving dialysis, and in theory the use of the technology
could have an impact on dialysis costs in survivors, as well as prolong survival on dialysis. Therefore, dialysis
costs are included in our base-case cost-effectiveness scenarios. However, it is a plausible argument that
the cost-effectiveness of dialysis reflected in our model does not capture its broader value to society,
relating to ethics and equity issues. Therefore, we also explored the impact of excluding dialysis costs.
Dialysis costs were taken from the current NHS reference costs.124 For HD costs, we took the weighted
average of the reference costs (per HD session) for the HRG codes LD01A to LD10A (at base and away
from base), weighted by the relative proportion of overall activity reported against each code. This was
multiplied by three sessions per week, and then by 52 to estimate the average annual cost of maintenance
HD. For PD, we applied the weighted average of the reference costs (per day) for HRG codes LD11A to
LD13A. These costs were multiplied by 365 to estimate total annual maintenance PD costs.
Transplantation costs were also taken from the reference costs, applying the average costs for HRG codes
LA01A, LA02A and LA03A (elective inpatient). We also included costs for follow-up post transplantation.
For year 1 this was derived from Treharne et al.97 To this we added the costs of immunosuppressant in
year 1, based on an initiation regimen in the first 2 weeks, and a maintenance regimen thereafter. For
the initiation period, we costed basiliximab [(Simulect®, Novartis Pharmaceuticals UK Ltd, Frimley, UK) day 0
and day 4], prednisolone [(Concordia International, Oakville, ON, Canada) 60 mg per day], mycophenolate
mofetil [(Cellcept®, Roche Products Limited, Welwyn Garden City, UK) 1 g twice daily] and tacrolimus
[5 mg twice daily (we used the average list price of Adoport®, Sandoz Ltd, Frimley, Camberley, Surrey, UK;
Prograf®, Astellas Pharma Ltd, Chertsey, UK; and Advagraf®, Astellas Pharma Ltd, Chertsey, UK)]. For
the maintenance period, we costed prednisolone (7.5 mg per day), mycophenolate mofetil (1 g twice
per day) and tacrolimus (5 mg twice daily). Beyond year 1 post transplant, we applied maintenance
immunosuppression costs and added average outpatient costs observed in the transplant cohort (see
Outpatient costs below). The maintenance dialysis and transplantation costs are provided in Table 10.
TABLE 10 Maintenance dialysis and transplantation costs
Resource use item Cost (£)
Quartile
Parameter
distribution SourceLower Upper
HD per session 154 130 169 Gamma NHS Reference Costs
2014 to 2015124
PD per day 69 50 69 Gamma NHS Reference Costs
2014 to 2015124
Transplant 14,915 11,720 17,797 Gamma NHS Reference Costs
2014 to 2015124
Follow-up post transplant (year 1)a 11,204 Treharne et al., 201497
Immunosuppressant costs (year 1) 10,622 NICE guidance (2015);125
expert opinion, BNF126
Annual immunosuppressant costs
(beyond year 1)
9054
BNF, British National Formulary.
a Excluding immunosuppressant drugs.
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Costs of unplanned inpatient hospitalisations
Annual inpatient hospital costs for patients on maintenance dialysis and post transplant were estimated
using the two-part model developed by Li et al.,100 as described above (see Modelled baseline risks and
Tables 7 and 8). The second part of this model predicts annual inpatient costs conditional on experiencing
any hospitalisation event(s) within a given year. Estimates are based on age, sex, years on dialysis (or years
following transplant), dialysis modality and the comorbidity status of the modelled cohort. The model also
accounts for increased costs in the year of death and the year preceding deaths that occur in the first half
of the following year. This reflects the increasing level of morbidity experienced by patients towards the
end of life.
To generate estimates of the cost incurred per hospitalisation event rather than costs per year, the
predicted annual cost is divided by the expected number of events per patient-year in our model. The
expected event rate is derived from the estimated annual probability of experiencing any hospital inpatient
event, assuming a constant event rate across the year. This results in a cost per hospitalisation event that
varies by the underlying characteristics of the modelled cohort, but comes to ≈ £4500 per event for
patients receiving HD and £4300 per event for patients receiving PD. These estimates are substantially
higher than costs per hospitalisation event that have been applied in previous models in the area of
ESRD.17,97,98 However, these previous models generally applied averages of aggregate reference costs. The
estimates derived from the data reported by Li et al.100 are based on a large data set of actual hospital
episodes costed according to admission code and adjusting for length of stay. Thus, the estimates derived
from Li et al.100 are applied in the base-case analysis. Alternative estimates are applied in a sensitivity
analysis. Furthermore, as the above approach makes a simplifying structural assumption of one
hospitalisation event per quarter, it will actually slightly underestimate annual inpatient hospital costs as
predicted by the published two-part model of Li et al.100 Therefore, we also applied a structural sensitivity
analysis in which the annual probability of hospitalisation and the conditional annual costs were applied
only in the first cycle of whole years.
A further limitation of the inpatient cost models reported by Li et al.100 is that they predict average costs
across all causes of admission. Thus, our base-case model assumes that both CV and other cause-related
hospitalisation events incur the same cost on average. A further uncertainty relates to the fact that some
inpatient costs will be unrelated to ESRD. However, as Li et al.100 noted, it is difficult to judge whether
individual admissions are related or unrelated, as ESRD is associated with increased risks of hospitalisation
across many major causes. The inclusion of all-cause hospitalisation as an outcome in a number of the
bioimpedance trials further justifies the inclusion of all-cause hospitalisation events in the baseline model.
Outpatient costs
Total outpatient costs for dialysis and transplant patients were also included in the base-case model.
These were taken simply as the observed annual outpatient costs on dialysis and transplant as reported by
Li et al.:100 £1202 per year for dialysis patients, and £2388 per year for transplant patients. These were
divided by four and applied per quarterly cycle in the model.
Costs of background medications for dialysis patients
Unit costs and the proportion of patients taking blood pressure medicine have been applied to provide the
total cost of blood pressure medicine (Table 11). The percentage of patients taking different types of blood
pressure medicine was taken from the baseline data of a RCT,127 which recruited dialysis patients from
three UK dialysis centres: Stoke-on-Trent, Leeds and Sheffield. For the different classifications of drugs,
prices for specific drug names commonly prescribed under each classification (informed by the clinical
advisor of the assessment group) were taken from the British National Formulary (BNF).126 Drugs were
costed at the recommended dose as described in the BNF.
We further considered the potential impact of incorporating an effect of bioimpedance testing on the
use/cost of blood pressure medication. Only two of the existing BCM trials reported on this outcome.60,63
Luo et al.63 reported no significant changes in the dose of blood pressure medication in either the control
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or BCM groups of their trial. Onofriescu et al.60 reported that there was no statistically significant change
from baseline to end of study in the percentage of patients taking blood pressure medication in the
control group of their trial, but they did report a significant within-group reduction in the BCM arm (from
66% to 55%). No formal comparison was reported for this outcome. However, as an exploratory analysis,
we assessed the impact of assuming a 10% reduction in blood pressure medication use in the bioimpedance
assessment arm of our model. To estimate the associated cost reduction, we assumed 68.4% of the cohort
would be taking at least one blood pressure medication,128 at an average cost of £129.81 (£88.76/£0.684)
per year. The average cost reduction associated with an absolute 10% reduction in the proportion of
patients on any blood pressure medication was then estimated:
(0:684 × £129:81) − (0:584 × £129:81) = £12:98: (4)
The unit costs, units per week and proportion of patients taking ESAs were applied to provide an estimate of
the total annual cost for ESAs for dialysis patients (Table 12). The proportion of patients taking an ESA was
taken from the UK Renal Registry report,99 that is, 87% of those receiving HD and 68% of those receiving PD.
The median dose for the corresponding population receiving HD and PD was 7400 international units (IUs)
and 4500 IU per week, respectively. Based on opinion obtained from the clinical advisor of the assessment
group, the unit cost per IU was derived as the average of the unit costs for epoetin beta (NeoRecormon®,
Roche Diagnostics, Hertford, UK) and darbepoetin alfa (Aranesp®, Amgen, Thousand Oaks, CA, USA) as
reported in the BNF (£0.00718 per IU). Thus, the total annual cost of ESAs was estimated to be £2403.69
( = 0.87 × 7400 × 52 × 0.00718) for people receiving HD and £1142 ( = 0.68 × 4500 × 52 × 0.00718) for
people receiving PD (see Table 12).
TABLE 11 Estimated average costs of blood pressure medications
Drug
Unit cost
per year (£)
Proportion of patients
under each classification
Total average
cost (£) Source
ACE inhibitor 33.33 0.211 7.03 Tan et al., 2016;127 BNF126
ARBs 98.19 0.156 15.29 Tan et al., 2016;127 BNF126
Calcium channel blockers 258.95 0.219 56.75 Tan et al., 2016;127 BNF126
Diuretics 10.82 0.487 5.26 Tan et al., 2016;127 BNF126
Beta blockers 17.14 0.248 4.25 Tan et al., 2016;127 BNF126
Alpha blockers 13.69 0.172 0.17 Tan et al., 2016;127 BNF126
Total average cost per year 88.76
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; BNF, British National Formulary.
TABLE 12 Cost of ESAs for patients receiving dialysis
Cost element
Dialysis
SourceHD PD
Proportion taking
ESAs (%)
87 68 UK Renal Registry 18th Annual Report of the Renal Association, 201599
Dose (IU) per week 7400 4500 UK Renal Registry 18th Annual Report of the Renal Association, 201599
Unit cost per IU (£) 0.00718 0.00718 BNF, 2016126 [average price per IU for NeoRecormon® (Roche Diagnostics,
Hertford, UK) and Aranesp® (Amgen, Thousand Oaks, CA, USA)]
Cost per year (£) 2403.69 1142
IU, international unit.
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Costs of bioimpedance testing/monitoring
The costs of the devices, provided by the companies (Table 13), were annuitised over 5 years using an
annual depreciation rate of 3.5%. The cost of the BCM was applied in the base-case analysis because of a
lack of clinical effectiveness evidence for the alternative devices. For comparison, we also estimated the
costs per patient-year and cost per test for the alternative devices, with identical assumptions about
numbers of tests and staff time requirements per patient. Estimated costs of BCM equipment maintenance
were provided at two levels: £250 for an annual maintenance contract, and £600 for annual maintenance,
including parts and labour. We included the higher-cost maintenance contract in the base-case scenarios,
but also assessed the impact of removing the maintenance costs in a sensitivity analysis.
The unit costs of staff involved in bioimpedance testing were taken from the Unit Costs of Health and
Social Care 2015 (Table 14).129 These were applied to estimates of staff time required to conduct and
interpret tests. They were also used to place a cost on staff time invested in training in the use of
bioimpedance testing. The company responsible for the BCM device indicated that it takes, on average,
5–10 minutes to conduct a test.4 In the base-case analysis, the time to perform the measurement was
assumed to be 7 minutes. The company responsible for the BCM device indicated that they provide free
training on its use, taking a half-day to attend. In the base-case analysis, the training was assumed to take
3.5 hours.
TABLE 13 Costs of the bioimpedance devices
Device
Purchase
price (£)
Expected service
life (years)
Cost (£)
EAC Quarterly Maintenance
Maintenance, including
parts and labour
BCM 5750 5 1273.52 318.38 250 600
MultiScan 5000 7600 5 1683.26 420.81 70a –
BioScan 920-II 4950 5 1096.33 274.08 333b –
InBody S10 8100 5 1794.00 448.50 – –
EAC, equivalent annual cost.
a Assumes a replacement set of leads annually.
b Assumes replacement or repair of cables every 2 years and an annual calibration check.
TABLE 14 Staff unit costs
Staff
Cost (£)
Source
Per patient
contact hour
Per contracted
hour
Per patient contact,
assumed to be
7 minutes in duration
Grade 6 hospital nurse 109.00 45.00 12.72 PSSRU, 2015129
Consultant medical 139.65 105.00 16.29 PSSRU, 2015; PSSRU, 2010129
Clinical support workera 52.47 21.19 6.12 PSSRU, 2014129
Registrar group
(40 hour week)b
65.17 49.00 7.60 PSSRU, 2015129
Hospital dietitian 45.00 34.00 5.28 PSSRU, 2010; PSSRU, 2015129
a The technicians are costed at the same band as clinical support workers.
b The cost per hour of patient contact is not available for the registrar group; therefore, the same ratio for a hospital
consultant was assumed.
DOI: 10.3310/hta22010 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 1
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Scotland et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
To gain a better understanding of the number of bioimpedance devices required to cover quarterly testing
of the dialysis population, a brief questionnaire (see Appendix 11) was sent to the specialist members of
the appraisal committee. Six different members responded, although three were from a single large centre
covering adults and children. Therefore, we had information on testing practices from three centres
covering adults, and two centres covering children (one exclusively). The adult centres were relatively large,
with 538–942 dialysis patients in total, compared with the average in England of 456.99 The impact of
adopting lower extremes of device throughput was assessed in the sensitivity analysis.
The questionnaire included questions about centre size (number of HD and PD patients), number of
satellite units, current practice with respect to fluid management decisions, and current practice regarding
the use of bioimpedance testing. Questions were also included about the estimated level of resource that
would be required to conduct quarterly testing of all HD and PD patients for whom the individual’s centre
was responsible. Respondents from two of the centres described a situation in which the majority of their
patients were already being monitored using bioimpedance testing at least every 3 months. For the third
centre, it was noted that bioimpedance testing was not currently performed systematically, but was rather
used for selected patients. Consequently, only the anticipated resource use required for quarterly
bioimpedence testing was used for this centre.
Details of relevant resources and costs required for quarterly testing, based on the responses from the
three adult centres, are summarised in Table 15. Total equipment costs were estimated by multiplying the
equivalent annual cost per device by the estimated number of devices required for quarterly monitoring of
all dialysis patients across the centres. This was then divided by the total number of patients to estimate
the cost of equipment per patient per year, and then further divided by four to estimate the equipment
costs per test performed. For example, centre A reported 15 bioimpedance devices to cover a total of 585
patients [(£1273.52 × 15)/585 = £32.65]. The maintenance costs also depended on the reported number
of devices required by the centre to cover quarterly testing of its dialysis population. The total estimated
annual maintenance cost, with and without parts and labour, was allocated across patients using the same
approach as for equivalent annual costs of equipment. The larger centre latterly reported that it did not
take out a maintenance contract on its machines, and so we also explored the impact of removing these
costs completely.
Staff costs associated with the time required to conduct each test were estimated based on 7 minutes of
direct patient contact with a band 6 nurse [7 × (£109/60) = £12.72]. This was further multiplied by four to
estimate the staff costs per patient per year (£12.72 × 4 = £51). The added consultant time required to
interpret the findings of each bioimpedance test was assumed to be 5 minutes in the base-case analysis
[5 × (105/60) = £8.75]. Total training costs for each centre were estimated based on the number of
different grades of staff trained, multiplied by their costs per contract hour and the number of hours of
training attended. This total initial investment was spread over 5 years, and the equivalent annual cost was
divided by the number of patients in the centre to give a cost per patient per year. For example, for centre
A the total training costs were estimated to be £11,171. Annuitised over 5 years, this comes to £2474 and
£4.23 per patient per year (2474/585).
Finally, to estimate the total annual cost of adding bioimpedance testing to standard practice, the total
cost of consumables (electrodes and patient cards), also based on quarterly testing (Table 16), was added
to the estimated device, maintenance, staff time and training costs. The total estimated cost per patient-
year for each adult centre, and the average cost per patient across centres, is reported in Table 17 for each
device. For the base-case cost-effectiveness analysis, we applied the average cost per patient per year using
the BCM, based on the higher maintenance costs (£101.41), and applied a distribution incorporating the
lower and upper 95% confidence limits of £85 to £125. Given some uncertainty regarding the ongoing
maintenance costs for each device, Table 17 also presents estimated costs per patient-year for each device,
excluding all maintenance costs. The costs are very similar across the different devices. In addition to the
estimates presented in Table 17, based on responses from dialysis units, we also estimated a cost per
patient-year based on responses from two paediatric units. As a result of substantially lower throughput,
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TABLE 15 Resource use and costs of bioimpedance testing
Resource use
Centre
A B C
Patients/equipment
Number of patients receiving HD 529 788 456
Number of patients receiving HD 56 154 82
Total number of dialysis patients 585 942 538
Assumed number of tests per year 4 4 4
Estimated number of devices required 15 5 6
Estimated equipment cost per patient-year (£) 32.65 6.76 14.20
Estimated equipment cost per patient test, assuming four tests per year (£) 8.16 1.69 3.55
Estimated maintenance cost per patient (£) 6.41 1.33 2.79
Estimated maintenance cost per patient, including parts and labour (£) 15.38 3.18 6.69
Total staff cost (£)a 12.72 12.72 12.72
Total staff cost per year, assuming four tests per year at 7 minutes of band
6 nurse time
51.00 51.00 51.00
Total cost of interpreting results of test, assuming four tests per year at
5 minutes of consultant time
9.00 9.00 9.00
Staff for training, n
Consultant nephrologists – 2 –
Trainee nephrologists – 8 –
Nurses 60 32 8
Technicians
Dieticians 2 2 5
Others 20 – –
Total training cost, assuming a 3.5-hour commitment (£) 11,171.16 7385.00 1855.00
Assumed average useful life of training (years) 5 5 5
Total EAC of training (£) 2474.20 1635.64 410.85
EAC of total training per patient (£) 4.23 1.74 0.76
EAC, equivalent annual cost.
a Assume nurse (band 6) performs the measurement using the BCM.
TABLE 16 Cost (£) of device consumables
Consumable
Device
BCM Multiscan 5000 Inbody S10 BioScan 920-II
Electrodes (per test) 3.00 1.10 Reusable 0.65
Electrodes (per year) – assuming four tests annually 12.00 4.40 Reusable 2.60
Patient cards (per card) – 20 readings 6.28 N/A N/A N/A
Patient cards (per year) – assuming four tests annually 1.26 N/A N/A N/A
Results sheets (per year) – assuming four tests annually N/A N/A 2.08 N/A
Total 13.26 4.40 2.08 2.60
N/A, not applicable.
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the costs were significantly higher: £149–349 based on four tests per year and £243–451 based on
12 tests per year. However, these may be overestimated in situations where devices can be shared
between adults and children.
Health measurement and valuation
Health state utility values for patients on dialysis and post transplant were identified from a focused review
of the literature. We first identified two systematic reviews of utility data in the context of ESRD incorporating
studies relevant to the NICE reference case [reporting EuroQol-5 Dimensions (EQ-5D) data for UK patients].130,131
We focused our searches on identifying any more recent studies published following December 2010 (the end
date of the search conducted for the most recent systematic review). This identified no further studies reporting
EQ-5D values, specifically for UK patients. The systematic review conducted by Wyld et al.131 included a random-
effects metaregression to predict utility based on several factors: treatment (transplant, dialysis, pre-treatment,
conservative management) and method of utility elicitation. This model predicted an EQ-5D utility value of
0.64 for patients receiving dialysis and 0.75 for transplant patients. However, a limitation of this study was that
some of the EQ-5D scores were measured from mapping algorithms, and the age to which the mean utility
estimates applied was not reported. The earlier systematic review by Liem et al.130 restricted a meta-analysis to
those studies using the EQ-5D index directly for each modality of RRT, and reported the pooled mean age and
sex distribution for the corresponding pooled EQ-5D values. These are reported in Table 18. The age- and
sex-matched EQ-5D UK population norms were calculated using an equation published by Ara and Brazier132
and used to derive age-/sex-adjusted utility multipliers from the raw pooled estimates.133 The alternative utility
values derived from Wyld et al.131 were applied in a sensitivity analysis, assuming the same age and sex
distributions, as reported by Liem et al.130 for purposes of adjustment.
A significant proportion of inpatient hospitalisations are associated with CV events in the dialysis
population, as assumed in the model. It is reasonable to assume that such events will be associated with
short-term and lasting disutility. This is the assumption that is used in CV event models in non-dialysis
populations, and the best-recognised source of English EQ-5D data for different CV event histories is the
Health Survey for England, as reported by Ara and Brazier.132 Therefore, these data were used to estimate
age-adjusted utility multipliers during the first and subsequent years following different types of CV event.
A weighted average of these multipliers for the first and subsequent years was then calculated (based on
relative frequency of CV event histories in the dialysis population) and applied to the proportion of the
cohort modelled to experience an incident CV event. For example, a cohort of 60-year-old patients, who
were stable and receiving HD, would be assigned a utility value of 0.56, whereas a cohort of 60-year-old
patients, receiving HD who experienced an incident CV event within 1 year, would be assigned a utility of
TABLE 17 Estimated annual cost (£) per patient per year for quarterly testing using the BCM and alternative devices
Device
Centre, annual cost
per patient
Average cost per patient
across all centresA B C
BCM, including maintenance contract without parts and labour 116 83 91 96.50
BCM, including maintenance cost with parts and labour 125 85 95 101.41
Multiscan 5000 114 75 85 91.22
Inbody S10 119 74 86 93.03
Bioscan 103 72 79 84.51
BCM, excluding any maintenance costs 110 81 88 92.99
Multiscan 5000, excluding any maintenance costs 112 75 84 89.88
Inbody S10, excluding any maintenance costs 114 73 83 90.36
Bioscan, excluding any maintenance costs 95 70 75 79.85
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TABLE 18 Utility estimates and age-adjusted utility multipliers applied in the model
Model state
Health state
utility value SE
Age of
cohort
(years)
Proportion of
patients who
were male
Age-related
population
norm
Age-adjusted
multiplier for
use in model
Adjusted
SE Source
Stable HD 0.560 0.033 60.400 0.580 0.826 0.678 0.040 Liem et al. 2008;130 Ara and Brazier, 2010132
Stable PD 0.580 0.043 57.900 0.550 0.836 0.694 0.052 Liem et al. 2008;130 Ara and Brazier, 2010132
Stable post transplant 0.810 0.046 51.400 0.600 0.863 0.939 0.053 Liem et al. 2008;130 Ara and Brazier, 2010132
CV events
MI within 12 months 0.721 0.045 65.4 0.500 0.803 0.898 0.056 HSE data (Ara and Brazier, 2010)132
MI history 0.742 0.02 65.1 0.500 0.804 0.923 0.025 HSE data (Ara and Brazier, 2010)132
Angina within 12 months 0.615 0.019 68.8 0.500 0.787 0.782 0.024 HSE data (Ara and Brazier, 2010)132
Angina history 0.775 0.015 68.0 0.500 0.790 0.981 0.019 HSE data (Ara and Brazier, 2010)132
Stroke within 12 months 0.626 0.038 67.9 0.500 0.791 0.792 0.048 HSE data (Ara and Brazier, 2010)132
Stroke history 0.668 0.018 66.8 0.500 0.796 0.839 0.023 HSE data (Ara and Brazier, 2010)132
Any new CV event within
12 months
– – – – – 0.832 0.042 Weighted average of parameters above
New CV event history – – – – – 0.931 0.022 Weighted average of parameters above
HSE, Health Survey for England; MI, myocardial infarction.
D
O
I:10.3310/hta22010
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.1
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Scotland
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
51
0.466 (0.56 × 0.832) and a cohort of 60-year-old patients, who had gone over 1 year since an incident CV
event had occurred, would be assigned a utility value of 0.521 (0.56 × 0.931).
Finally, hospitalisations for any other reason were also assumed to incur an acute utility decrement. These
were taken from the modelling used to inform the NICE guidelines on PD.17 In the modelling for these
guidelines, a 6% reduction was applied to any dialysis complication.17 The same 6% reduction is applied in
our model for the second half of the 3-month cycle in which complications occur.
Time horizon and discounting of costs and benefits
The modelling was analysed over the lifetime of patients: 30 years for a cohort of 66-year-old patients in the
base-case analysis. The time horizon was extended in years for scenario analyses involving younger cohorts.
The lifetime horizon was chosen to fully capture any survival or ongoing quality-of-life benefits associated
with bioimpedance testing. All future costs and benefits were discounted at a rate of 3.5% per annum.
Analysis
The results of the model are presented in terms of a cost–utility analysis over the lifetime of the simulated
cohorts. The bioimpedance-guided fluid management strategy is compared incrementally with standard
care, to estimate its incremental costs and QALYs. This is expressed as the ICER. The net benefit framework
is used to identify the optimal fluid management strategy at different threshold ratios of willingness to pay
per QALY. To characterise the joint uncertainty surrounding point estimates of incremental costs and
effects, probabilistic sensitivity analyses were undertaken. All costs were assigned either normal or gamma
distributions, utility multipliers were assigned beta distributions and HRs were assigned log-normal
distributions using the point estimates and CIs (or SEs) reported in Tables 6, 9, 10 and 18. The parameters
of the derived Weibull survival functions were entered deterministically for the dialysis cohort, but as a
multivariate normal distribution for post-transplant survival. Distributions for the computed hospitalisation
rates and associated costs were assigned SDs set at 10% of the mean. The results of the probabilistic
analyses are presented in the form of cost-effectiveness acceptability curves (CEACs). Further deterministic
sensitivity analyses were used to address other forms of uncertainty.
The primary analysis was conducted for a mixed cohort of patients receiving HD or PD. Subgroup analyses
were conducted to explore any differences in cost-effectiveness by mode of dialysis and, when data
allowed, by characteristics of the patient population. The impact of applying different assumptions with
respect to testing frequency and throughput was also explored through scenario analyses. Scenario
analyses were also used to explore the impact on cost-effectiveness of other sources of uncertainty.
Cost-effectiveness results
The model was first set up to assess the cost-effectiveness of bioimpedance-guided fluid management
versus standard care for a mixed cohort of HD (87%) and PD (13%) patients.
The key assumptions of the base model are as follows:
l The starting age of the cohort is 66 years.
l Survival with HD and PD treatment is equivalent, and patients do not switch between dialysis modes.
l Survival to 10 years with dialysis treatment is based on parametric extrapolation of 5-year survival
curves, reported for patients in the European renal registry.102
l Survival beyond 10 years is estimated by applying published, age-specific, relative risks of death to RRT
cohorts compared with general population norms.99
l Fixed proportions of the cohort are on a waiting list for transplant, and wait a median of ≈ 3 years,
conditional on survival.107 No transplants occur beyond the age of 75 years.
l Following graft failure, transplant patients incur costs of dialysis, that is, no further transplants
are modelled.
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l Probabilities of all-cause inpatient hospitalisation are estimated by age band, time receiving RRT, RRT
modality, sex and comorbidity status, using a published regression based on linked UK Renal Registry –
HES data.100
l It is assumed that 17.6% of all inpatient hospitalisations are caused by CV events.
l Health state utility decrements are applied in the acute period for all hospitalisation events, and
ongoing health state utility decrements are also applied post CV event-related hospitalisation.110
l First-incident CV event-related hospitalisations increase the comorbidity burden on the cohort by one,
resulting in an increased risk of hospitalisation in subsequent cycles.
l Costs of dialysis, treatment for anaemia (ESA), blood pressure medication, all inpatient hospitalisations,
all outpatient attendances, renal transplants, post-transplant hospitalisations, outpatient attendances
and post-transplant immunosuppression are included in the base model.
l Costs of CV event-related hospitalisation are assumed to be equal to the average cost across all
hospitalisations in dialysis patients (i.e. CV events account for 17.6% of all hospitalisation costs).
l The incremental cost of monitoring patients using bioimpedance testing is added in the bioimpedance
assessment arm of the model (assuming four tests per year).
l Effects of bioimpedance monitoring on all-cause mortality are applied for 10 years in the model.
l Effects of bioimpedance monitoring on CV event-related or all-cause hospitalisation are applied over
the lifetime of the cohort.
l Costs and QALYs are discounted at a rate of 3.5% per annum.
The following set of results are based on several alternative base-case scenarios with respect to the
possible effects of bioimpedance-guided fluid management on mortality, hospitalisation rates and blood
pressure medication use. There is significant uncertainty surrounding the clinical effectiveness of
bioimpedance monitoring, as highlighted in the clinical effectiveness chapter. Therefore, the point
estimates of incremental cost-effectiveness should be treated with caution.
The main clinical effectiveness scenarios explored are described below and summarised in Table 19.
1. Only the pooled HR (0.689, 95% CI 0.228 to 2.084) for the effect of bioimpedance testing on
mortality is applied to the base model. It should be noted that this pooled effect from the meta-analysis
(see Figure 8) is not statistically significant, but directionally favours bioimpedance-guided fluid
management. Given uncertainty regarding long-term effects, this effect is applied over 10 years in the
model (up to cycle 40).
2. A possible effect of bioimpedance testing on non-fatal CV events is added to the effect on mortality in
scenario 1. The applied HR (0.9318, 95% CI 0.829 to 1.048) was derived as described in Incorporation
of relative treatment effects using published observational data on the prognostic value of PWV for CV
TABLE 19 Summary of effect estimates applied for bioimpedance-guided fluid management in the main scenarios
Scenario
Relative effect on
all-cause mortality,
HR (95% CI)
Relative effect
on non-fatal CV
hospitalisation,
HR (95% CI)
Effect on blood
pressure
medication costs
(mean reduction), £
Proportional
reduction in severe
overhydration
(ROH of > 15%)
Scenario 1 0.689 (0.228 to 2.084) 1 0 N/A
Scenario 2 0.689 (0.228 to 2.084) 0.932 (0.829 to 1.048) 0 N/A
Scenario 3 0.932 (0.829 to 1.048) 0.932 (0.829 to 1.048) 0 N/A
Scenario 4 0.932 (0.829 to 1.048) 0.932 (0.829 to 1.048) –12.98 N/A
Scenario 5 N/A N/A N/A 0.28
Scenario 6 N/A N/A N/A 0.38
N/A, not applicable.
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events and mortality (see Table 9), combined with the pooled mean reduction in PWV (see Figure 7)
observed across the bioimpedance trials included in our systematic review. This scenario is heavily
caveated by the application of non-significant effects on PWV, combined with observational prognostic
evidence, to model possible effects on health outcomes.
3. This scenario applies the same effect, derived through the pooled reduction in PWV, to both mortality
and non-fatal CV events in the model, that is, a HR of 0.9318 is applied to both all-cause mortality and
the CV event-related hospitalisation rate. This scenario comes with the same caveats as scenario 2.
4. Scenario 4 replicates scenario 3, but adds a possible effect of bioimpedance-guided fluid management
on blood pressure medication use. As described under Costs of background medications for dialysis
patients, a possible cost reduction of £12.98 per year was derived from existing trial evidence. Note,
however, that this was only observed/reported in one of the RCTs,57 and was not based on a formal
adjusted comparison.
5. Scenario 5 uses reported observational associations between baseline hydration status (as measured by
the BCM) and mortality and all-cause hospitalisation. The effect of bioimpedance testing is modelled
through a plausible reduction in the proportion of the cohort (25%) that is severely overhydrated
(ROH of > 15%).80 Using data reported by Huan-Sheng et al.,76 it was estimated that the proportion of
severely overhydrated patients could be reduced proportionally by 28–38% with bioimpedance-guided
fluid management relative to control. This scenario applies a 28% proportional reduction in severe
overhydration in the bioimpedance assessment arm of the model.
6. Scenario 6 replicates scenario 5, but applies a 38% proportional reduction in severe overhydration in
the bioimpedance assessment arm of the model.
Table 20 presents the model-based cost-effectiveness findings for the main clinical effectiveness scenarios
1–6 (described above). Across the scenarios, bioimpedance-guided fluid management comes out as the
more costly strategy, resulting in increased costs to the health service between £4519 and £35,680.
These increased costs are accompanied by QALY gains under the alternative effectiveness scenarios
between 0.07 and 0.58. The ICERs for bioimpedance testing range from £59,551 to £66,013 per QALY
gained. It should be noted that the increased costs associated with bioimpedance-guided fluid management
are primarily driven by the high dialysis costs during life-years gained. The cost of bioimpedance testing is
modest, adding, on average, £101 per patient-year.
As discussed in Costs of renal replacement therapy, others have argued for the exclusion of dialysis costs in
the assessment of technologies that aim to extend survival of patients receiving dialysis without influencing
the need for dialysis, as these technologies can act as an insurmountable hurdle to demonstrating
cost-effectiveness. The results for effectiveness scenarios 1–6 with dialysis costs excluded are therefore
provided for comparison in Table 21. It can be noted that this results in a large reduction in the ICERs for
bioimpedance testing, ranging between £15,644 and £21,206 per QALY gained. Note, however, that these
point estimates are based on uncertain effects incorporated as deterministic point estimates.
Markov traces
Figures 14 and 15 show the Markov traces for the standard care arm and the bioimpedance assessment
arm under clinical effectiveness scenario 3. In the standard care arm, the 10-year mortality for the cohort
of 66-year-old patients was 78.8%. This is consistent with the observed 10-year mortality in UK patients
receiving RRT surviving beyond 90 days (≈ 68% in 56- to 64-year-olds and ≈ 88% in 65- to 74-year-olds).99
Assuming a constant effect of bioimpedance-guided fluid management on mortality, the 10-year mortality
in the bioimpedance assessment arm was 76.6%. Over the lifetime of the modelled cohort, the gain in
undiscounted life expectancy was 0.29 years (6.29 vs. 6.0 years). The modelled lifetime cumulative incidence
of any CV hospitalisation event was 46.9% in the bioimpedance assessment arm of the model, and 47.1%
in the standard care arm. A total of 7.8% of patients in the bioimpedance assessment arm received a
transplant during their lifetime, while the corresponding figure was 7.6% in the standard care arm.
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Table 22 provides a breakdown of the cumulative costs for the standard care and bioimpedance
measurement arms, respectively, under clinical effectiveness scenario 3. The costs were higher across all
categories in the bioimpedance measurement arm, as a result of the slight increase in survival. However,
it can be noted that it was the additional dialysis costs in extra years that made up 74% of the total
incremental cost of the bioimpedance-guided strategy. This same pattern was consistent across all the
main clinical effectiveness scenarios (1–6). The actual increase in lifetime costs, as a result of bioimpedance
testing, was small (£491 per patient in clinical effectiveness scenario 3).
Deterministic sensitivity analysis
Figures 16 and 17 illustrate the effects of a one-way sensitivity analysis on key model input parameters,
with dialysis costs included (see Figure 16) and excluded (see Figure 17). The reference ICERs for both
these tornado diagrams reflected clinical effectiveness scenario 3, that is, a HR of 0.9318, inferred through
the pooled reduction in PWV, applied to both all-cause mortality and CV event-related hospitalisation.
When dialysis costs were included, the ICER for bioimpedance-guided fluid management was most
sensitive to changes in the HR for the effect on all-cause mortality. The most favourable ICER (£40,283)
occurred when the HR on all-cause mortality was equal to one, as this equalised survival and eliminated
the excess dialysis costs incurred in added years.
TABLE 20 Deterministic cost-effectiveness scenarios for bioimpedance-guided fluid management vs. standard
practice (including dialysis costs)
Strategy
Cost (£) QALYs
ICER (£) NMB (£)Mean Incremental Mean Incremental
1. Applying the point estimate for the pooled effect of BCM measurement on mortality only (HR = 0.689)
Standard care 158,124 – 2.7014 – – –104,097
BCM 193,805 35,680 3.2719 0.5706 62,532 –128,366
2. Applying the point estimate for the pooled effect of BCM measurement on mortality (HR = 0.689), and a linked effect on
non-fatal CV events through the pooled reduction in PWV (HR= 0.9318)
Standard care 158,124 – 2.7014 – – –104,097
BCM 193,497 35,373 3.2791 0.5777 61,228 –127,916
3. Applying linked effects on mortality and non-fatal CV events through the pooled reduction in PWV (HR = 0.9318)
Standard care 158,124 – 2.7014 – – –104,097
BCM 165,077 6952 2.817 0.1157 60,095 –108,736
4. Applying linked effects on mortality and non-fatal CV events through the pooled reduction in PWV (HR = 0.9318),
and a 10% reduction in the use of blood pressure medications
Standard care 158,124 – 2.7014 – – –104,097
BCM 165,014 6889 2.817 0.1157 59,551 –108,673
5. Modelling effects of bioimpedance testing through associations between severe overhydration and mortality and all
cause-hospitalisation (assumes a 28% reduction in severe overhydration)
Standard care 162,059 – 2.77 – – –106,708
BCM 166,578 4519 2.84 0.07 66,013 –109,858
6. Modelling effects of bioimpedance-guided fluid management through associations between severe overhydration and
mortality and all cause-hospitalisation (assumes a 38% reduction in severe overhydration)
Standard care 162,059 – 2.77 – – –106,708
BCM 168,019 5960 2.86 0.09 64,157 –110,810
NMB, net monetary benefit.
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When dialysis costs were excluded, the ICER remained most sensitive to the HR on all-cause mortality.
Results were also moderately sensitive to the utility multiplier for HD, the cost of HD and the HR for CV
event-related hospitalisation. However, when dialysis costs were included, the ICER remained well above
£30,000 when these parameters were varied within their ranges. Conversely, the ICERs all remained below
£30,000 when the parameters were varied individually within their ranges (referent to clinical effectiveness
scenario 3) with dialysis costs excluded.
Scenario analyses
Table 23 presents the results of further scenario analyses, referent to clinical effectiveness scenario 3
(HR of 0.9318 applied to all-cause mortality and CV event-related hospitalisation). Unless otherwise stated,
these additional scenarios excluded dialysis costs to better illustrate sensitivity (around the cost-effectiveness
threshold) when the exclusion of dialysis costs was considered to be appropriate for the purpose of
decision-making. Under most of the scenarios with dialysis costs excluded, the ICER for bioimpedance
monitoring remained below £30,000, and was most often below £20,000.
Under only a few scenarios did the ICER for bioimpedance monitoring fall close to or below £30,000 when
dialysis costs were included, when assuming that bioimpedance testing would result in a 5% or 10%
reduction in dialysis costs (scenarios 15 and 16) over the lifetime of patients and when it was assumed that
TABLE 21 Deterministic cost-effectiveness scenarios for bioimpedance-guided fluid management vs. standard
practice (excluding dialysis costs)
Strategy
Cost (£) QALYs
ICER (£) NMB (£)Mean Incremental Mean Incremental
1. Applying the point estimate for the pooled effect of BCM measurement on mortality only (HR = 0.689)
Standard care 46,234 – 2.7014 – – 7793
BCM 55,579 9345 3.2719 0.5706 16,378 9859
2. Applying the point estimate for the pooled effect of BCM measurement on mortality (HR = 0.689), and a linked effect on
non-fatal CV events through the pooled reduction in PWV (HR= 0.9318)
Standard care 46,234 – 2.7014 – – 7793
BCM 55,272 9038 3.2791 0.5777 15,644 10,309
3. Applying linked effects on mortality and non-fatal CV events through the pooled reduction in PWV (HR = 0.9318)
Standard care 46,234 – 2.7014 – – 7793
BCM 48,153 1919 2.817 0.1157 16,587 8188
4. Applying linked effects on mortality and non-fatal CV events through the pooled reduction in PWV (HR = 0.9318),
and a 10% reduction in the use of blood pressure medications
Standard care 46,234 – 2.7014 – – 7793
BCM 48,090 1856 2.817 0.1157 16,044 8250
5. Modelling effects of bioimpedance testing through associations between severe overhydration and mortality and
all-cause hospitalisation (assumes a 28% reduction in severe overhydration)
Standard care 47,066 – 2.77 – – 8285
BCM 48,517 1452 2.84 0.07 21,206 8203
6.Modelling effects of bioimpedance-guided fluid management through associations between severe overhydration and
mortality and all-cause-hospitalisation (assumes a 38% reduction in severe overhydration)
Standard care 47,066 – 2.77 – – 8285
BCM 48,863 1798 2.86 0.09 19,350 8346
NMB, net monetary benefit.
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FIGURE 14 Markov cohort trace: standard care arm (one stage equals 3 months).
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FIGURE 15 Markov cohort trace: BCM measurement arm, under clinical effectiveness scenario 3 (one stage equals 3 months).
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bioimpedance-guided fluid management would result in a 5% increase in health state utility, maintained
over the lifetime of all dialysis patients (scenario 13). However, there are very few data available to justify
these possible scenarios.
Subgroup analysis
Table 24 presents the results of the analysis that considered key subgroups of the dialysis population.
Separate analyses were considered by comorbidity status (none/at least one), dialysis modality (HD/PD),
starting age of the cohort (55 years rather than 64 years) and transplant listing (yes/no). For comparability,
all of these analyses were conducted with clinical effectiveness scenario 3 (HR of 0.912 for the effect of
bioimpedance monitoring on mortality and CV hospitalisation). Finally, we also conducted a subgroup
analysis using the overhydration states in the model (clinical effectiveness scenario 6), with the effect of
bioimpedance testing modelled through a plausible proportional reduction in severe overhydration (ROH of
TABLE 22 Breakdown of cumulative costs by categories
Cost category
Treatment arm, cost (£) Difference in cost (£)
between BCM measurement
and standard careStandard care BCM measurement
Cumulative inpatient hospital costs 21,795 22,281 486
Cumulative dialysis costs 111,890 116,923 5033
Cumulative medication costs 10,792 11,277 485
Cumulative outpatient costs 6076 6349 273
Cumulative acute transplant cost 1066 1093 27
Cumulative post-transplant follow-up costs 6505 6663 158
Bioimpedance testing costs N/A 491 491
Cumulative cost 158,124 165,077 6952
N/A, not applicable.
40 45 50 55 60 65 70
c_Transplant (11,720 to 17,797)
u_multiplier_CV_event (0.75 to 0.914)
u_multiplier_transplant (0.835 to 1)
u_multiplier_post_CV_event (0.888 to 0.974)
c_Peritoneal_Dialysis (18,263 to 25,202)
u_multiplier_PD (0.592 to 0.796)
c_annual_hospitalisation (± 25%)
c_Bioimp (70 to 125)
p_annual_hosp (± 25%)
c_Haemo_Dialysis (20,280 to 26,364)
u_multiplier_ICHD (0.6 to 0.756)
HR_BCM_CV_hosp (0.77 to 1.05)
HR_BCM_ACM (0.77 to 1.05)
ICER (£000)
EV: £60,095
FIGURE 16 One-way sensitivity analysis: BCM measurement vs. standard care (clinical effectiveness scenario 3,
including dialysis costs). ACM, all-cause mortality; Bioimp, bioimpedance; c, cost; EV, expected value;
ICHD, ischaemic coronary heart disease; p, probability; u, utility.
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9 14 19 24 29 34 39 44
c_Transplant (11,720 to 17,797)
u_multiplier_CV_event (0.75 to 0.914)
u_multiplier_transplant (0.835 to 1)
u_multiplier_post_CV_event (0.888 to 0.974)
u_multiplier_PD (0.592 to 0.796)
p_annual_hosp (– 25% to + 20%)
c_annual_hospitalisation (± 25%)
c_Bioimp (70 to 125)
u_multiplier_ICHD (0.6 to 0.756)
HR_BCM_CV_hosp (0.77 to 1.05)
HR_BCM_ACM (0.77 to 1.05)
ICER (£000)
EV: £16,587
FIGURE 17 One-way sensitivity analysis: BCM vs. standard care (clinical effectiveness scenario 3, excluding dialysis
costs). ACM, all-cause mortality; Bioimp, bioimpedance; c, cost; EV, expected value; ICHD, ischaemic coronary heart
disease; p, probability; u, utility.
TABLE 23 Scenario analyses referent to base clinical effectiveness scenario 3 (all analyses exclude dialysis costs
unless stated otherwise)
Strategy
Cost (£) QALYs
ICER (£) NMB (£)Mean Incremental Mean Incremental
Base-case scenario 3: applying linked effects on mortality and non-fatal CV events, estimated through the pooled reduction
in PWV (HR of 0.9318 applied to both all-cause mortality and CV event-related hospitalisation)
Standard care 46,234 – 2.7014 – – 7793
Bioimpedance-guided fluid
management
48,153 1919 2.817 0.1157 16,587 8188
Applying an increased cost of monitoring in adults by increasing the number of tests per patient to 12 annually (£229.65)
Standard care 46,234 – 2.7014 – – 7793
BCM 48,774 2540 2.817 0.1157 21,953 7567
1. Applying the estimated costs of bioimpedance monitoring in paediatric centres with lower throughput (assuming four
tests annually)a (£245.32)
Standard care 46,234 – 2.7014 – – 7793
BCM 48,850 2616 2.817 0.1157 22,609 7491
2. Applying the estimated costs of bioimpedance monitoring in paediatric centres with lower throughput (assuming 12 tests
annually)a (£347.06)
Standard care 46,234 – 2.7014 – – 7793
BCM 49,342 3108 2.817 0.1157 26,866 6998
3. Applying the cost of BioScan for bioimpedance monitoring (£84.51)
Standard care 46,234 – 2.7014 – – 7793
BioScan 48,071 1837 2.817 0.1157 15,880 8269
continued
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TABLE 23 Scenario analyses referent to base clinical effectiveness scenario 3 (all analyses exclude dialysis costs
unless stated otherwise) (continued )
Strategy
Cost (£) QALYs
ICER (£) NMB (£)Mean Incremental Mean Incremental
4. Applying the cost of Inbody S10 for bioimpedance monitoring (£90.36)
Standard care 46,234 – 2.7014 – – 7793
Inbody S10 48,100 1865 2.817 0.1157 16,125 8241
5. Applying the cost of MultiScan 5000 for bioimpedance monitoring (£91.22)
Standard care 46,234 – 2.7014 – – 7793
MultiScan 5000 48,104 1870 2.817 0.1157 16,161 8237
6. Applying the lowest estimated annual bioimpedance monitoring from Table 15 (£70)
Standard care 46,234 – 2.7014 – – 7793
BCM 48,001 1767 2.817 0.1157 15,273 8340
7. Applying the highest estimated annual bioimpedance monitoring cost from 15 (£125)
Standard care 46,234 – 2.7014 – – 7793
BCM 48,267 2033 2.817 0.1157 17,575 8073
8. Applying an alternative lower cost per CV event-related hospitalisation (£1386 per CV event)
Standard care 44,136 – 2.7014 – – 9891
BCM 46,110 1974 2.817 0.1157 17,063 10,231
9. Applying alternative age-adjusted utility multipliers for dialysis and post transplant131
Standard care 46,234 – 2.9813 – – 13,392
BCM 48,153 1919 3.1108 0.1295 14,822 14,062
10. Assume bioimpedance-guided management results in a 2% improvement in the health state utility over the lifetime of
patients receiving dialysis (including dialysis costs)
Standard care 158,124 – 2.7014 – – –104,097
BCM 165,077 6952 2.866 0.1646 42,230 –107,757
11. Assume bioimpedance-guided management results in a 2% improvement in the health state utility over the lifetime of
patients receiving dialysis (excluding dialysis costs)
Standard care 46,234 – 2.7014 – – 7793
BCM 48,153 1919 2.866 0.1646 11,656 9166
12. Assume bioimpedance-guided management results in a 5% improvement in the health state utility over the lifetime of
patients receiving dialysis (including dialysis costs)
Standard care 158,124 – 2.7014 – – –104,097
BCM 165,077 6952 2.9394 0.238 29,206 –106,289
13. Assume bioimpedance-guided management results in a 5% improvement in the health state utility over the lifetime of
patients receiving dialysis (excluding dialysis costs)
Standard care 46,234 – 2.7014 – – 7793
BCM 48,153 1919 2.9394 0.238 8062 10,635
14. Assume bioimpedance-guided management results in a 10% reduction in dialysis costs over the lifetime of patients
BCM 153,384 – 2.817 – – –97,043
Standard care 158,124 4740 2.7014 –0.1157 Dominated –104,097
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TABLE 23 Scenario analyses referent to base clinical effectiveness scenario 3 (all analyses exclude dialysis costs
unless stated otherwise) (continued )
Strategy
Cost (£) QALYs
ICER (£) NMB (£)Mean Incremental Mean Incremental
15. Assume bioimpedance-guided management results in a 5% reduction in dialysis costs over the lifetime of patients
Standard care 158,124 – 2.7014 – – –104,097
BCM 159,230 1106 2.817 0.1157 9,560 –102,890
16. Applying an effect only on non-fatal CV events (HR = 0.9318), excluding any effect on mortality (including dialysis costs)
Standard care 158,124 – 2.7014 – – –104,097
BCM 158,348 224 2.7069 0.0056 40,283 –104,210
17. Applying a smaller effect on mortality and non-fatal CV events (HR= 0.95 for both)
Standard care 46,234 – 2.7014 – – 7793
BCM 47,757 1523 2.7853 0.084 18,135 7949
18. Applying a larger effect of bioimpedance monitoring on both CV events and mortality (0.844); consistent with the
cross-sectional main effect of a unit change in PWV reported by Verbeke et al.114
Standard care 46,234 – 2.7014 – – 7793
BCM 50,163 3929 2.9791 0.2777 14,145 9419
19. Applying differential effects on mortality (HR = 0.95) and non-fatal CV events (HR = 0.844), including dialysis costs
Standard care 158,124 – 2.7014 – – –104,097
BCM 162,903 4778 2.7946 0.0933 51,222 –107,010
20. Applying differential effects on mortality (HR = 0.95) and non-fatal CV events (HR = 0.844), excluding dialysis costs
Standard care 46,234 – 2.7014 – – 7793
BCM 47,359 1125 2.7946 0.0933 12,054 8534
21. Excluding all non-CV event-related causes of hospitalisation form the analysis, including dialysis costs
Standard care 144,951 – 2.7138 – – –90,676
BCM 151,315 6364 2.83 0.1163 54,726 –94,714
22. Applying no effects of bioimpedance monitoring beyond 3 years; HR of 0.9318 for all-cause mortality and CV
event-related hospitalisation up to 3 years
Standard care 46,234 – 2.7014 – – 7793
BCM 47,531 1297 2.7663 0.065 19,963 7795
23. Applying no effects of bioimpedance monitoring beyond 3 years; HR of 0.95 for all-cause mortality and CV
event-related hospitalisation up to 3 years
Standard care 46,234 – 2.7014 – – 7793
BCM 47,308 1074 2.7488 0.0474 22,642 7667
NMB, net monetary benefit.
a These scenarios are not conducted for child cohorts, they simply reflect higher estimated costs of bioimpedence testing
based on the level of throughput observed in paediatric dialysis centres (NMB at a willingness to pay of £20,000 per QALY).
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> 15%), reducing the risk of all-cause mortality and CV event-related hospitalisation. This analysis focused
on the subgroups that were identified as being severely overhydrated at baseline, and assumed a 38%
reduction over the follow-up period (see Table 24, scenarios 8 and 9).
These analyses did not reveal any large differences in cost-effectiveness by subgroups. The ICER was
slightly higher in the subgroup on a waiting list for a transplant, as the patients spent less time on dialysis
TABLE 24 Subgroup analysis (using clinical effectiveness scenario 3 unless otherwise stated)
Strategy
Cost (£) QALYs
ICER (£) NMB (£)Mean cost Incremental Mean Incremental
1. People receiving dialysis who have comorbidities and higher hospitalisation ratesa
Standard care 47,021 – 2.6974 – – 6927
BCM 48,961 1940 2.813 0.1156 16,780 7299
2. People receiving dialysis with no comorbidities and lower hospitalisation ratea
Standard care 42,638 – 2.7166 – – 11,693
BCM 44,456 1818 2.8325 0.116 15,675 12,195
3. People receiving HD (start age of 67 years; 3 years receiving dialysis)
Standard care 45,833 – 2.5803 – – 5773
BCM 47,763 1930 2.6933 0.113 17,078 6103
4. People receiving PD (start age of 64 years; 2 years receiving dialysis)
Standard care 53,237 – 3.3991 – – 14,745
BCM 55,021 1783 3.5183 0.1192 14,959 15,346
5. Mixed cohort of patients aged 55 years receiving HD/PD
Standard care 80,080 – 4.7224 – – 14,368
BCM 82,251 2171 4.8502 0.1278 16,986 14,753
6. Patients listed for a transplanta
Standard care 87,370 – 4.1844 – – –3682
BCM 89,563 2193 4.2891 0.1047 20,950 –3781
7. Patients not listed for a transplanta
Standard care 39,807 – 2.4696 – – 9586
BCM 41,683 1876 2.587 0.1174 15,980 10,058
8. Chronically overhydrated patients only, at increased risk of mortality and all-cause hospitalisation, using modelling
structure and assumptions of clinical effectiveness scenario 6 (38% reduction of chronic overhydration with bioimpedance
monitoring relative to standard practice); dialysis costs included
Standard care 119,413 – 2.04 – – –78,613
BCM 168,019 48,606 2.86 0.82 59,382 –110,819
9. Chronically overhydrated patients only, at increased risk of mortality and all-cause hospitalisation, using modelling
structure and assumptions of clinical effectiveness scenario 6 (38% reduction of chronic overhydration with bioimpedance
monitoring relative to standard practice); dialysis costs excluded
Standard care 36,932 – 2.04 – – 3868
BCM 48,863 11,931 2.86 0.82 14,576 8337
NMB, net monetary benefit.
a The model is not designed to adjust for different mortality rates in these subgroups.
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and so benefited less from the modelled reduction in all-cause mortality and CV event-related hospitalisation
conferred by bioimpedance-guided fluid management. In the scenario focusing on the severely overhydrated
subgroup, the ICER was ≈ £5000 lower than in the corresponding base case for that clinical effectiveness
scenario, but when dialysis costs are included the ICER remains well above the accepted thresholds
(£59,318), as it does for all the subgroups (results not shown).
For comparison with the deterministic results in Tables 20 and 21, Tables 25 and 26 present the results for
clinical effectiveness scenarios 1, 3 and 4 based on 1000 probabilistic iterations of the model, with dialysis
costs included (see Table 25) and excluded (see Table 26). The point estimates of the ICERs are very similar
to the deterministic ICERs. The final columns in Tables 25 and 26 indicate the probability of standard
TABLE 25 Probabilistic cost-effectiveness scenarios for bioimpedance-guided fluid management vs. standard
practice (including dialysis costs)
Strategy
Cost (£) QALYs
ICER (£)
Probability of being
cost-effective at the
£20,000 thresholdMean Incremental Mean Incremental
1. Clinical effectiveness scenario 1; applying the point estimate for the pooled effect of BCM on mortality only
Standard care 159,712 – 2.6868 – – 0.737
BCM 191,748 32,036 3.1875 0.5007 63,983 0.263
2. Clinical effectiveness scenario 3; applying linked effects on mortality and non-fatal CV events through the pooled
reduction in PWV (HR= 0.9318 for both CV events and mortality)
Standard care 157,558 – 2.6952 – – 0.875
BCM 164,632 7074 2.8138 0.1186 59,666 0.125
3. Clinical effectiveness scenario 4; applying linked effects on mortality and non-fatal CV events through the pooled
reduction in PWV (HR= 0.9318 for both CV events and mortality), and a 10% reduction in BP medications use
Standard care 158,312 – 2.6887 – – 0.87
BCM 165,217 6906 2.8038 0.1151 59,981 0.13
TABLE 26 Probabilistic cost-effectiveness scenarios for bioimpedance-guided fluid management vs. standard
practice (excluding dialysis costs)
Strategy
Cost (£) QALYs
ICER (£)
Probability of being
cost-effective at the
£20,000 thresholdMean Incremental Mean Incremental
1. Clinical effectiveness scenario 1, applying the point estimate for the pooled effect of BCM on mortality only
Standard care 45,967 – 2.7003 – – 0.328
BCM 53,907 7940 3.1884 0.4881 16,269 0.672
2. Clinical effectiveness scenario 3, applying linked effects on mortality and non-fatal CV events through the pooled
reduction in PWV (HR= 0.9318 for both CV events and mortality)
Standard care 45,966 – 2.6905 – – 0.387
BCM 47,836 1871 2.8063 0.1158 16,150 0.613
3. Clinical effectiveness scenario 4, applying linked effects on mortality and non-fatal CV events through the pooled
reduction in PWV (HR= 0.9318 for both CV events and mortality), and a 10% reduction in the use of blood pressure
medications
Standard care 46,190 – 2.6873 – – 0.369
BCM 48,004 1814 2.8017 0.1144 15,859 0.631
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practice or bioimpedance testing being the preferred strategy, given a willingness to pay of £20,000 per
QALY gained. With dialysis costs included, the probability of bioimpedance testing being cost-effective is
≈26% in scenario 1 and < 13% in scenarios 3 and 4.
With the dialysis costs excluded, the probability of bioimpedance testing being cost-effective at a threshold
of £20,000 increased to ≈61–67% across effectiveness scenarios 1, 3 and 4 (see Table 26). There remains
a high degree of uncertainty inherent in the approach required to link possible effects of bioimpedance
monitoring on arterial stiffness (PWV) to effects on mortality and non-fatal CV events, which is not fully
captured in the probabilistic model. Thus, the probability of cost-effectiveness in scenarios 3 and 4 may
give a somewhat unrealistic impression of precision.
For further comparison, the incremental cost-effectiveness scatterplots for bioimpedance testing versus
standard practice, and the corresponding CEACs, are presented in Figures 18–21 for scenarios 1 and 3
(including dialysis costs). The corresponding scatterplots and CEACs with dialysis costs excluded are
presented in Figures 22–25.
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FIGURE 18 Incremental cost-effectiveness scatterplot: BCM vs. standard care (clinical effectiveness scenario 1,
including dialysis costs).
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FIGURE 19 Cost-effectiveness acceptability curves: BCM vs. standard care (clinical effectiveness scenario 1, including
dialysis costs). WTP, willingness to pay.
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FIGURE 20 Incremental cost-effectiveness scatterplot: BCM vs. standard care (clinical effectiveness scenario 3,
including dialysis costs).
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FIGURE 21 Cost-effectiveness acceptability curves: BCM vs. standard care (clinical effectiveness scenario 3, including
dialysis costs). WTP, willingness to pay.
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FIGURE 22 Incremental cost-effectiveness scatterplot: BCM vs. standard care (clinical effectiveness scenario 1,
excluding dialysis costs).
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FIGURE 23 Cost-effectiveness acceptability curves: BCM vs. standard care (clinical effectiveness scenario 1, excluding
dialysis costs). WTP, willingness to pay.
– 4
– 2
0
2
4
6
8
10
12
14
– 0.4 – 0.2 0.0 0.2 0.4 0.6 0.8 1.0
In
cr
em
en
ta
l c
o
st
 (
£0
00
)
Incremental effectiveness (QALYs)
FIGURE 24 Incremental cost-effectiveness scatterplot: BCM vs. standard care (clinical effectiveness scenario 3,
excluding dialysis costs).
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FIGURE 25 Cost-effectiveness acceptability curves: BCM vs. standard care (clinical effectiveness scenario 3, excluding
dialysis costs). WTP, willingness to pay.
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Interpretation of the cost-effectiveness results
The cost-effectiveness results above are based on limited evidence for the effects of bioimpedance-guided
fluid management on mainly surrogate end points (PWV and hydrations status). There is very limited
high-quality evidence available by which to link intervention-induced changes in these surrogate end points
to changes in health outcomes. Therefore, the indirect/linked modelling scenarios rely on observational
associations to estimate possible effects of bioimpedance-guided fluid management on final health
outcomes. It should also be noted that the pooled estimate of the effect on PWV is non-significant and
based on data from only two trials, showing inconsistent results. As a consequence, the results of the
cost-effectiveness modelling are somewhat speculative and subject to considerable uncertainty, which is
not fully reflected in the probabilistic sensitivity analysis.
Nevertheless, the results reveal some useful insights. Given the high costs of dialysis, it is unlikely that
bioimpedance-guided management will be cost-effective against the accepted thresholds (£20,000–30,000
per QALY gained) if it reduces mortality with these costs included in the model. Table 22 indicates that
dialysis costs in additional years make up 74% of the incremental cost of bioimpedance-guided management
under clinical effectiveness scenario 3 (a modest and equal effect on both mortality and CV event-related
hospitalisation). Further scenario analyses suggest that the effect on mortality would have to be accompanied
by a 5% reduction in dialysis costs over the lifetime of patients for the ICER to drop below £20,000 under
clinical effectiveness scenario 3. Alternatively, with an accompanying 5% improvement in quality of life over
the lifetime of patients, the ICER drops close to £30,000. With greater effects on mortality (and dialysis costs
included), the magnitude of these accompanying effects would also have to increase to offset the greater
increases in dialysis costs in extra years. The ICER for bioimpedance-guided fluid management also drops
substantially, with dialysis costs included, when no effect on mortality is assumed, but an effect on the CV
event-related hospitalisation rate is retained. This all but eliminates the incremental cost associated with the
bioimpedance-guided strategy (reducing it to £224), but also greatly reduces the QALY gain that comes
primarily from increased survival in the base-case clinical effectiveness scenarios. The plausibility of these
additional scenarios is uncertain, given the available clinical evidence.
It can also be noted from the modelled scenarios that when dialysis costs are excluded from the model,
the effects of bioimpedance-guided management do not need to be large for the ICER to remain below
£20,000. The added cost of testing patients quarterly with bioimpedance spectroscopy is low (conservatively
estimated to be ≈£100 per patient-year), and so relatively small effects on mortality and/or non-fatal CV
events will compensate for this when dialysis costs in additional years are not included. That said, the
modelled effects of bioimpedance monitoring are subject to considerable uncertainty, and so probabilities
of cost-effectiveness at a willingness-to-pay threshold of £20,000 per QALY only reach ≈61–67%, even
with dialysis costs excluded.
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Chapter 4 Discussion
Clinical effectiveness
This assessment is based on six RCTs (analysing 1039 participants) and eight non-randomised studies
(analysing 4915 participants) evaluating the use of the BCM for fluid management in people with CKD
receiving dialysis. None of the studies involved paediatric populations or the other multiple-frequency
bioimpedance devices specified in the protocol. The results of the assessment indicate that:
l of the five RCTs, one was rated as being at a high risk of bias, and the remaining four trials were rated
as being at an unclear risk of bias
l four RCTs enrolled patients receiving HD and one RCT enrolled patients receiving PD
l all five RCTs were conducted in countries other than the UK and all involved adult populations
l absolute overhydration and ROH were significantly lower in the BCM group than in the standard
clinical assessment group (WMD –0.44, 95% CI –0.72 to –0.15, p = 0.003, I2 = 49%; and WMD –1.84,
95% CI –3.65 to –0.03, p = 0.05, I2 = 52%, respectively)
l compared with standard clinical methods, the use of the BCM reduced SBP, but the difference did not
reach the level of statistical significance (mean difference –2.46, 95% CI –5.07 to 0.15; p = 0.06, I2 = 0%).
l the pooled effects of bioimpedance monitoring on arterial stiffness (mean difference –1.18, 95% CI
–3.14 to 0.78; p = 0.24, I2 = 92%) and mortality (HR 0.69, 95% CI 0.23 to 2.08; p = 0.51) were not
statistically significant
l there was a difference in absolute hydration at follow-up between patients receiving HD and patients
receiving PD, but the difference was not large enough to suggest a significant effect of type of dialysis
l no evidence was found regarding the use of the other devices specified for this assessment in the
relevant clinical population
l CV events and hospitalisation were reported by few studies and not in a consistent way
l patient-reported outcomes were lacking in the included studies
l evidence regarding adverse events associated with hypotensive episodes was mixed; some studies
reported no difference between the groups at follow-up, but there was evidence that patients in the
bioimpedance assessment group experienced significantly more cramping, chest tightness and
headaches, but significantly less hypotension and itching, than those in the standard clinical
methods group
l caution should be applied in using bioimpedance to assess outcomes, such as absolute overhydration
and ROH, as bias in favour of bioimpedance may be introduced
l although none of the included studies directly assessed residual renal function as per the European
Renal Association guidelines, two studies reported a tendency towards a greater decrease in urine
output in patients randomised to bioimpedance-guided fluid management; this is a potential harm that
requires further investigation
l conversely, careful use of bioimpedance monitoring, to avoid underhydration in new dialysis patients,
may reduce the loss of residual renal function; the ongoing BISTRO (Bio-Impedance Spectroscopy To
maintain Renal Output) trial94 is currently investigating this relationship.
Comparison with other reviews
We have reinforced and extended the findings of the 2015 CADTH’s review,53 which included narrative
descriptions of the studies by Onofriescu et al.60 and Ponce et al.,61 and concluded that the evidence base
was limited, but there was a trend of decreased blood pressure and fluid overload in people whose
management was guided by the BCM. The authors were unable to comment on the effects these changes
would have on ‘hard end points’, such as hospitalisation and death. Furthermore, the original CADTH
review, published in 2014,53 concluded that bioimpedance-based fluid management was associated with
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signs of better blood pressure control than the standard of care. Our study addressed some of these
questions by conducting meta-analyses of both intermediate outcomes (SBP, arterial stiffness and absolute
and relative fluid overload) and a clinical outcome (mortality). Notably, our assessment also included one
study involving people receiving PD. Our study is also the first to explore the potential cost-effectiveness of
bioimpedance-guided fluid management by using a decision-modelling framework to link estimated effects
on surrogate end points to possible effects on health outcomes and health service costs. No other reviews
or models were identified for comparison.
Cost-effectiveness
A cost-effectiveness Markov model was developed to simulate the progression of the prevalent dialysis
cohort through a set of mutually exclusive health states capturing mortality, CV event-related and other
causes of hospitalisation and transplantation (for those listed). The model included costs to the health
service of providing dialysis treatment, inpatient and outpatient hospital costs, transplant costs, post-
transplant follow-up and immunosuppressant costs and costs of dialysis following transplant graft failure.
Health state utility multipliers were identified and incorporated for the dialysis and post-transplant states,
allowing cumulative QALYs to be estimated. Further proportional reductions in health state utility were
modelled in the short term for all hospitalisation events, and in the long term following incident CV
hospitalisation events.
The added costs and possible effects of bioimpedance-guided fluid management were added to the
baseline model, and the cumulative costs and QALYs were simulated over the lifetime of the cohorts under
standard care and the bioimpedance-guided strategy. The base-case effectiveness scenarios modelled
proportional reductions in all-cause mortality and CV event-related or all-cause hospitalisation with the
bioimpedance-guided strategy. Given the limited direct evidence from the clinical effectiveness review,
these effects were generally estimated by linking effects on surrogate end points [arterial stiffness (PWV),
hydration status] to effects on the final outcomes using secondary published sources.
The costs and effects of the bioimpedance-guided strategy were compared incrementally to standard care
under several possible clinical effectiveness scenarios. The impact of including and excluding dialysis costs
was also explored for each of these.
Key findings from the analyses are as follows.
l Under all of the main effectiveness scenarios, the ICER for bioimpedance-guided fluid management
remained well above accepted thresholds for cost-effectiveness when dialysis costs were included in the
model, and this was a result of the high costs of dialysis in the added years under the bioimpedance
strategy.
l For bioimpedance-guided management to appear cost-effective with dialysis costs included (assuming
an effect on mortality), it would also have to provide a significant reduction in dialysis costs across the
lifetime of patients or a constant percentage improvement in the health state utility of patients
receiving dialysis.
l There is little evidence to justify the modelled scenarios under which bioimpedance-guided fluid
management becomes cost-effective (against standard thresholds) when dialysis costs are included in
the model.
l When dialysis costs are excluded from the model, the effects of bioimpedance-guided management do
not need to be great for the ICER to remain below £20,000.
l The added monitoring costs associated with the strategy are small (conservatively estimated to be
≈£100 per patient-year), and so relatively small effects on mortality and/or non-fatal CV events justify
the added costs. That said, the costs in added years remain quite substantial, given the high
background rates of other-cause hospitalisation.
l With considerable uncertainty surrounding the modelled effect estimates, probabilities of
cost-effectiveness at accepted thresholds remain low (≈61–67% at a willingness to pay of £20,000
per QALY gained).
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Strength and limitations of the assessment
This assessment has been conducted in accordance with current standards and recommendations and the
methods were specified a priori in a research protocol. Comprehensive literature searches of the major
electronic databases were conducted, all potentially eligible studies were assessed for inclusion in the
review and the methodological quality of all included studies was assessed using the recommended
risk-of-bias tools. Despite these efforts, it is still possible that some relevant evidence may have been
missed, although any omissions are likely to be minimal.
The economic model was able to draw on UK and European registry data to inform baseline mortality,
all-cause hospitalisation rates and the likelihood of progression to transplant. Systematic searches were
undertaken to identify suitable sources for other parameters in the model, such as the health state utility
weights, and costs of RRT were based on standard NHS sources. A short survey of centres with expertise in
using bioimpedance testing was carried out to get an accurate picture of the likely incremental cost of
adopting it as an adjunct to standard clinical practice. There are limitations relating to the availability of
evidence to inform clinical effects of bioimpedance testing in the model, and several simplifying
assumptions had to be made in light of the data available to inform baseline probabilities.
The following limitations also need to be acknowledged:
l We were able to include only studies involving the BCM because of a lack of published evidence of the
effectiveness of the other specified bioimpedance devices. As the generalisability of the effects of
bioimpedance devices has yet to be determined, we cannot generalise our findings across the devices
beyond the BCM.
l The longest follow-up period in the included RCTs was 2.5 years and the long-term effectiveness of the
BCM in this population is yet to be established.
l Overall risk of bias was rated as being unclear or high in the majority of included trials, with only one
trial being rated as having a low risk of bias.
l Units of measurement of some reported outcomes (e.g. hospitalisation) varied across trials and
hampered the possibility of synthesising data.
l Some clinically relevant outcomes (e.g. incidence of CV events, residual renal function, achievement of
target weight) were lacking or not consistently reported.
l We were unable to conduct the planned subgroup analyses, but were able to make some comparisons
of the outcomes of people receiving HD and those receiving PD.
l The majority of RCTs excluded patients with amputations, cardiac pacemakers and defibrillators.
These exclusions further limit the generalisability of the current findings.
l Frequency of assessment using the BCM varied across trials and the optimal frequency of assessment is
yet to be determined.
l With respect to the economic model, baseline risks of CV event-related hospitalisation had to be
estimated as a set proportion of all-cause hospitalisation.
l Plausible effects in the cost-effectiveness model had to be informed by linking effects on surrogate end
points to effects on final health outcomes.
l To keep the model manageable, and in keeping with the available data, some simplifying assumptions
had to be made:
¢ Mortality and hospitalisation rates could not be linked to certain explanatory variables and event
histories in the model, limiting our ability to explore heterogeneity in cost-effectiveness.
¢ It was difficult to capture the long-term health state utility impact of recurrent hospitalisation
events, partly because of the constraints of the Markov modelling approach, and partly because of
a lack of available data to inform the cost and utility impact of recurrent events.
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l With many differences between adults and paediatric dialysis patients, and a complete lack of evidence
for the clinical effectiveness of bioimpedance-guided fluid management in children, we were not able
to assess cost-effectiveness in children. As well as requiring data on clinical effectiveness in children,
a different baseline cost-effectiveness model would also be required, including different mortality and
hospitalisation rates, different costs and utilities and greater structural complexity, to allow for extrapolation
over a much longer time horizon (e.g. allowing for multiple transplants over the lifetime of the cohort).
l We were able to obtain a reasonable estimate of what it would cost to monitor children with bioimpedance
spectroscopy, as a result of a lower throughput in paediatric centres and the need for more frequent
testing. Although the estimated cost is substantially higher than in adults, the cost-effectiveness findings in
adults were not found to be sensitive to increases in the monitoring cost to this level.
Uncertainties
l Current evidence focuses exclusively on the use of BCM and not on other multiple-frequency
bioimpedance devices.
l The identified RCTs were all conducted outside the UK and the applicability of the results to the UK
population is uncertain, with the greatest uncertainty relating to the comparability of the standard
clinical assessments in these trials.
l Included studies focused exclusively on adult populations. Therefore, our findings are not generalisable
to paediatric populations.
l The main uncertainty in the cost-effectiveness modelling relates to the plausibility of the modelled effects,
which were extrapolated from mainly non-significant effects on surrogate end points [arterial stiffness
(PWV) and blood pressure] using other external sources of evidence. Critically, there were no ideal sources
of evidence to link intervention-induced changes in the relevant surrogates to effects on mortality and
hospitalisation rates. Therefore, possible effects were informed by reference to cross-sectional prognostic
studies, leading to great uncertainty in the robustness of the cost-effectiveness findings.
DISCUSSION
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Appendix 1 Search strategies
Multiple-frequency bioimpedance devices for fluid management in
people with chronic kidney disease receiving dialysis
Clinical effectiveness
EMBASE Classic and EMBASE
Date range searched: 1947 to week 40 2016.
Epub ahead of print, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE(R)
Daily (via Ovid) and MEDLINE(R) (via Ovid)
Date range searched: 1946 to 10 October 2016.
Ovid multifile search, URL: https://shibboleth.ovid.com/
Date searched: 10 October 2016.
Search strategy
1. exp Renal Insufficiency, Chronic/ use ppez
2. exp chronic kidney disease/ use emcz
3. exp chronic kidney failure/ use emcz
4. ckd.tw,kw.
5. (chronic adj3 (kidney or renal)).tw,kw.
6. or/1-5
7. exp renal dialysis/ use ppez
8. exp renal replacement therapy/ use emcz
9. (haemodialysis or hemodialysis or dialysis).kw,tw.
10. or/7-9
11. 6 and 10
12. bioimpedance.tw,kw.
13. bioelectric$ impendance.tw,kw.
14. body composition monitor$.tw,kw.
15. bioscan$.tw,kw.
16. bio scan$.tw,kw.
17. multiscan$.tw,kw.
18. multi scan$.tw,kw.
19. inbody.tw,kw.
20. or/12-19
21. 10 and 20
22. hypervol?emi?.tw,kw.
23. euvol?emi?.tw,kw.
24. hypovol?emi?.tw,kw.
25. (fluid adj3 (status or overload or monitor$ or level? or balance or imbalance)).tw,kw.
26. (hydration adj3 (status or monitor$)).tw,kw.
27. ((under or over) adj3 hydration).tw,kw.
28. underhydrat$.tw,kw
29. overhydrat$.tw,kw.
30. normohydrat$.tw,kw.
31. ((dry or target) adj weight).tw,kw.
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32. ultrafiltration volume.tw,kw.
33. or/22-32
34. 11 and 33
35. 21 or 34
36. (editorial or comment or note or letter).pt.
37. 35 not 36
38. exp animals/ not humans/ use ppez
39. nonhuman/ not human/ use emcz
40. 37 not 38 use ppez
41. 37 not 39 use emcz
42. 40 or 41
43. remove duplicates from 42
Science Citation Index
Date range searched: 1970 to 27 June 2016.
Web of Knowledge URL: http://wok.mimas.ac.uk/
Date searched: 27 June 2016.
Search strategy
#1. TS=(haemodialysis or hemodialysis or dialysis)
#2. TS=bioimpedance
#3. TS=bioelectric* impendance
#4. TS=body composition monitor$*
#5. TS= (bioscan$* or bio scan*)
#6. TS=(multiscan* or multi scan*)
#7. TS=inbody
#8. #2 or #3 or #4 or #5 or #6 or #7
#9. #1 and #8
The Cochrane Library
Cochrane Database of Systematic Reviews: Issue 6 of 12, June 2016.
Cochrane Central Register of Controlled Trials: Issue 5 of 12, May 2016.
URL: www3.interscience.wiley.com/
Date searched: 27 June 2016.
Search strategy
#1. MeSH descriptor: [Renal Dialysis] explode all trees
#2. haemodialysis or hemodialysis or dialysis:ti,ab,kw (Word variations have been searched)
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#3. #1 or #2
#4. bioimpedance.:ti,ab,kw (Word variations have been searched)
#5. bioelectric* impendance.ti,ab,kw
#6. body composition monitor*.ti,ab,kw
#7. (bioscan* or bio scan*) .ti,ab,kw.
#8. (multiscan* or multi scan*) .ti,ab,kw
#9. inbody.ti,ab,kw
#10. #4 or #5 or #6 or #7 or #8 or #9
#11. #3 and #10
Database of Abstracts of Reviews of Effects: December 2014
Centre for Reviews and Dissemination, URL: http://nhscrd.york.ac.uk/welcome.htm
Date searched: 27 June 2016.
Search strategy
#1. MeSH DESCRIPTOR Renal Dialysis EXPLODE ALL TREES IN DARE
#2. (haemodialysis) OR (hemodialysis) OR (dialysis)
#3. #1 OR #2
#4. (bioimpedance) OR (impedance)
#5. (body composition monitor*) OR (bioscan*) OR (bio scan*)
#6. (inbody) OR (multiscan*) OR (multi scan*)
#7. #4 OR #5 OR #6
#8. #3 AND #7
Additional conference proceedings
ERA-EDTA Congress 2014, Amsterdam, the Netherlands, 31 May to 3 June.
ERA-EDTA Congress 2015, London, UK, 28–31 May.
Kidney Week (Journal of the American Society of Nephrology) American Society of Nephrology 2014,
Philadelphia, PA, USA, 11–16 November.
Kidney Week (Journal of the American Society of Nephrology) American Society of Nephrology 2015,
San Diego, CA, USA, 3–8 November.
Annual Dialysis Conference 2014, Atlanta, GA, USA, 8–11 February.
Annual Dialysis Conference 2015, New Orleans, LA, USA, 31 January to 3 February.
Annual Dialysis Conference 2016, Seattle, WA, USA, 27 February to 1 March.
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Clinical Trials (June 2016)
URL: http://clinicaltrials.gov/ct/gui/c/r
Date searched: 4 July 2016.
Search strategy
bioimpendance AND dialysis
or
bioimpendance AND hemodialysis
World Health Organization’s International Clinical Trials Registry Platform (June 2016)
URL: www.who.int/ictrp/en/
Date searched: 4 July 2016.
Search strategy
bioimpendance AND dialysis
or
bioimpendance AND hemodialysis
European Union Clinical Trials Register (June 2016)
URL: www.clinicaltrialsregister.eu/
Date searched: 4 July 2016.
Search strategy
bioimpedance
Body Composition Monitor validation studies
EMBASE Classic and EMBASE
Date range searched: 1947 to week 39 2016.
Epub ahead of print, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE(R)
Daily (via Ovid) and MEDLINE(R) (via Ovid)
Date range searched: 1946 to 2016.
OVID multifile search, URL: https://shibboleth.ovid.com/
Date searched: 27 September 2016.
Search strategy
1. exp Renal Insufficiency, Chronic/ use ppez
2. exp chronic kidney disease/ use emcz
3. exp chronic kidney failure/ use emcz
4. ckd.tw,kw.
5. (chronic adj3 (kidney or renal)).tw,kw.
6. or/1-5
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7. exp renal dialysis/ use ppez
8. exp renal replacement therapy/ use emcz
9. (haemodialysis or hemodialysis or dialysis).kw,tw.
10. or/7-9
11. 6 and 10
12. bioimpedance.tw,kw.
13. bioelectric$ impendance.tw,kw.
14. body composition monitor$.tw,kw.
15. bioscan$.tw,kw.
16. bio scan$.tw,kw.
17. multiscan$.tw,kw
18. multi scan$.tw,kw.
19. inbody.tw,kw.
20. or/12-19
21. 10 and 20
22. hypervol?emi?.tw,kw.
23. euvol?emi?.tw,kw.
24. hypovol?emi?.tw,kw.
25. (fluid adj3 (status or overload or monitor$ or level? or balance or imbalance)).tw,kw
26. (hydration adj3 (status or monitor$)).tw,kw.
27. ((under or over) adj3 hydration).tw,kw.
28. underhydrat$.tw,kw.
29. overhydrat$.tw,kw.
30. normohydrat$.tw,kw.
31. ((dry or target) adj weight).tw,kw.
32. ultrafiltration volume.tw,kw.
33. or/22-32
34. validation studies/
35. measurement accuracy/
36. “reproducibility of results”/
37. (validation or validity).tw,kw.
38. (accuracy or accurate).tw,kw.
39. 44 or 45 or 46 or 47 or 48
40. 21 and 39
41. 11 and 33 and 39
42. 40 or 41
43. remove duplicates from 42
Cost-effectiveness
EMBASE Classic and EMBASE
Date range searched: 1947 to week 27 2016.
Epub ahead of print, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE(R)
Daily (via Ovid) and MEDLINE(R) (via Ovid)
Date range searched: 1946 to 2016.
OVID multifile search, URL: https://shibboleth.ovid.com/
Date searched: 5 July 2016.
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Search strategy
1. exp Renal Insufficiency, Chronic/ use ppez
2. exp *chronic kidney disease/ use emcz
3. exp *chronic kidney failure/ use emcz
4. ckd.tw,kw.
5. (chronic adj1 (kidney or renal)).tw,kw.
6. or/1-5
7. exp renal dialysis/ use ppez
8. exp renal replacement therapy/ use emcz
9. (haemodialysis or hemodialysis or dialysis).kw,tw.
10. or/7-9
11. 6 and 10
12. exp “costs and cost analysis”/ use ppez
13. exp economic evaluation/ use emcz
14. economics/
15. health economics/ use emcz
16. exp health care cost/ use emcz
17. exp economics,hospital/ use ppez
18. exp economics,medical/ use ppez
19. economics,pharmaceutical/ use ppez
20. pharmacoeconomics/ use emcz
21. exp models, economic/ use ppez
22. exp decision theory/
23. monte carlo method/
24. markov chains/
25. exp technology assessment, biomedical/
26. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
27. economics model$.tw.
28. (economic$ or pharmacoeconomic$).tw.
29. price or prices or pricing).tw.
30. budget$.tw.
31. (value adj1 money).tw.
32. (expenditure$ not energy).tw.
33. markov$.tw.
34. monte carlo.tw.
35. decision$ adj2 (tree? or analy$ or model$)).tw.
36. or/12-35
37. (metabolic adj cost).tw.
38. ((energy or oxygen) adj (cost or expenditure)).tw.
39. 36 not (37 or 38)
40. (letter or editorial or note or comment).pt.
41. 39 not 40
42. 11 and 41
43. remove duplicates from 42
Health Technology Assessment, June 2016 and NHS Economic Evaluation Database,
December 2014
Centre for Reviews and Dissemination, URL: http://nhscrd.york.ac.uk/welcome.htm
Date searched: 5 July 2016.
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Search strategy
#1. MeSH DESCRIPTOR Renal Dialysis EXPLODE ALL TREES IN NHSEED
#2. (dialysis) OR (hemodialysis) OR (haemodialysis)
#3. #1 OR #2
#4. MeSH DESCRIPTOR Renal Insufficiency, Chronic EXPLODE ALL TREES IN NHSEED
#5. (ckd) OR (chronic renal) OR (chronic kidney)
#6. #4 OR #5
#7. #3 AND #6
Research Papers in Economics
URL: http://repec.org/
Search strategy
dialysis | hemodialysis |haemodialysis | CKD | renal | kidney
Quality of life/utilities
EMBASE Classic and EMBASE
Date range searched: 1947 to week 27 2016.
Epub ahead of print, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE(R)
Daily (via Ovid) and MEDLINE(R) (via Ovid)
Date range searched: 1946 to 2016.
Ovid multifile search, URL: https://shibboleth.ovid.com/
Date searched: 8 July 2016.
Search strategy
1. exp Renal Insufficiency, Chronic/ use ppez
2. exp chronic kidney disease/ use emcz
3. exp chronic kidney failure/ use emcz
4. ckd.tw,kw.
5. (chronic adj3 (kidney or renal)).tw,kw.
6. or/1-5
7. exp renal dialysis/ use ppez
8. exp renal replacement therapy/ use emcz
9. (haemodialysis or hemodialysis or dialysis).kw,tw.
10. or/7-9
11. 6 and 10
12. quality adjusted life year/
13. “Value of Life”/ use ppez
14. (qaly? or qald? or qale? or qtime?).tw,kf.
15. (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or
euroqual5d or euroqol5d).tw,kf.
16. (eq-sdq or eqsdq).tw,kf.
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17. (hye or hyes).tw,kf.
18. health$ year$ equivalent$.tw,kf.
19. (hui or hui1 or hui2 or hui3).tw,kf.
20. (quality adjusted or adjusted life year$).tw,kf.
21. disability adjusted life.tw,kf.
22. daly?.tw,kf.
23. ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).tw,kf.
24. (multiattribute$ or multi attribute$).tw,kf.
25. (utility adj3 (score? or scoring or valu$ or measur$ or evaluat$ or scale? or instrument? or weight or
weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$ or
disease$ or mean or cost$ or expenditure? or gain or gains or loss or losses or lost or analysis or index$
or indices or overall or reported or calculat$ or range$ or increment$ or state or states or status)).tw,kf.
26. utility.ab. /freq=2
27. utilities.tw,kf.
28. disutili$.tw,kf
29. (hsuv or hsuvs).tw,af.
30. (illness state$ or health state$).tw,kf.
31. (shortform$ or short form$).tw,kf.
32. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).tw,kf.
33. (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).tw,kf.
34. (sf12 or sf 12 or sf twelve or sftwelve).tw,kf.
35. (sf16 or sf 16 or sf sixteen or sfsixteen).tw,kf.
36. (sf20 or sf 20 or sf twenty or sftwenty).tw,kf.
37. (15d or 15-d or 15 dimension).tw,kf.
38. standard gamble$.tw,kf.
39. (time trade off$ or time tradeoff$ or tto or timetradeoff$).tw,kf.
40. (case report or editorial or letter).pt.
41. case report/
42. or/12-39
43. 42 not (40 or 41)
44. 11 and 43
45. remove duplicates from 44
Cost-effectiveness Analysis Registry: July 2016
URL: https://research.tufts-nemc.org/cear4/default.asp
Date searched: 8 July 2016.
Search strategy
Dialysis or hemodialysis or haemodialysis
School of Health and Related Research Health Utilities Database: July 2016
URL: www.scharrhud.org/
Date searched: 8 July 2016.
Search strategy
Dialysis or haemodialysis or haemodialysis
Websites consulted
Agency for Healthcare Research and Quality, URL: www.ahrq.gov/
American Society of Nephrology, URL: www.asn-online.org/
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Belgian Health Care Knowledge Centre (KCE), URL: https://kce.fgov.be/
Bodystat, URL: www.bodystat.com/products/
CADTH, URL: www.cadth.ca/
ERA-ETDA, URL: http://era-edta.org/
French National Authority for Health (HAS), URL: www.has-sante.fr/
Fresenius Medical Care, URL: www.bcm-fresenius.com/
Health Information and Quality Authority, URL: www.hiqa.ie/
Inbody Co. Ltd, URL: www.inbody.com/eu
Institute for Clinical and Economic Review, URL: www.icer-review.org/
Institute for Quality and Efficiency in Health Care, URL: www.iqwig.de/
Maltron, URL: http://maltronint.com/industry/medical/dialysis.php
Medicines and Healthcare products Regulatory Agency, URL: www.mhra.gov.uk/
NICE, URL: www.nice.org.uk/
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), URL: www.niddk.nih.gov/
NHS Healthcare Improvement Scotland, URL: www.healthcareimprovementscotland.org/
US Food and Drug Administration, URL: www.fda.gov/default.htm
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Appendix 2 Characteristics of excluded
non-randomised studies that focused on a
paediatric population
Study details Participant characteristics Study aims Main outcomes
Allinovi et al., 201672 l Enrolled: n= 13
l Age (years), median (range):
4.0 (0.8–14.0)
l HD/PD: n= 5/8
l Inclusion criteria: all infants
and children (age range
0–18 years) with ESRD
receiving HD or PD in the
authors’ regional paediatric
nephrology centre between
1 May 2015 and
1 October 2015
l Exclusion criteria: coexistent
lung fibrosis, atelectasis,
lymphangitis, interstitial lung
disease, cardiac failure,
acute respiratory distress
syndrome or congenital
cardiac anomalies
To evaluate the accuracy of
bioimpedance spectroscopy,
echocardiographic
assessment of inferior vena
cava and lung ultrasound in
detecting fluid overload in
children with ESRD and to
compare them with clinical
measures, including weight,
physical examination and
SBP
The correlation of fluid
overload by weight and
the BCM measurement
was reported as r = 0.43
(p= 0.2), although it is
unclear which parameter(s)
assessed by the device
were used in the
correlation
Country: UK
Number of centres: one
Study design: prospective
observational study
Device used: BCM [in
children aged > 2 years
only (n = 11), as the
authors stated that the
technique was not
validated with
appropriate reference
algorithms in children
aged < 2 years]
Canpolat et al., 201373 l Enrolled: n= 33
l Age range (years): 5.7–19.9
l HD/PD: 15/18
l Inclusion criteria: patients
aged 5–20 years who were
receiving dialysis for at least
3 months
l Exclusion criteria: patients
with overt infections, acute
inflammation or active
vasculitis at the time of the
study and those with
congenital or structural heart
disease or who were
receiving anti-inflammatory
medications, such as
corticosteroids and aspirin
To examine the prevalence
of malnutrition and its
possible associations with
inflammation and vascular
disease in children receiving
chronic dialysis
Mean RRF was 0.41
(0.60) ml/min/1.73 m2 in
patients receiving HD and
3.41 (2.52) ml/min/1.73 m2
in patients receiving PD
(p< 0.001). Fat mass,
as assessed by the BCM,
was significantly lower in
patients than in controls
(20.6% vs. 24.6%;
p= 0.048)
Country: Turkey
Number of centres: NR
Study design:
cross-sectional
Device used: BCM
Zaloszyc et al., 2013;24
Zaloszyc et al., 201674
l Enrolled: n= 23
l Age (years), mean (SD):
13.9 years (5.1 years)
l HD/PD: 23/0
l Inclusion criteria: aged
< 20 years, receiving stable
HD for at least 3 months,
able to co-operate with
BCM measurements and
devoid of severe
malnutrition, defined as
having a BMI of < 2.5 kg/m2
SD score
l Exclusion criteria: NR
To assess the current
practice of clinical estimate
of hydration status and
blood pressure control in
children receiving long-term
HD, the frequency of
hypertension and its
correlation with individual
patient hydration status
measured by means of the
BCM were evaluated. In
addition, the impact of
dialysis prescription on
blood pressure control,
considering Napl, the
prescribed NaD and the
achieved dry weight, was
Mean (SD) predialytic ROH
was 6.3 (7.1%) (range:
–6.1% to 21%). Of the
total 463 dialysis sessions
assessed, in 52 sessions
(11.2%) the patients were
assessed as being
moderately overhydrated
(i.e. mean ROH of > 15%),
of which 5.6% of sessions
showed pre- and post-HD
hypertension; 21% of
sessions were in the range
7–15%, with 26.8% of
sessions showing pre- and
post-HD hypertension;
62.4% of sessions were
Country: Germany and
France
Number of centres: three
Study design:
retrospective
Device used: BCM
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Study details Participant characteristics Study aims Main outcomes
evaluated. The urea
distribution volume
determined by the BCM
was compared with that
obtained from four
different anthropometric
formulas of which only the
Morgenstern equation was
validated in children
receiving PD
classed as normohydrated
(i.e. mean ROH of –7%
to 7%), of which 20%
involved pre- and
post-HD hypertension.
Urea distribution volume,
as determined by the
BCM, was in agreement
with the Morgenstern
anthropometric equation
NaD, dialysate sodium concentration; Napl, plasma sodium; NR, not reported; RRF, residual renal function.
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Appendix 3 Data extraction form: details of
outcomes extracted
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Data extraction
section Information provided in each section
Study
characteristics 1
Publication status Study design Country/ies Number of
centres
Recruitment
method
Allocation
method
Study dates
Study
characteristics 2
Secondary
outcomes reported
Adverse events
reported
Study power
and statistical
analysis
Funding
source
Intervention
characteristics
Study ID Intervention
and comparator
names (one per
row)
Full details Length of
follow-up
Participant
characteristics
Study ID Total/
intervention/
comparator
(one per row)
Enrolled, n Randomised,
n
Analysed, n Lost to follow-up,
n
Lost to follow-up,
reasons
Age (years), mean
(SD); p-value if
reported
Sex (male/female);
p-value if
reported
BMI (kg/m2) Weight (kg),
mean (SD)
Dialysis modality Dialysis
vintage
(months),
mean (SD)
Diabetes
mellitus, n (%)
AHT medication,
n (%)
Dry weight (kg),
mean (SD)
SBP (mmHg),
mean (SD)
Diastolic BP
(mmHg), mean
(SD)
Cause of ESRD,
n (%)
Presence of
LVH
LVMI (g/m2) OH (l),
mean (SD)
TBW (l),
mean (SD)
ECW (l), mean
(SD)
ICW (l), mean
(SD)
ECW/I, mean (SD) Lean tissue index
(kg/m2)
Fat tissue mass Comorbid
conditions
Intermediate
outcomes
Study ID Total/
intervention/
comparator
(one per row)
Number of HD
sessions
Length of HD
sessions
Number of
unplanned
hospital visits/
admissions as
a result of FO
or dehydration
Use of AHT
medication
Incidence of
anaemia
SBP (mmHg),
mean (SD)
Diastolic BP
(mmHg), mean
(SD)
Presence of left
ventricular
hypertrophy
LVMI (g/m2),
mean (SD)
Arterial stiffness
PWV (m/s),
mean (SD)
Incidence of
overhydration
Incidence of
underhydration
Change of dialysis
modality as a
result of FO
Adherence with
recommended
fluid intake
Hydration status Relative hydration
status
Clinical outcomes Study ID Total/
intervention/
comparator
(one per row)
Incidence of CV
events (including
stroke and heart
attack)
Mortality RRF Incidence of
oedema
Incidence of
peritonitis
Adverse effects
associated with
hypotensive
episodes (including
cramps, fatigue,
diarrhoea, nausea,
dizziness, fainting)
A
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Data extraction
section Information provided in each section
Patient-reported
outcomes
Study ID Post-dialysis
recovery time
Fatigue HRQoL
NRS outcomes Study ID Summary of
outcomes/
conclusions
Any other
information
Risk-of-bias RCT Adequate
sequence
generation?
Allocation
concealment?
Blinding:
participants?
Blinding:
outcome
assessment?
(Report each
outcome
separately)
Incomplete
outcome data
addressed?
(Report each
outcome
separately)
Free of selective
reporting?
Other sources of
bias?
Risk-of-bias NRS Were participants
a representative
sample selected
from a relevant
patient
population?
Were the
inclusion/
exclusion
criteria of
participants
clearly
described?
Were
participants
entering the
study at a
similar point in
their disease
progression, i.e.
disease severity?
Was selection
of patients
consecutive?
Was data
collection
undertaken
prospectively?
Were the groups
comparable on
demographic
characteristics
and clinical
features?
Was the
intervention (and
comparison)
clearly defined?
Was the
intervention
undertaken by an
experienced
person?
Was the setting
appropriate?
Were the staff,
place and facilities
where the patients
were treated
appropriate for
performing the
procedure?
Were any of
the important
outcomes
considered?
Were objective
(valid and
reliable)
outcome
measures used?
Was the
assessment of
the main
outcomes
blind?
Was follow-up
long enough
to detect
important
effects on
outcomes of
interest?
Was information
provided on non-
respondents,
dropouts, etc.?
Did the
withdrawals,
dropouts, etc.,
have similar
characteristics as
those who
completed the
study?
Was length of
follow-up similar
between
comparison
groups?
Were the
important
prognostic factors
identified, for
example age,
duration of
disease, disease
severity?
Were the analyses
adjusted for
confounding
factors?
AHT, antihypertensive; BP, blood pressure; FO, fluid overload; HRQoL, health-related quality of life; ID, identification; LVH, left ventricular hypertrophy; NRS, non-randomised study;
OH, overhydration; TBW, total body water.
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Appendix 4 Risk-of-bias form: randomised
controlled trials (Cochrane risk-of-bias tool)
Domain Support for judgement Review authors’ judgement
Selection bias
Random sequence generation Describe the method used to generate the
allocation sequence in sufficient detail to
allow an assessment of whether or not it
should produce comparable groups
Selection bias (biased allocation
to interventions) as a result of
inadequate generation of a
randomised sequence
Allocation concealment Describe the method used to conceal the
allocation sequence in sufficient detail to
determine whether or not intervention
allocations could have been foreseen in
advance of, or during, enrolment
Selection bias (biased allocation
to interventions) as a result of
inadequate concealment of
allocations prior to assignment
Performance bias
Blinding of participants and personnel:
assessments should be made for each
main outcome (or class of outcomes)
Describe all measures used, if any, to blind
study participants and personnel to
knowledge of which intervention a
participant received. Provide any information
relating to whether or not the intended
blinding was effective
Performance bias as a result of
knowledge of the allocated
interventions by participants and
personnel during the study
Detection bias
Blinding of outcome assessment:
assessments should be made for each
main outcome (or class of outcomes)
Describe all measures used, if any, to blind
outcome assessors to knowledge of which
intervention a participant received. Provide
any information relating to whether or not
the intended blinding was effective
Detection bias as a result of
knowledge of the allocated
interventions by outcome
assessors
Attrition bias
Incomplete outcome data:
assessments should be made for each
main outcome (or class of outcomes)
Describe the completeness of outcome data
for each main outcome, including attrition
and exclusions from the analysis. State
whether or not attrition and exclusions were
reported, the numbers in each intervention
group (compared with total randomised
participants), reasons for attrition/exclusions
when reported, and any reinclusions in
analyses performed by the review authors
Attrition bias as a result of the
amount, nature or handling of
incomplete outcome data
Reporting bias
Selective reporting State how the possibility of selective
outcome reporting was examined by the
review authors and what was found
Reporting bias as a result of
selective outcome reporting
Other bias
Other sources of bias State any important concerns about bias not
addressed in the other domains in the tool. If
particular questions/entries were prespecified
in the review protocol, responses should be
provided for each question/entry
Bias as a result of problems not
covered elsewhere in the table
RRF, residual renal function.
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Appendix 5 Risk-of-bias checklist for
non-randomised studies
Criteria Yes No Unclear Comments
1. Were participants a representative sample selected from a relevant patient
population?
2. Were the inclusion/exclusion criteria of participants clearly described?
3. Were participants entering the study at a similar point in their disease
progression, i.e. severity of disease?
4. Was selection of patients consecutive?
5. Was data collection undertaken prospectively?
6. Were the groups comparable on demographic characteristics and clinical
features?
7. Was the intervention (and comparison) clearly defined?
8. Was the intervention undertaken by someone experienced at performing the
procedure?
9. Were the staff, place, and facilities where the patients were treated appropriate
for performing the procedure (e.g. access to back-up facilities in hospital or special
clinic)?
10. Were any of the important outcomes considered, i.e. on clinical effectiveness,
cost-effectiveness or learning curves?
11. Were objective (valid and reliable) outcome measures used, including
satisfaction scale?
12. Was the assessment of main outcomes blind?
13. Was follow-up long enough to detect important effects on outcomes of
interest?
14. Was information provided on non-respondents, dropouts?
15. Was length of follow-up similar between comparison groups?
16. Were the important prognostic factors identified, for example age, duration of
disease, disease severity?
17. Were the analyses adjusted for confounding factors?
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Study details Participant characteristics Intervention characteristics Aims and outcomes
RCTs (A = study group; B = control group; C = total, both groups)
l First author, year: Huan-Sheng, 201676
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: six
l Setting: dialysis centres
l Country: Taiwan
l Start/end dates: October 2013 to
September 2013
l Prospective/retrospective data
collection: prospective
l Study design: RCT
l Randomisation method: using a
computer-generated sequence
l Length of follow-up: 12 months
l Source of funding: NephroCare Asia
Pacific, Taiwan Division (grant
number 102030)
l Type of device used: the BCM-BIS
l Enrolled: C = 322
l Randomised: A= 148, B = 150, C= 298
l Analysed: A= 148, B= 150, C = 298
l Age (years), mean (SD): A= 62.7 years
(12.1), B = 62.1 (11.5), C = 62.4 (11.8)
l Sex (male), n (%): A = 65 (43.9), B= 80
(53.3), C = 145 (48.7)
l Diabetes mellitus, n (%): A= 56 (37.8),
B= 56 (37.3), C = 112 (37.6)
l Inclusion criteria: MHD patients aged
≥ 18 years and with a dialysis vintage of
≥ 3 months
l Exclusion criteria: coronary stents or
pacemaker implantation; metallic devices
in body, such as artificial joints or pins;
contralateral or bilateral amputations;
pregnancy
l A: PDTW was adjusted according to
bioimpedance spectroscopy (BSM-BIS)
algorithm
¢ All the parameters relevant to fluid
were revealed to the primary care
staff and they adjusted PDTW
according to these data
l B: PDTW was adjusted according to
clinical symptoms and signs by one or
two fixed experienced dialysis staff in
each centre
¢ The data about fluid were not
disclosed to primary care staff
l Frequency of measurement: Both groups
received monthly measurements before
their mid-week dialysis sessions
l Aims: To determine if the algorithm for
adjusting PDTW with BCM-BIS is
beneficial on the hospitalisation rate
and other pivotal clinical outcomes in
MHD patients
l Outcomes: incidence of intradialysis
hypotension was significantly lower in
the study group
l The incidence of AFO or CV-related
events were lower in the study group
and lower among non-diabetes mellitus
patients in the study group
l PDTW was achieved in 88.38% of
months in which adjustment of PDTW
was in the same direction as the
BCM results
l First author, year: Hur, 201377
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: two
l Setting: dialysis centres (operated by
Fresenius Medical Care)
l Country: Turkey
l Start/end dates: NR
l Prospective/retrospective data
collection: prospective
l Study design: RCT
l Randomisation method: NR
l Length of follow-up: 12 months
l Source of funding: unrestricted grant
from the European Nephrology and
Dialysis Institute
l Enrolled: C = 327
l Randomised: A= 78, B= 78, C= 156
l Analysed: A= 64, B = 62, C= 126
l Age (years) mean (SD): A= 50.9 (13.2),
B= 52.4 (11.4)
l Sex (male), n (%): A = 44/64 (68.8),
B= 43/62 (69.4), C = 87/127 (68.5)
l Diabetes mellitus, n (%): A= 15/78 (19.2),
B= 12/78 (15.4), C= 27/156 (17.3)
l Inclusion criteria: patients who were
willing to participate in the study with
written informed consent, aged
> 18 years, and on MHD therapy
scheduled thrice weekly (12 hours
weekly) for = 3 months were included
l A: fluid overload information was
provided to treating physicians and used
to adjust fluid removal during dialysis.
Fluid overload was assessed twice monthly
l B: fluid overload information was not
provided to treating physicians and fluid
removal during dialysis was adjusted
according to usual clinical practice
l C: dry weight was assessed by routine
clinical practice. Echocardiography,
48-hour ambulatory BP measurement and
pulse wave analysis were performed at
baseline and 12 months
l Aims: whether or not objective
measurement of fluid overload with
bioimpedance spectroscopy is helpful in
optimising fluid status
l Outcomes: LVMI (g/m2) decreased
significantly in the intervention group
and had no statistical significant change
in the control group
l The LVMI decrease in the intervention
group was significantly higher than in
the control group
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l Type of device used: BCM l Exclusion criteria: presence of a
pacemaker or defibrillator, artificial joints
or pins, amputation, permanent or
temporary catheters, being scheduled
for living donor kidney transplantation,
presence of serious life-limiting comorbid
situations (e.g. malignancy, uncontrollable
infection, and end-stage cardiac, pulmonary
or hepatic disease), being pregnant or
lactating
l Frequency of intervention: for the study
group, fluid overload was assessed twice
monthly; for the control group, this was
assessed every 3 months before the
mid- or end-week HD session
l Urine output: significant increase in
proportion of anuric patients and
significant decrease in urine output in
non-anuric patients at 12 months in the
bioimpedance assessment group. No
change in the proportion of anuric
patients in the control group and the
decrease in urine output in non-anuric
patients was not significant at follow-up
l First author, year: Luo, 201163
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: NR
l Setting: PD clinic in the hospital
l Country: China
l Start/end dates: September 2008
to NR
l Prospective/retrospective data
collection: prospective
l Study design: RCT
l Randomisation method: NR
l Length of follow-up: 3 months
(terminated 3 months early)
l Source of funding: grants from the
National Natural Science Foundation
of China (project 30900681) and
Beijing Municipal Science &
Technology
l Commission (D09050704310905)
l Type of device used: BCM
l Enrolled: C = 165
l Randomised: A= 80, B= 85, C= 165
l Analysed: A= 78, B = 82, C= 160
l Age (years), mean (SD): A= 59.63
(13.89), B= 60.28 (16.01)
l Sex (male), n (%): A = 34 (43.6),
B= 40 (48.8)
l Diabetes mellitus, n (%): A= 21 (26.9),
B= 23 (28.0)
l Inclusion criteria: stable CAPD patients.
At recruitment, all patients were aged
> 18 years, had been receiving PD for a
minimum of 3 months and had no acute
infection or new CV event in the prior
month
l Exclusion criteria: patients who had been
on one or two exchanges per day
because of economic limitation were not
included in the present study
l A: the patients and their primary nurses
were informed of the overhydration value
provided by bioimpedance spectroscopy
l B: values provided by bioimpedance
spectroscopy were not revealed and
patients’ volumes were measured by the
standard methods
l C: all recruited patients were closely
followed and assessed by an experienced
dietitian and bioimpedance assessment
during each clinic visit
l All patients, investigators and dialysis
staff were not blinded to treatment
assignment
l At the outpatient review, the dietitian and
primary nurse educated all of the patients
in the same ways
l Frequency of measurement: for all patients,
every = 6 weeks
l Aims: to test if the recent use of OH
provided by bioimpedance spectroscopy
and patients’ education would help to
control overhydration
l Outcomes: OH and ECW were
significantly different pre- and
post-study with both the study group
and the control group
l OH and ICW were significantly different
between study and control groups at
12 weeks
l Urine volume: non-significant decrease
in urine volume in both bioimpedance
and control groups at 12 weeks, but
there was a larger decrease in the
bioimpedance assessment group
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l First author, year: Onofriescu, 201460
l Secondary report: Onofriescu, 201281
l Language: English
l Publication type: full text
l Number of centres: one
l Setting: Dr C.I. Parhon University
Hospital dialysis centre
l Country: Romania
l Start/end dates: July 2008 to
December 2011
l Prospective/retrospective data
collection: prospective
l Study design: RCT
l Randomisation method: block
randomisation technique
l Length of follow-up: 30 months
l Source of funding: part of this study
was funded by the University of
Medicine and Pharmacy Ias¸i, grant
IDEI-PCE 2011, PN-II-
IDPCE-2011–3–0637
l Type of device used: BCM
l Enrolled: NR
l Randomised: A= 62, B= 69, C= 131
l Analysed: A= 62, B = 69, C= 131
l Age (years), mean (SD): A= 52 (13),
B= 54 (13); p= 0.5
l Sex (male), n (%): A = 33/62 (53.2),
B= 36/69 (52.2); p = 0.7
l Diabetes mellitus n (%): A = 6 (10),
B= 6 (9)
l Inclusion criteria: all adult patients (aged
≥ 18 years) from the Dr C.I. Parhon
University Hospital dialysis centre already
on MHD therapy for > 3 months
l Exclusion criteria: patients with limb
amputations, metallic joint prostheses,
absence of a permanent vascular access,
decompensated cirrhosis, pregnancy,
or a cardiac stent or pacemaker were
excluded from the study because
bioimpedance assessment cannot be
performed accurately in such cases. In
addition, patients with a life expectancy
of < 1 year were not considered
l A: target dry weight was prescribed
exclusively based on readouts from the
bioimpedance device measurements
l Results were disclosed to clinicians for
only the bioimpedance intervention arm,
in the form of a strict target interval
(bioimpedance-recommended dry weight
6 1.1 kg) to be achieved during the next
month. Thus, in the bioimpedance
assessment arm, all patients, either under-
or overhydrated, were brought to the
bioimpedance-recommended dry weight,
with 200-g weight adjustments per
dialysis session
l B: dry weight was determined/adjusted in
the clinical methods group by clinical
reference criteria (BP value, presence
of oedema, intradialytic hypotension,
cramps, etc.)
l C: after the 2.5-year intervention period,
during the last year of the study, all
patients were left free of any intervention
and managed according to the standard
medical practice of the dialysis centre. At
the end of the study, at 3.5 years, a third
PWV measurement was performed in
all patients
l Frequency of measurement: every
3 months
l Aims: to compare strict volume control
based on bioimpedance vs. clinical
methods for guiding ultrafiltration
prescriptions in HD patients
l Outcomes: all-cause mortality (both
unadjusted and multivariate adjusted)
was significantly lower in the
bioimpedance assessment group than
in the clinical methods group
l Proportion of patients maintained
within 1.1 kg of the bioimpedance-
recommended dry weight was
statistically significantly higher in the
bioimpedance assessment group than
in the clinical methods group at around
half of the quarterly assessments
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l First author, year: Ponce, 201461
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: 23
l Setting: dialysis units
l Country: Portugal
l Start/end dates: 2010–12
l Prospective/retrospective data
collection: prospective
l Study design: RCT
l Randomisation method: NR
l Length of follow-up: 12 months
l Source of funding: NR
l Type of device used: BCM
l Enrolled: C = 218
l Randomised: A= 101, B = 88, C= 189
l Analysed: A= 101, B= 88, C= 189
l Consecutive:
¢ Age (years), mean (SD): A= 65.8
(14.6), B= 66.7 (15.1)
¢ Sex (male), n (%): A= 72/101 (71.3),
B= 72/88 (81.8), C= 144/189 (76.2)
¢ Diabetes mellitus, n (%): A = 39
(38.6), B= 35 (39.8)
Inclusion criteria: incident and prevalent HD
patients were included if they were aged
> 18 years, with a relative predialytic OH
[relative OH (%) =OH (l)/ECW (l) × 100] at a
baseline of > 15% (on average > 2.5 litres),
as assessed by the BCM
l Exclusion criteria: patients with an
implanted electronic medical device or
who were connected to an external
electronic medical device were excluded.
Further exclusion criteria were any kind of
metal implants or metal prosthetic joints,
for example implanted defibrillators,
cardiac pacemakers. On the other hand,
dental implants and piercings were
allowed. Patients with major amputations,
pregnant women and patients with
symptomatic aortic valve stenosis were
also excluded
l A: data of pre-dialysis measurements
were only accessible to the treating
physicians of the study group
l B: patients’ fluid status, as measured by
the BCM, was not communicated to
physicians or nurses in the blinded centre
l Used all conventional fluid management
techniques according to traditional centre
standards, in order to assess dry weight
of their patients and to adjust
ultrafiltration
l Frequency of measurement: in both
groups, the hydration status of patients
was measured once per month by the
BCM at mid-week dialysis treatment, prior
to the dialysis session
l Aims: to compare the performance of
bioimpedance spectroscopy device vs.
conventional clinical judgement in
assessing the hydration status of HD
patients and determine their ideal weight
l Outcomes: compared with baseline, the
reduction of OH after 12 months was
significant in both groups. Hospitalisation
and survival rates were not significantly
different between the two groups
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Study details Participant characteristics Intervention characteristics Aims and outcomes
NRSs
l First author, year: Castellano, 201486
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: 29
l Setting: HD units in the Fresenius
Medical Care network
l Country: Spain
l Start/end dates: December 2011 to
December 2012
l Prospective/retrospective data
collection: NR
l Study design: longitudinal cohort
l Randomisation method: N/A
l Length of follow-up: 6 months
l Source of funding: NR
l Type of device: BCM
l Analysed: total, n= 2959
l Age (years), mean (SD): 68.20 (14.51)
l Sex (male), %: 62.1
l Diabetes mellitus, %: 27.10
l Inclusion criteria: patients aged > 18 years,
dialysed with high-permeability membrane,
on average, three times per week and with
an average effective time of 240 minutes
per session. All of them had a monthly
measuring with the BCM
l Exclusion criteria: amputees or patients
with pacemakers were excluded
l All patients had a monthly measuring
with the BCM and the first six
measurements were assessed
l Patients were classified as overhydrated
or normohydrated, and the aim was
to move overhydrated patients into the
normohydrated zone
l Frequency of measurement: monthly
measurements and first six measurements
were assessed
l Aims: to identify the characteristics of
patients with maintained hyperhydration
status and to show the haemodynamic
and analytical changes that are related
to the reduction in hydration status
l Outcomes: those who had a reduced
hydration status also show a better
control in BP and anaemia with less
hypotensive drugs (AHT drugs)
and ESAs
l First author, year: Hoppe, 201587
l Secondary reports: No
l Language: English
l Publication type: full text
l Number of centres: one
l Setting: NR
l Country: Poland
l Start-end dates: NR
l Prospective/retrospective data
collection: prospective
l Study design: cohort study with
follow-up
l Randomisation method: N/A
l Length of follow-up: 30 months
l Source of funding: grant from the
Baxter Healthcare Corporation to the
Karolinska Institutet
l Type of device: BCM
l Analysed: short-dialysis vintage group,
n= 119; long-dialysis vintage
group, n= 122
l Age (years), mean (SD): SDVG of 62
(13.1); LDVG of 61.7 (12); p= 0.65
l Sex (male), n (%): SDVG, 77/119 (64.7);
LDVG, 83/122 (68.0); p = 0.65
l Diabetes mellitus, n (%): SDVG, 47
(39.5); LDVG, 29 (23.8); p< 0.01
l Inclusion criteria: patients receiving MHD
l Exclusion criteria: NR
l Frequency of measurement: before
mid-week dialysis session
l Value of cardiac troponin T and hydration
parameters (according to BCM) of short-
dialysis vintage patients and long-dialysis
vintage participants were compared
l Aims: to assess cardiac troponin T and
hydration status as CV event risk
markers in HD patients
l Outcomes: the long-dialysis vintage
group was associated with a
significantly higher rate of deaths
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l First author, year: Kim, 201285
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: three
l Setting: dialysis centre
l Country: South Korea
l Start/end dates: NR
l Prospective/retrospective data
collection: prospective
l Study design: interventional
cohort study
l Randomisation method: N/A
l Length of follow-up: 16 weeks
l Source of funding: in part by Fresenius
Medical Care, South Korea
l Length of follow-up: 16 weeks
l Analysed: total, n= 120; dehydrated,
n= 18; hyperhydrated, n= 44;
normohydrated, N/A
l Age (years), mean (SD): total, 56.4
(13.2); dehydrated, 53.3 (14.3);
hyperhydrated, 58.4 (11.3);
normohydrated, 55.9 (14.1)
l Sex (male), n (%): total 67 (55.4);
dehydrated, 8 (42.1); hyperhydrated,
28 (63.6); normohydrated, 30 (52.6)
l Diabetes mellitus, n (%): NR
l Inclusion criteria: aged 18 years, no
change in dialysate composition and a
change of < 5% in dry weight within
3 months. Clinically euvolaemic for at
least 3 months
l Exclusion criteria: any diagnosed acute or
inflammatory state within 3 months,
hospitalisation-related dialysis within
3 months, diseases that produce local
fluid accumulation and oedema, active
malignancy, currently taking diuretics
or any medication with the potential
to influence body composition,
malnutrition, pregnancy, cardiac
pacemaker or amputation of
any extremity
l Patients were divided into two groups:
hyperhydrated (fluid overload ≥ 1.1 l)
or dehydrated (fluid overload < –1.1 l).
Normohydrated patients were not
subsequently included in the analyses
l Frequency of measurement: before, and
30 minutes after, HD sessions every
4 weeks
l Aims: whether or not the objective
measurement and optimisation of
fluid status could be beneficial for
haemodynamic and biochemical
parameters in HD patients
l Outcomes: after 16 weeks, SBP
and pulse pressure decreased in the
hyperhydrated group, while there was
no increase in BP in the dehydrated
group after the intervention
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l First author, year: Kim, 201550
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: one
l Setting: hospital
l Country: South Korea
l Start/end dates: June 2009 to
April 2014
l Prospective/retrospective data
collection: prospective
l Study design: cohort study
l Randomisation method: N/A
l Length of follow-up: mean (SD) for
survival analysis
l Mean (SD) for admission rates
analysis: OG, 20.6 (15.8) months;
NOG, 16.2 (15.2) months; p= 0.04
l Source of funding: Chungnam
National University Hospital in 2009
and Chungnam National University
in 2010
l Type of device: BCM
l Analysed: overhydrated, n= 160;
non-overhydrated, n = 80; total, n= 240
l Age (years), mean (SD): overhydrated,
65.6 (12.8); non-overhydrated,
65.7 (12.6)
l Sex (male), n (%): total, 67 (55.4);
dehydrated, 8 (42.1); hyperhydrated,
28 (63.6); normohydrated, 30 (52.6)
l Diabetes mellitus, n (%): overhydrated,
112 (71.3); non-overhydrated, 49 (61.3)a
l Inclusion criteria: all patients were
diagnosed with ESRD and started MHD
between June 2009 and April 2014
l Exclusion criteria: patients who started
dialysis because of acute kidney injury, a
patient whose date of dialysis start and
death were in the same admission period
and a patient with a history of renal
transplantation, a history of PD for
> 1 month, or active malignancy (all solid
organ cancer and haematological
malignancy)
l Extent of overhydration and dry body
weight were assessed with the BCM.
Patients were classified into 2 groups:
¢ OG – OH/ECW of > 15%
¢ NOG – OH/ECW of ≤ 15%
l The value of initial OH measured with
BCM was used without modification if it
was measured on the first dialysis day.
If it was measured with BCM after the
first dialysis day, the value of initial
overhydration was calculated by the
difference between initial body weight
and dry body weight measured with
the BCM
l Frequency of measurement: BCM
measurement was performed within the
first week from the start of HD
l Aims: to evaluate the clinical usefulness
of BIA for predicting the survival rate of
patients receiving HD in South Korea
l Outcomes: the ratio of OH to ECW
volume measured with the BCM is
related to the overall survival of ESRD
patients who started receiving MHD
l Admission rates analysis (no significant
difference between the OG and
the NOG
l Patients in the OG had a higher risk for
all-cause mortality
l First author, year: O’Lone, 201482
l Secondary reports:
Santhakumaran, 201684
l Language: English
l Publication type: full text
l No of centres: one
l Setting: NR
l Country: UK
l Start-end dates: 1 January 2008 to
30 March 2012
l Prospective/retrospective data
collection: prospective
l Study design: cohort study with
follow-up
l Randomisation method: N/A
l Length of follow-up: 57 months
l Source of funding: NR
l Type of device: BCM
l Analysed: incident (enrolment into study
was within 90 days of PD initiation),
n= 225; prevalent, n= 304;
total, n= 529
l Age (years), median (IQR): incident, 53.7
(42.9–66.9); prevalent, 58.6 (48.4–69.8);
p< 0.01; total, 57.0 (46.7–68.8)
l Sex (male), n (%): NR
l Incident: 131 (60%); prevalent: 198
(65%); total: 329 (62%)
l Diabetes mellitus, n (%): incident, 78
(35); prevalent, 95 (28); total, 173 (33)
l Inclusion criteria: all CAPD and APD
patients who had at least one
BCM reading
l Exclusion criteria: all patients with
amputations, cardiac pacemakers or
defibrillators were excluded
l Different parameters (OH, ECW : total
body water or OH : ECW) have been
proposed to indicate hydration status.
We wished to determine which parameter
(if any) was most predictive of all-cause
mortality, and if this was independent of
nutritional indices
l OH index (OH and OH : ECW) was the
independent predictor of mortality in
multivariate analysis
l Frequency of measurement: BCM
measurements were usually performed
during their PD training but if this was
not possible, it was performed quarterly
for stable patients and more frequently as
clinically dictated
l Aims: to determine which parameter
(if any) was most predicative of all-cause
mortality and if this was independent of
nutritional indices
l Outcomes: OH index (OH and
OH : ECW) was the independent
predictor of mortality in multivariate
analysis ECW : total body water as a
continuous variable was not associated
with increased risk of death. In
contrast, patients that were severely
overhydrated (highest 33%) had HRs
that were statistically significant
irrespective of the parameter used to
define hydration
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l First author, year: Oei, 201683
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: one
l Setting: NR
l Country: UK
l Start/end dates: 1 January 2008 to
20 March 2012
l Prospective/retrospective data
collection: retrospective
l Study design: cohort study
l Randomisation method: N/A
l Length of follow-up: mean,
23.9 months
l Source of funding: NR
l Type of device: BCM
l Analysed: all, n= 336; survivors, n= 288;
non-cardiac death, n= 35; cardiac death,
n= 13; severe OH, n= 66
l Age (years) median (IQR): all, 57.9
(48.1–69.0); survivors, 55.4 (46.9–66.6)
¢ Non-cardiac death, 68.9 (61.8–77.0);
cardiac death, 68.9 (62.9–76.5);
severe OH, 60.1 (51.1–71.1)
l Sex (male), n (%): all, 207 (62)
l Survivors, n (%): 167 (58)
l Non-cardiac death, n (%): 27 (77)
l Cardiac death, n (%): 13 (100)
l Severe OH, n (%): 44 (67)
l Diabetes mellitus, n: survivors, 288;
non-cardiac death, 35; cardiac death,
13; severe OH, 66
l Inclusion criteria: a cohort of patients
from a single PD unit, consisting of all
CAPD and APD patients between
1 January 2008 and 30 March 2012
who had contemporaneous baseline
BIS/cardiac troponin T readings
l Exclusion criteria: all patients with
amputations, cardiac pacemakers or
defibrillators were excluded, as we were
unable to perform BIS measurements.
Only patients who recovered renal
function or who were transferred to
another dialysis unit for geographic
relocation reasons were censored at that
time point, as their survival follow-up
could not be accurately determined
l Wished to explore if PD patients who died
from cardiac causes were more severely
overhydrated than patients who died
from other causes
l Also wished to determine if OH in PD
patients predicted cardiac mortality, and if
there was a correlation between OH and
cardiac troponin T
l Thus, studied patients to determine if
severe OH did improve, and if it led to
corresponding decrements of cardiac
troponin T
l Frequency of measurement: NR
l Aims: to study the relationship between
OH in patients receiving PD and
cardiac mortality
l Outcomes: patients with cardiac causes
of death had significantly shorter
dialysis vintage and were significantly
more overhydrated by BCM
measurement
l In the severely overhydrated patients,
reduction in OH values over 6 months
correlated with the lowering of cardiac
troponin T levels
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l First author, year: Onofriescu, 201588
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: one
l Setting: HD unit
l Country: Romania
l Start-end dates: May 2008 to
December 2010
l Prospective/retrospective data
collection: prospective
l Study design: cohort study with
follow-up
l Randomisation method: N/A
l Length of follow-up: median 66.2
(42.4–70.2) months
l Source of funding: University of
Medicine and Pharmacy ‘Gr. T. Popa’
Iasi, grant number 1643/01.02.2013
and uefiscdi idei pce, grant number
PN-II-ID-PCE-2011–03–0637
l Type of device: BCM
l Analysed: total, n= 221
l Age (years), mean (SD): total, 53.8 (13.9)
l Sex (male): 116/221
l Diabetes mellitus, n (%): 23/221 (10.4)
l Inclusion criteria: all patients (n = 298)
undergoing HD treatment for CKD for at
least 3 months in the ‘Dr. C. I. Parhon’
HD unit
l Exclusion criteria: bioimpedance was not
performed in patients with metallic joint
prostheses (n= 11), cardiac pacemakers
(n = 8), decompensated cirrhosis (n= 5)
and limb amputations (n = 13). Other
exclusion criteria were refusal to take
part in the study, aged < 18 years, active
systemic infections and terminal
illnesses (n = 40)
l Investigate the impact of OH on all-cause
mortality and CV events by using a
previously reported cut-off value for
overhydration and also investigating a
new cut-off value derived from our
analysis of this specific cohort
l Frequency of measurement: BCM
measurement was used before dialysis.
Dialysis was performed three times
per week
l Aims: to assess if the relationship
between bioimpedance-assessed OH
and survival is maintained when
adjustments for echocardiographic
parameters are considered
l Outcomes: in the entire study
population, patients considered
overhydrated had a significantly
increased risk for all-cause mortality in
both univariate and multivariate Cox
survival analyses
l The number of CV events was
significantly higher in overhydrated
patients in both univariate and
multivariate Cox regression analyses
l First author, year:
Santhakumaran, 201684
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: one
l Setting: NR
l Country: UK
l Start/end dates: 1 January 2008 to
1 October 2012
l Prospective/retrospective data
collection: prospective
l Study design: cohort study with
follow-up
l Analysed: below median (< 6.1) time-
averaged hydration status (OH/ECW): 90
l Above median (< 6.1) time-averaged
hydration status (OH/ECW): 290
l Age (years), mean (SD): below median
(< 6.1 OH/ECW), 54.5 (0.9); above
median (> 6.1 OH/ECW), 59.1 (0.9);
p< 0.0005; total, 55.8 (0.6)
l Sex (male), %: below median, 46.9%;
above median, 80.7; total, 63.8%
l Diabetes mellitus (%): below median,
23.80%; above median, 45.9%;
p< 0.0001; total, 34.80%
l Looked at the relationship between
hydration parameters and PD-related
peritonitis as well as the variables likely to
impact peritonitis rates
l Compared peritonitis rates of patients
with above or below the median time-
averaged hydration parameter (OH/ECW)
l Frequency of measurement: NR
l Aims: to determine if OH is an
independent risk factor for peritonitis
l Outcomes: OH was a predictor of
peritonitis-free survival from enteric
organisms on univariate analysis.
This may be partly caused by the high
comorbidity of patients (who had an
advanced age and diabetes mellitus).
Only inclusion of nutritional parameters
reduced this association
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Study details Participant characteristics Intervention characteristics Aims and outcomes
l Randomisation method: N/A
l Length of follow-up: 78 months
l Source of funding: research grants
from Fresenius medical company and
Baxter Healthcare
l Type of device: BCM
l Inclusion criteria: same cohort of patients
as in O’Lone 2014,82 but with a slightly
longer recruitment period and 51 extra
participants, consisting of all CAPD and
APD patients who had at least one
contemporaneous BCM measurement
l Exclusion criteria: all patients with
amputations, cardiac pacemakers or
defibrillators were excluded as we were
unable to perform BIS measurements
l First author, year: Wizemann, 200930
l Secondary reports: no
l Language: English
l Publication type: full text
l Number of centres: three
l Setting: dialysis centre
l Country: Europe
l Start/end dates: 2003 to
1 January 2007
l Prospective/retrospective data
collection: prospective
l Study design: cohort study with
follow-up
l Randomisation method: N/A
l Length of follow-up: 42 months
l Source of funding: NR
l Type of device: BCM
l Analysed: hyperhydrated, 58;
normohydrated, 211; total, 269
l Age (years), mean (SD): hyperhydrated,
65 (14.8); normohydrated, 66 (15.2);
total, 65 (15)
l Sex (male): NR
l Diabetes mellitus (%): hyperhydrated,
15; normohydrated, 32; total, 28
l Inclusion criteria: all patients who
received HD treatment in the three study
centres in 2003
l Exclusion criteria: the patients with
pacemakers/implanted defibrillators or
amputation of a major limb
were excluded
l Measurements taken once only, before
dialysis, and patients divided into
hyperhydrated (relative hydration of
> 15%) or normohydrated groups, which
were then compared on hydration
parameters and mortality
l Frequency of measurement: three times
per week, before the start of
HD treatment
l Aims: to investigate how the
magnitude of the prevailing OH
influences long-term survival in patients
receiving HD
l Outcomes: significant predictors of
mortality – age, SBP, diabetes mellitus,
peripheral vascular disease, relative
hydration status pre-dialysis
AFO, acute fluid overload; AHT, antihypertensive; APD, automated PD; BCM-BIS, BCM-bioimpedance spectroscopy; BIA, bioimpedance analysis; BIS, bioimpedance spectroscopy; BP, blood
pressure; CAPD, continuous ambulatory PD; FOR, relative fluid overload; IQR, interquartile range; LDVG, long-dialysis vintage group; MHD, maintenance HD; N/A, not applicable;
NOG, non-overhydrated group; NR, not reported; NRS, non-randomised study; OG, overhydrated group; OH, overhydration; SDVG, short-dialysis vintage group.
a Diabetic nephropathy.
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Appendix 8 Risk-of-bias assessment:
non-randomised studies
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ReBIP criteria
Study: first author and year of publication
Castellano
et al., 201486
Hoppe et al.,
201587
Kim et al.,
201285
Kim et al.,
201550
Oei et al.,
201683
O’Lone
et al., 201482
Onofriescu
et al., 201588
Santhakumaran
et al., 201684
Wizemann
et al., 200930
Representative sample ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Inclusion/exclusion criteria clearly
defined
✓ ✗ ✓ ✗ ✓ ✓ ✓ ✓ ✗
Participants at a similar point in
disease progression
✓ ✗ ✓ ✓ ✓ ✗ ✓ ✗ ✓
Consecutive selection of participants ? ? ? ? ? ? ? ? ?
Prospective data collection ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Clearly defined intervention ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Intervention delivered by
experienced person
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Intervention delivered in appropriate
setting
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Important outcomes considered ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Objective outcome measured ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Blind assessment of main outcomes ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Long enough follow-up ✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓
Information on non-respondents,
dropouts
✓ ✓ ✓ ✓ ✗ ✓ ? ✗ ✓
Withdrawals likely to introduce bias ✓ ✓ ? ✗ ? ? ? ? ?
Important prognostic factors
identified
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
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Appendix 9 Outcome measures extracted from
the included randomised controlled trials
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Indicator/group
assessed Hospitalisation
AHT
medication
SBP (mmHg),
mean (SD)
Diastolic BP
(mmHg),
mean (SD)
Presence of
left
ventricular
hypertrophy
LVMI
(g/m2),
mean (SD)
Arterial stiffness
PWV (m/s),
mean (SD)
Absolute
hydration status
Relative
hydration status
Huan-Sheng et al., 201676
Indicator Incidence, IR ratio and HR (per
patient-year) for all diabetes
mellitus and non-diabetes
mellitus patients, 95% CI
Pre-dialysis SBP FO and FOpost for all
patients; for patients
with initial FO of
> 2.5 l and for
patients with initial
FO of ≤ 2.5 l; change
with baseline
FOR for all patients;
for patients with
initial FO of > 2.5 l
and for patients
with initial FO of
≤ 2.5 l; change with
baseline
Total
Study
(bioimpedance)
Overall: 71 events; IR= 0.52
(95% CI 0.44 to 0.61);
diabetes mellitus, 30 events;
IR= 0.58, 95% CI 0.46 to
0.73; non-diabetes mellitus,
41 events; IR= 0.48, 95% CI
0.39 to 0.60
All: 136 (23)/FO
of ≤ 2.5 l, 136
(23); FO of
≥ 2.5 l, 133 (21);
p< 0.05
All: FO= 1.49
(SD 1.04); FOpost,
–0.50 (SD 1.21),
p< 0.05; FO of
≤ 2.5 l, FO= 1.40
(SD 1.00), p< 0.01;
FOpost= –0.56 (SD
1.21), p< 0.001; FO
of ≥ 2.5 l, FO= 2.21
(SD 1.07), p< 0.001;
FOpost= 0.02
(SD 1.07), p< 0.05
All: 0.10 (SD 0.07);
FO of ≤ 2.5 l, 0.09
(SD 0.06), p< 0.05;
FO of ≥ 2.5 l, 0.14
(SD 0.006),
p< 0.001
Control l Overall: 73 events;
incidence= 0.54
(95% CI 0.46 to 0.63);
IR= 0.97 (95% CI 0.70
to 1.34); HR= 1.19
(95% CI 0.79 to 1.80)
l Diabetes mellitus: 38
events; incidence= 0.76
(95% CI 0.65 to 0.89);
IR= 0.76 (95% CI 0.47 to
1.23); HR= 1.13 (95% CI
0.61 to 2.09)
l Non-diabetes mellitus: 35
events; incidence= 0.41
(95% CI 0.32 to 0.53);
IR= 1.18 (95% CI 0.75 to
1.85); HR= 1.23 (95% CI
0.70 to 2.14)
l All: 136 (22)
l FO of ≤ 2.5 l:
134 (21)
l FO of ≥ 2.5 l:
143 (22)
All: FO= 1.64
(SD 1.40); FOpost:
–0.23 (SD 1.52); FO
of ≤ 2.5 l: FO= 1.25
(SD 1.16); FOpost=
–.53 (SD 1.39);
p< 0.05; FO of
≥ 2.5 l: FO= 3.07
(SD 1.27); p< 0.05;
FOpost= 0.89
(SD 1.48)
All: FOR: 0.11
(SD 0.09); FO of
≤ 2.5 l: FOR= 0.09
(SD 0.09); FO of
≥ 2.5 l: 0.19
(SD 0.07); p< 0.05
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Indicator/group
assessed Hospitalisation
AHT
medication
SBP (mmHg),
mean (SD)
Diastolic BP
(mmHg),
mean (SD)
Presence of
left
ventricular
hypertrophy
LVMI
(g/m2),
mean (SD)
Arterial stiffness
PWV (m/s),
mean (SD)
Absolute
hydration status
Relative
hydration status
Luo et al., 201163
Indicator Total daily
defined dose,
mean (SD) at
12 weeks
OH ECW/ICW
Total (N= 160)
Bioimpedance
(n= 78)
2.33 (1.76) 132.99 (19.47);
p< 0.5; change
with baseline and
between groups
77.63 (12.04);
p< 0.5; change
with baseline
1.72 (SD 1.51);
p< 0.05; change
with baseline
0.95 (SD 0.13);
p< 0.05; change
with baseline
Control
(n= 82)
2.94 (1.87) 139.07 (22.40);
p< 0.5; change
with baseline and
between groups
80.85 (14.15);
p< 0.5; change
with baseline
2.52 (SD 1.83);
p< 0.05; change
with baseline and
between groups
1.00 (SD 0.14);
p< 0.05; change
with baseline
Hur et al., 201377
Indicator Hospitalisation rate/
100 patients
Pre and post
dialysis; p-value –
change from
baseline
Pre and post
dialysis; p-value –
change from
baseline
p-value –
change from
baseline
p-value –
change
from
baseline
FOpre and FOpost,
change with baseline
Totala
Study
(bioimpedance)
Hospitalised, n= 6;
hospitalisation rate/100
patient-year, n= 12.5
Pre dialysis: 120
(19); p< 0.001;
post dialysis: 105
(18); p< 0.001
(9); p< 0.001;
post dialysis: 65
(9); p< 0.001
28/64
(43.8%);
p= 0.4
116 (29);
p< 0.001
–0.52 (1.38) FOpre= 0.87 (SD 0.88);
FOpost= –1.33
(SD 0.99); p< 0.001;
change with baseline:
FOpre= –0.6 (SD 0.8);
FOpost= –0.5 (SD 0.9)
Control Hospitalisation, n= 4;
hospitalisation rate/100
patient-year: 30.9; p=NS,
difference between groups
Pre dialysis: 125
(19); p= 0.006;
post dialysis: 113
(21); p= 0.03
Pre dialysis: 76
(9); p= 0.2; post
dialysis: 70 (10);
p= 0.07
31/62 (50%);
p= 0.9
120 (30);
p= 0.9
0.11 (1.31);
difference between
groups= –0.5,
95% CI –0.9 to
–0.0; p= 0.04
FOpre= 1.41 (SD 1.26);
FOpost= –1.01
(SD 1.44); change:
FOpre= 0.2 (SD 1.2);
FOpost= 0.0 (SD 1.3)
Between-group
changes
(95% CI)
FOpre: –0.4 (95% CI
–0.6 to –0.3);
p< 0.001; FOpost:
–0.5 (95% CI –0.8
to –0.1); p= 0.01
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Pre dialysis: 73
Indicator/group
assessed Hospitalisation
AHT
medication
SBP (mmHg),
mean (SD)
Diastolic BP
(mmHg),
mean (SD)
Presence of
left
ventricular
hypertrophy
LVMI
(g/m2),
mean (SD)
Arterial stiffness
PWV (m/s),
mean (SD)
Absolute
hydration status
Relative
hydration status
Onofriescu et al., 2014;60 did not report DBP60
Indicator n= patients
not treated
with AHT
medication,
within-group
change
Change with
baseline
RFO, % (SD)
change within
groups (95% CI)
Bioimpedance n= 45;
p= 0.05
138.9 (14.7):
–6.54 (95% CI
–13.62 to –4.53);
p= 0.04
7.46 (5.77), –2.05
(–5.70 to –1.10);
p= 0.03
Control n= NR;
p= NS
140.5 (11.4)
–4.00 (95% CI
–10.83 to 2.63);
p= 0.4
11.24 (7.62), 0.94
(–2.50 to 4.40);
p= 0.9
Between-group
changes
Between-group
mean difference
(end of
intervention):
1.67 (95% CI
–5.24 to 8.60);
p= 0.9; between-
group mean
difference
(change from
baseline to end of
intervention):
–2.43 (95% CI
–7.70 to 2.84);
p= 0.4
End of intervention:
3.77 (2.20 – 7.35);
p= 0.03; change
from baseline to
end of intervention:
–2.99 (–5.00 to
–0.89); p= 0.05
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Indicator/group
assessed Hospitalisation
AHT
medication
SBP (mmHg),
mean (SD)
Diastolic BP
(mmHg),
mean (SD)
Presence of
left
ventricular
hypertrophy
LVMI
(g/m2),
mean (SD)
Arterial stiffness
PWV (m/s),
mean (SD)
Absolute
hydration status
Relative
hydration status
Ponce et al., 201461
Indicator Hospitalised at least once Pre and post
dialytic
Pre and post
dialytic
OH (l) (SD),
compared with
baseline
ROH, % (SD)
compared with
baseline
Total
Study
(bioimpedance)
40/101 (39.6%) Predialytic SBP:
134.6 (27.3);
post-dialytic SBP:
132.8 (28.6)
Predialytic DBP:
65.4 (15.8);
post-dialytic
DBP: 63.4 (15.0)
2.92 (1.47);
p< 0.0001
15.40 (6.36);
p= NS
Control 28/88 (31.8%) Predialytic SBP:
136.5 (24.7);
post-dialytic SBP:
129.3 (24.0)
Predialytic DBP:
64.5 (16.2);
post-dialytic
DBP: 61.4 (12.9)
Mean OH: 3.36
(1.75); p= 0.0216
16.26 (8.48);
p= NS
Between-group
difference
0.4184 (95% CI
–0.02 to 0.86);
p= 0.0622
p= NS
AHT, antihypertensive; BP, blood pressure; DBP, diastolic blood pressure; FO, fluid overload; FOR, relative fluid overload; IR, incidence rate; NS, not significant; OH, overhydration;
RFO, relative fluid overload.
a Ten patients hospitalised as a result of new CV events during the study period.
D
O
I:10.3310/hta22010
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.1
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Scotland
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
131

Appendix 10 Characteristics of ongoing trials
Study details Participant characteristics Aims and outcomes
l Study title: Probing the Dry Weight
(DW) by Bioimpedance (BIA): Which
is the Gold Standard Between
Clinical DW and BIA DW? (REST)91
l ClinicalTrials.gov identifier:
NCT02446535
l Responsible party: Carlo Basile, MD,
Scientific Director of the Division of
Nephrology, Miulli General Hospital
l Last updated: 13 May 2015
l (Estimated) study completion date:
December 2016
l Trial status: this study is currently
recruiting participants
l Study type: interventional
l Country: Italy
l Setting: NR
l Allocation: NR
l Estimated enrolment: 60
l Inclusion criteria: patients aged
≥ 18 years who have had MHD
three times weekly
l Exclusion criteria: dialysis vintage
of < 3 months, overt oedema,
liver cirrhosis, cardiac failure,
serum albumin concentration of
< 3 g/dl, pregnancy, metallic
implants or pacemaker,
limb amputation
l Intervention model: single
group assignment
l Aims: to verify if BIA-based DW
control is truly superior to
current volume management in
patients receiving HD
l Primary outcomes: the definition
for each patient of the gold
standard DW when comparing
the clinical and the BIA DW
l Secondary outcomes: NR
l Study title: Fluid Management
Guided by Bioimpedance Analysis in
Peritoneal Dialysis (PD) Patients92
l ClinicalTrials.gov identifier:
NCT02000128
l Responsible party: Xue Qing Yu,
Director, Institute of Nephrology,
Sun Yat-sen University, Sun Yat-sen
University
l Last updated: 19 May 2015
l (Estimated) study completion date:
19 April 2016
l Trial status: this study has been
completed
l Study type: interventional
l Country: China
l Setting: The First Affiliated Hospital
of Sun Yat-Sen University
l Allocation: randomised
l Estimated enrolment: 240
l Inclusion criteria: patients who
are undergoing PD and clinically
stable for at least 3 months;
aged ≥ 18 years; ratio of ECW to
total body water of ≥ 0.4; signed
the informed consent form
l Exclusion criteria: patients who
have mental graft; amputation;
patients who are unable to
accomplish the BIA in a standing
position for 3 minutes; patients
whose heart function is class IV,
estimated by the NYHA
standard; patients who have
acute complications within
30 days prior to study enrolment;
patients whose life expectancy is
within 6 months; patients who
are pregnant; patients who are
unable to give consent
l Intervention model: parallel
assignment
l Aims: to investigate the effect of
BIA-guided fluid management
vs. experiential way on clinical
outcome in PD patients
l Primary outcomes: all-cause,
mortality, CV event-related
mortality
l Secondary outcomes: technique
survival, CV events, peritonitis,
RRF
l Study title: Control Of Fluid Balance
Guided by Body Composition
Monitoring in Patients on PeritoneAl
dialySiS (COMPASS)93
l ClinicalTrials.gov identifier:
NCT01887262
l Responsible party: Kook-Hwan Oh,
Associate Professor, Seoul National
University Hospital
l Last updated: 17 June 2014
l Estimated study completion date:
July 2015
l Trial status: this study is currently
recruiting participants
l Study type: interventional
l Country: South Korea
l Setting: Seoul National University
Hospital Clinical Trial Centre
l Allocation: randomised
l Estimated enrolment: 138
l Inclusion criteria: aged
between 20 and 75 years; PD
of > 4 weeks duration; written
consent; daily urine output
of > 500ml
l Exclusion criteria: subjects who
are contraindicated to the
bioimpedance measurement
(pacemaker insertion state,
defibrillator state, amputee,
prosthesis, metal implants);
pregnant women; subjects
who are expected to discontinue
PD within 1 year; mixed
dialysis modality (PD and HD);
hypoalbuminaemic subjects
(serum albumin concentration
of < 3.3 g/dl); high BP
l Aims: bioimpedance-guided
fluid management in patients
receiving PD may provide better
protection of RRF over a 1-year
period than management guided
by clinical information alone
l Primary outcomes: change of
GFR from baseline to the
12th month
l Secondary outcomes: GFR
measured by urine collection;
time to the anuric; parameters
obtained by echocardiographic
measurements such as LVMI; left
ventricular end-diastolic volume;
left ventricular ejection fraction;
left atrial volume index; SBP/DBP,
pulse pressure; fatal and non-
fatal CV events – AMI; stroke;
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Study details Participant characteristics Aims and outcomes
(> 160/100 mmHg despite AHT
medications); severe heart failure
(NYHA functional classification III
or IV)
l Intervention model: parallel
assignment
unstable angina, amputation, CV
revascularisation; parameters
measured by BCM
l Study title: Bioimpedance
Spectroscopy to Maintain Renal
Output (BISTRO)94
l ClinicalTrials.gov identifier:
ISRCTN11342007
l Responsible party: Kidney Unit,
Royal Stoke University Hospital,
University Hospitals of North
Midlands NHS Trust
l Last updated: 4 July 2016
l (Estimated) study completion date:
recruitment until 2 January 2018
l Trial status: recruitment starts
2 January 2017
l Study type: interventional
l Country: UK (30 UK dialysis units)
l Setting: University of Keele
l Allocation: randomised
l Estimated enrolment: 516
l Inclusion criteria: adults aged
> 18 years commencing
centre-based MHD because of
advanced CKD stage 5, planned
or unplanned, via arteriovenous
fistula, graft or central venous
catheter (i.e. with or without
permanent vascular access);
commencing dialysis on any
regimen, including having
incremental dialysis initiation;
residual kidney function – for
patients who have not yet
started dialysis treatment, they
should have a daily urine volume
of > 500ml/day and/or a
measured mean urea and
creatinine clearance of > 3ml/
min/1.72 m2 determined from a
24-hour collection; for patients
already on dialysis, they should
have a urine volume of > 500ml
during the short interdialytic
period and/or a measured mean
urea and creatinine clearance of
> 3 ml/min/1.72 m2, determined
from the same timed interdialytic
urine collections and an average
of the post- and pre-dialysis
plasma urea and creatinine
concentrations
l Exclusion criteria: unable or
unwilling to give informed
consent; unable to comply with
trial procedures, for example
collection of urine output; likely
survival prognosis or planned
modality transfer of < 6 months;
subjects with limb amputations
when the foot is not accessible
and it is not possible to take
hand-to-hand measurements
l Intervention model: NR
l Aims: to test whether or not
taking regular measurements
with a bioimpedance device
improves outcomes for people
who have recently started HD
treatment for kidney failure
l Primary outcomes: time to
anuria (loss of urine output),
< 100ml/day or 200 ml in the
short interdialytic period
confirmed by a further collection
after 2 weeks to exclude
temporary illness
l Secondary outcomes: the rate at
which kidney function reduces;
vascular access failure; CV events;
hospital admissions; death
AHT, antihypertensive; AMI, acute myocardial infarction; BIA, bioimpedance analysis; DW, dry weight; MHD, maintenance
HD; NR, not reported; NYHA, New York Heart Association; RRF, residual renal function.
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Appendix 11 Questions for clinical experts on
bioimpedance testing
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